<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Nutritional interventions for reducing morbidity and mortality in people with HIV - Grobler, L - 2013 | Cochrane Library</title> <meta content="Nutritional interventions for reducing morbidity and mortality in people with HIV - Grobler, L - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004536.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Nutritional interventions for reducing morbidity and mortality in people with HIV - Grobler, L - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004536.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004536.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Nutritional interventions for reducing morbidity and mortality in people with HIV" name="citation_title"/> <meta content="Liesl Grobler" name="citation_author"/> <meta content="liesl.nicol@gmail.com" name="citation_author_email"/> <meta content="Nandi Siegfried" name="citation_author"/> <meta content="Marianne E Visser" name="citation_author"/> <meta content="Stellenbosch University" name="citation_author_institution"/> <meta content="Sarah SN Mahlungulu" name="citation_author"/> <meta content="Eastern Cape Department of Health" name="citation_author_institution"/> <meta content="Jimmy Volmink" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD004536.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004536.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004536.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004536.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Diet [standards]; Dietary Carbohydrates [*administration &amp; dosage]; Dietary Fats [*administration &amp; dosage]; Disease Progression; Energy Intake; HIV Infections [complications, *diet therapy, mortality]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004536.pub3&amp;doi=10.1002/14651858.CD004536.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="u3GUW7vS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004536\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004536\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","pt","ja","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004536.pub3",title:"Nutritional interventions for reducing morbidity and mortality in people with HIV",firstPublishedDate:"Feb 28, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane HIV/AIDS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=u3GUW7vS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004536.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004536.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004536.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004536.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004536.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004536.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004536.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004536.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004536.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004536.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5587 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004536.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-sec-0103"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-sec-0044"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-sec-0045"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-sec-0097"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/appendices#CD004536-sec-0108"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/table_n/CD004536StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/table_n/CD004536StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Nutritional interventions for reducing morbidity and mortality in people with HIV</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information#CD004536-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Liesl Grobler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information#CD004536-cr-0003">Nandi Siegfried</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information#CD004536-cr-0004">Marianne E Visser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information#CD004536-cr-0005">Sarah SN Mahlungulu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information#CD004536-cr-0006">Jimmy Volmink</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information/en#CD004536-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004536.pub3">https://doi.org/10.1002/14651858.CD004536.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004536-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004536-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004536-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004536-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004536-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004536-abs-0003">日本語</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004536-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004536-abs-0001" lang="en"> <section id="CD004536-sec-0001"> <h3 class="title" id="CD004536-sec-0001">Background</h3> <p>Adequate nutrition is important for optimal immune and metabolic function. Dietary support may, therefore, improve clinical outcomes in HIV‐infected individuals by reducing the incidence of HIV‐associated complications and attenuating progression of HIV disease, improving quality of life and ultimately reducing disease‐related mortality. </p> </section> <section id="CD004536-sec-0002"> <h3 class="title" id="CD004536-sec-0002">Objectives</h3> <p>To evaluate the effectiveness of various macronutrient interventions, given orally, in reducing morbidity and mortality in adults and children living with HIV infection. </p> </section> <section id="CD004536-sec-0003"> <h3 class="title" id="CD004536-sec-0003">Search methods</h3> <p>We searched CENTRAL (up to August 2011), MEDLINE (1966 to August 2011), EMBASE (1988 to August 2011), LILACS (up to February 2012), and Gateway (March 2006‐February 2010). We also scanned reference lists of articles and contacted authors of relevant studies and other researchers. </p> </section> <section id="CD004536-sec-0004"> <h3 class="title" id="CD004536-sec-0004">Selection criteria</h3> <p>Randomised controlled trials evaluating the effectiveness of macronutrient interventions compared with no nutritional supplements or placebo in the management of adults and children infected with HIV. </p> </section> <section id="CD004536-sec-0005"> <h3 class="title" id="CD004536-sec-0005">Data collection and analysis</h3> <p>Three reviewers independently applied study selection criteria, assessed study quality, and extracted data. Effects were assessed using mean difference and 95% confidence intervals. Homogenous studies were combined wherever it was clinically meaningful to do so and a meta‐analysis using the random effects model was conducted. </p> </section> <section id="CD004536-sec-0006"> <h3 class="title" id="CD004536-sec-0006">Main results</h3> <p>Fourteen trials (including 1725 HIV positive adults and 271 HIV positive children), were included in this review. Neither supplementary food nor daily supplement of Spirulina significantly altered the risk of death compared with no supplement or placebo in malnourished, ART naive adult participants in the two studies which reported on this outcome. A nutritional supplement enhanced with protein did not significantly alter the risk of death compared to standard nutritional care in children with prolonged diarrhoea. Supplementation with macronutrient formulas given to provide protein and/or energy and fortified with micronutrients, in conjunction with nutrition counselling, significantly improved energy intake (3 trials; n=131; MD 393.57 kcal/day; 95% CI: 224.66 to 562.47;p&lt;0.00001) and protein intake (2 trials; n=81; MD 23.5 g/day; 95% CI: 12.68, 34.01; p&lt;0.00001) compared with no nutritional supplementation or nutrition counselling alone in adult participants with weight loss. In general supplementation with specific macronutrients such as amino acids, whey protein concentration or Spirulina did not significantly alter clinical, anthropometric or immunological outcomes compared with placebo in HIV‐infected adults and children. </p> </section> <section id="CD004536-sec-0007"> <h3 class="title" id="CD004536-sec-0007">Authors' conclusions</h3> <p>Given the current evidence base, which is limited to fourteen relatively small trials all evaluating different macronutrient supplements in different populations at different stages of HIV infection and with varying treatment status, no firm conclusions can be drawn about the effects of macronutrient supplementation on morbidity and mortality in people living with HIV. It is, however, promising to see more studies being conducted in low‐income countries, and particularly in children, where macronutrient supplementation both pre‐antiretroviral treatment and in conjunction with antiretroviral treatment might prove to be beneficial. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004536-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004536-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD004536-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD004536-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004536-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004536-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004536-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004536-abs-0007">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004536-abs-0005" lang="en"> <h3>Nutritional interventions for reducing morbidity and mortality in people with HIV</h3> <p>Achieving and maintaining optimal nutrition is considered an important adjunct in the clinical care of patients infected with HIV, as good nutrition can improve an individual's immune function, limit disease‐specific complications, and improve quality of life and survival. We sought to determine whether macronutrient interventions, either given to provide protein and/or energy or test the effect of specific macronutrients (i.e. ch as amino acids, whey protein concentrate or Spirulina), given orally, influence morbidity and mortality in adults and children living with HIV infection. Our review, based on fourteen small trials, evaluating different macronutrient supplements, found limited evidence that balanced macronutrient formulas increase protein and energy intake. However, we found no evidence that such supplementation translates into reductions in disease progression or HIV‐related complications, such as opportunistic infections or death. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004536-sec-0103" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004536-sec-0103"></div> <h3 class="title" id="CD004536-sec-0104">Implications for practice</h3> <section id="CD004536-sec-0104"> <p> <ul id="CD004536-list-0065"> <li> <p>In keeping with previous WHO recommendations everything possible should be done to promote and support adequate dietary intake and food security, while recognising that this may not be sufficient to correct specific deficiencies in all HIV‐infected individuals; </p> </li> </ul> <ul id="CD004536-list-0066"> <li> <p>There is evidence of a low quality that provision of a balanced macronutrient supplement, fortified with micronutrients, increases the daily energy and protein intake when compared to receipt of nutritional counselling alone; the choice of supplement is likely to be determined by cost and availability. </p> </li> </ul> </p> </section> <h3 class="title" id="CD004536-sec-0105">Implications for research</h3> <section id="CD004536-sec-0105"> <p> <ul id="CD004536-list-0067"> <li> <p>Adequately powered studies are required to determine the efficacy and safety of macronutrient supplements in HIV‐infected  adults and children; </p> </li> </ul> <ul id="CD004536-list-0068"> <li> <p>Choice of supplements for future research should be guided by the evidence‐base and focus on determining the optimal composition and dosage of: </p> </li> </ul> <ul class="plain" id="CD004536-list-0069"> <li> <ul id="CD004536-list-0070"> <li> <p>Balanced macronutrient supplements fortified with micronutrients</p> </li> <li> <p>Fortified food supplementation delivered by food programmes</p> </li> </ul> </li> </ul> <ul id="CD004536-list-0071"> <li> <p>The cost‐benefit or cost‐effectiveness of all the nutritional interventions requires evaluation; </p> </li> </ul> <ul id="CD004536-list-0072"> <li> <p>Research participants should be diverse with respect to stage of disease, use of antiretroviral therapy, immune status, and nutritional status. </p> </li> </ul> </p> <p>In summary, there is limited evidence, from randomized trials mainly conducted in high‐income countries that targeted supplementation of the diet with balanced macronutrient supplementation increases energy and protein intake in HIV‐infected adults on antiretroviral therapy. The effects of nutritional supplementation on mortality, morbidity, body weight, and immunological parameters remain unclear. There is limited evidence for the optimal type and amount of supplement delivered by food programme interventions for people infected with HIV. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004536-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004536-sec-0036"></div> <div class="table" id="CD004536-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Balanced nutritional supplement compared to counselling or nutritional placebo in patients with weight loss for reducing morbidity and mortality in people with HIV</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Balanced nutritional supplement compared to counselling or nutritional placebo in patients with weight loss for reducing morbidity and mortality in people with HIV</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with reducing morbidity and mortality in people with HIV <br/> <b>Settings:</b> <br/> <b>Intervention:</b> Balanced nutritional supplement <br/> <b>Comparison:</b> counselling or nutritional placebo in patients with weight loss </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Counselling or nutritional placebo in patients with weight loss</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Balanced nutritional supplement</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Energy intake (kcal/day)</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean energy intake (kcal/day) ranged across control groups from <br/> <b>1,777 to 2,412 kcal/day</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean energy intake (kcal/day) in the intervention groups was <br/> <b>393.57 higher</b> <br/> (224.66 to 562.47 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 <br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Protein intake (g/day)</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean protein intake (g/day) ranged across control groups from <br/> <b>79 to 81 g/day</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean protein intake (g/day) in the intervention groups was <br/> <b>23.35 higher</b> <br/> (12.68 to 34.01 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> <br/> Follow‐up: 6 ‐ 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight ranged across control groups from <br/> <b>71.8 to 73.3 kg</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight in the intervention groups was <br/> <b>0.17 lower</b> <br/> (1.1 lower to 0.75 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 <br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fat mass measured in % of TBW</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fat mass measured in % of tbw ranged across control groups from <br/> <b>8.5 to 15.5 %</b><sup>8</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fat mass measured in % of tbw in the intervention groups was <br/> <b>1.14 lower</b> <br/> (2.58 lower to 0.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 <br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fat free mass</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fat free mass ranged across control groups from <br/> <b>‐0.3 to 3.8 Change in fat free mass in kg</b><sup>9</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fat free mass in the intervention groups was <br/> <b>0.37 lower</b> <br/> (2.77 lower to 2.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218 <br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cd4 ranged across control groups from <br/> <b>311 to 559 Cells/mm3</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cd4 in the intervention groups was <br/> <b>114.48 lower</b> <br/> (233.2 lower to 4.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>3,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load (log10 copies/ml)</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean viral load (log10 copies/ml) in the intervention groups was <br/> <b>3.71 lower</b> <br/> (12.16 lower to 4.74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 <br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> All three trial reports were unclear regarding randomisation and selection bias may be present. The trials were not blinded for participants and personnel possibly leading to performance bias. Blinding was not clearly reported for outcome assessment and detection bias may be present. Attrition was high in the Berneis trial at 16%. <br/> <sup>2</sup> The trials are relatively small with Berneis only having 15 participants. This could lead to imprecision <br/> <sup>3</sup> Trial reports were unclear regarding randomisation and selection bias may be present. The trials were not blinded for participants and personnel possibly leading to performance bias. Blinding was not clearly reported for outcome assessment and detection bias may be present. Attrition was high in the Berneis trial at 16%. <br/> <sup>4</sup> Both are small trials, Berneis only has 15 participants so results are likely to be imprecise. <br/> <sup>5</sup> The meta‐analysis included combining mean change scores from baseline to study endpoint (Schwenk and Rabeneck)and actual mean weight measurements at study endpoint (Berneis and De Luis) as described in the Cochrane Review Handbook. No mean weights in the control groups were reported for the two trials in which change scores were provided and the range reported here only reflects that of the Berneis and De Luis trials. <br/> <sup>6</sup> All four trial reports were unclear regarding randomisation and selection bias may be present. The trials were not blinded for participants and personnel possibly leading to performance bias. Blinding was not clearly reported for outcome assessment and detection bias may be present. Attrition was high in the Berneis trial at 16% and in Rabeneck at 24%. Attrition bias is likely. <br/> <sup>7</sup> As all the sample sizes are small, Imprecision is likely in the indiviudal trials. This is reduced by the meta‐analysis. <br/> <sup>8</sup> The meta‐analysis included combining mean change scores from baseline to study endpoint and actual mean measurements at study endpoint as described in the Cochrane Review Handbook. No fat free mass in % TBW was reported in the control group for Rabeneck and so we included the change score instead. In Schwenk it is not clear that the data presented are % TBW as they reflect the Area under the Curve. However the trial adds very little weight (0.6%) so we retained it in the analysis. <br/> <sup>9</sup> The De Luis trial did not report change scores and so the actual mean weights are reported. In the control group this was 57.6kg <br/> <sup>10</sup> Berneis is a small trial with 15 participants leading to imprecision. As there is only one other trial in the meta‐analysis imprecision is likely. <br/> <sup>11</sup> Results are for one trial only with a high risk of selection, performance, and detection bias. <br/> <sup>12</sup> Results are from one trial only and as the sample size is small imprecision is likely. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004536-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004536-sec-0037"></div> <section id="CD004536-sec-0038"> <h3 class="title" id="CD004536-sec-0038">Description of the condition</h3> <section id="CD004536-sec-0039"> <h4 class="title">HIV/AIDS and macronutrient deficiency</h4> <p>Adequate nutrition is critical for optimal immune function. Dietary therapy is therefore regarded as an important adjunct in the clinical care of patients infected with HIV. It is believed that achieving and maintaining optimal nutrition will improve the individual's immune function, reduce the incidence of complications associated with HIV infection, attenuate the progression of HIV infection, improve quality of life, and ultimately reduce mortality associated with the disease (<a href="./references#CD004536-bbs2-0067" title="dePeeS , SembaRD . Role of nutrition in HIV infection: review of evidence for more effective programming in resource‐limited settings. Food Nutr Bull2010;31(4):S313‐44. ">de Pee 2010</a>; <a href="./references#CD004536-bbs2-0072" title="HsuJWC , PencharzPB , MacallanD , TomkinsA . Macronutrients and HIV/AIDS: a review of current evidence. http://www.who.int/nutrition/topics/Paper%20Number%201%20‐%20Macronutrients.pdf2005. ">Hsu 2005</a>). </p> <p>People living with HIV are at great risk of nutritional disorders. This is the case in both untreated (i.e. not receiving antiretroviral therapy (ART)) and treated (i.e. receiving some form of ART) HIV‐infected individuals. Furthermore, HIV infection is most prevalent in parts of the world where food security is compromised. Populations at high risk of HIV infection may lack appropriate nourishment prior to infection by HIV. Starvation and undernourishment severely compromise the immune system thereby increasing both susceptibility to HIV infection and progression of HIV/AIDS. (<a href="./references#CD004536-bbs2-0087" title="ScrimshawNS , SanGiovanniJP . Synergism of nutrition, infection, and immunity: an overview. American Journal of Clinical Nutrition1997;66(2):464S‐477S. ">Scrimshaw 1997</a>; <a href="./references#CD004536-bbs2-0065" title="AnabwaniG , NavarioP . Nutrition and HIV/AIDS in sub‐Saharan Africa: an overview. Nutrition2005;21(1):96‐99. ">Anabwani 2005</a>; <a href="./references#CD004536-bbs2-0086" title="SchaibleUE , KaufmannSH . Malnutrition and infection: complex mechanisms and global impacts.. PLoS Med2007;4(5):e115. ">Schaible 2007</a>).   </p> <p>Untreated HIV infection is characterised by increased resting energy expenditure (REE, <a href="./references#CD004536-bbs2-0076" title="KosmiskiL . Energy expenditure in HIV infection.. Am J Clin Nutr.2011;94(6):1677S‐1682S. Epub 2011 Nov 16. ">Kosmiski 2011</a>), decreased appetite, decreased intake and digestion of food and decreased absorption of nutrients (<a href="./references#CD004536-bbs2-0075" title="KoetheJR , HeimburgerDC . Nutritional aspects of HIV‐associated wasting in sub‐Saharan Africa.. Am J Clin Nutr.2010;91(4):1138S‐1142S. Epub 2010 Feb 10. ">Koethe 2010</a>). HIV‐infected individuals receiving antiretroviral therapy may experience the adverse effects of antiretroviral drugs such as nausea and insomnia, which also have a negative impact on nutrient status. Poor nutrient status may in turn exacerbate these adverse effects, in part by increased drug toxicity (<a href="./references#CD004536-bbs2-0064" title="AmmassariA , MurriR , PezzottiP , TrottaMP , RavasioL , DeLongisP , Lo CaputoS , NarcisoP , PauluzziS , CarosiG , NappaS , PianoP , IzzoCM , LichtnerM , RezzaG , MonforteA , IppolitoG , d'Arminio MoroniM , WuAW , AntinoriA , AdICONA Study Group. Self‐reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr.2001;28(5):445‐449. ">Ammassari 2001</a>; <a href="./references#CD004536-bbs2-0090" title="World Health Organisation (WHO). Scaling up antiretroviral therapy in resource‐limited settings: treatment guidelines for a public health approach. 2003 revision. Geneva, Switzerland. WHO2004. ">WHO 2004</a>; <a href="./references#CD004536-bbs2-0069" title="HardonAP , AkurutD , ComoroC , EkezieC , IrundeHF , GerritsT , KglatwaneJ , KinsmanJ , KwasaR , MaridadiJ , MorokaTM , MoyoS , NakiyembaA , NsimbaS , OgenyiR , OyabbaT , TemuF , LaingR . Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care2007;19(5):658‐665. ">Hardon 2007</a>). </p> <p>As a result of the increased REE in untreated HIV infection, both fat and protein stores are oxidised to fuel the body's energy requirements (<a href="./references#CD004536-bbs2-0081" title="MacallanDC , NobleC , BaldwinC , JebbSA , PrenticeAM , CowardWA , et al. Energy expenditure and wasting in human immunodeficiency virus infection. New England Journal of Medicine1995;333(2):83‐88. ">Macallan 1995a</a>; <a href="./references#CD004536-bbs2-0066" title="BatterhamM , GarsiaRA . A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology2001;24(4):232‐40. ">Batterham 2001</a>; <a href="./references#CD004536-bbs2-0076" title="KosmiskiL . Energy expenditure in HIV infection.. Am J Clin Nutr.2011;94(6):1677S‐1682S. Epub 2011 Nov 16. ">Kosmiski 2011</a>). Whole‐body protein turnover is up to 25% higher in untreated HIV‐infected individuals than in HIV‐negative controls (<a href="./references#CD004536-bbs2-0082" title="MacallanDC , McNurlanMA , MilneE , CalderAG , GarlickPJ , GriffinGE . Whole‐body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. American Journal of Clinical Nutrition1995;61(4):818‐826. ">Macallan 1995b</a>) and fat stores are replenished more readily than protein stores even when nutrition is adequate (<a href="./references#CD004536-bbs2-0078" title="KotlerDP , RosenbaumK , WangJ , PiersonRN . Studies of body composition and fat distribution in HIV‐infected and control subjects. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1999;20(3):228‐237. ">Kotler 1999</a>). The resultant loss of body protein could further compromise the immune system of the HIV‐infected individual (<a href="./references#CD004536-bbs2-0086" title="SchaibleUE , KaufmannSH . Malnutrition and infection: complex mechanisms and global impacts.. PLoS Med2007;4(5):e115. ">Schaible 2007</a>). </p> <p>HIV‐associated weight loss and wasting are independent contributing factors to poor clinical outcomes in people living with HIV/AIDS (<a href="./references#CD004536-bbs2-0089" title="WheelerDA , GibertCL , LaunerCA , MuurahainenN , ElionRA , AbramsDI , BartschGE . Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol.1998;18(1):80‐85. ">Wheeler 1998</a>; <a href="./references#CD004536-bbs2-0077" title="KotlerDP . Malnutrition in HIV infection and AIDS. AIDS1989;3(Suppl 1):S175‐80. ">Kotler 1989</a>). In most cases, acute weight‐loss episodes are associated with secondary infections (<a href="./references#CD004536-bbs2-0080" title="MacallanDC , NobleC , BaldwinC , FoskettM , McManusT , GriffinGE . Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. The American Journal of Clinical Nutrition1993;58(3):417‐424. ">Macallan 1993</a>). Once the secondary infections are successfully treated and energy intake is increased sufficiently, patients are able to regain weight and remain weight‐stable (<a href="./references#CD004536-bbs2-0083" title="MacallanDC . Sir David Cuthbertson Prize Medal Lecture. Metabolic abnormalities and wasting in human immunodeficiency virus infection. The Proceedings of the Nutrition Society1998;57(3):373‐380. ">Macallan 1998</a>). Instances of chronic weight loss are normally associated with secondary gastrointestinal infections and subsequent malabsorption (<a href="./references#CD004536-bbs2-0080" title="MacallanDC , NobleC , BaldwinC , FoskettM , McManusT , GriffinGE . Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. The American Journal of Clinical Nutrition1993;58(3):417‐424. ">Macallan 1993</a>). </p> <p>Weight loss and low Body Mass Index (BMI &lt; 17kg.m<sup>‐2</sup>), a proxy for poor nutritional status, are independent predictors of mortality, particularly in resource‐limited settings (<a href="./references#CD004536-bbs2-0084" title="MarazziMC , LiottaG , GermanoP , GuidottiG , AltanAD , CeffaS , LioMM , Nielsen‐SainesK , PalombiL . Excessive early mortality in the first year of treatment in HIV type 1‐infected patients initiating antiretroviral therapy in resource‐limited settings. AIDS Res Hum Retroviruses.2008;24(4):555‐560. ">Marazzi 2008</a>; <a href="./references#CD004536-bbs2-0079" title="LiuE , SpiegelmanD , SemuH , HawkinsC , ChalamillaG , AveikaA , NyamsangiaS , MehtaS , MtasiwaD , FawziW . Nutritional status and mortality among HIV‐infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis.2011;204(2):282‐290. ">Liu 2011</a>). This remains true despite the introduction of ART. In a recent study, <a href="./references#CD004536-bbs2-0079" title="LiuE , SpiegelmanD , SemuH , HawkinsC , ChalamillaG , AveikaA , NyamsangiaS , MehtaS , MtasiwaD , FawziW . Nutritional status and mortality among HIV‐infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis.2011;204(2):282‐290. ">Liu 2011</a> found that HIV‐infected patients with low BMI (BMI&lt;17kg.m<sup>‐2</sup>) had a significantly higher risk of early mortality (death within 3 months) following the initiation of ART. Of the patients who survived the first 3 months of ART, those who experienced weight loss had a higher risk of subsequent death compared to those who were weight stable during this period. </p> </section> </section> <section id="CD004536-sec-0040"> <h3 class="title" id="CD004536-sec-0040">Description of the intervention</h3> <section id="CD004536-sec-0041"> <h4 class="title">Macronutrients and macronutrient interventions</h4> <p>Macronutrients are variably defined but are classically understood to be essential nutrients that are required by the body in relatively large amounts. Dorland’s Illustrated Medical Dictionary defines macronutrients as carbohydrates, fats and proteins and states that: ‘minerals necessary in relatively large amounts (for example Calcium, Chloride, Magnesium, Phosphorus, Potassium and Sulphur) are sometimes included and sometimes excluded.’ (<a href="./references#CD004536-bbs2-0068" title="DorlandWAN . Dorland's illustrated medical dictionary. Philadelphia: Sanders, 2007. ">Dorland 2007</a>). </p> </section> <section id="CD004536-sec-0042"> <h4 class="title">Macronutrient interventions</h4> <p>In this review, a macronutrient intervention could be any intervention given to provide protein and/or energy, ie through carbohydrates and/or fat, by replacing or supplementing the normal diet (for example, high or low fat/carbohydrate/protein diets). Macronutrient interventions can also include dietary supplements not given specifically to provide energy but rather to test the effectiveness of specific nutritional elements (for example, amino acids, whey protein concentrate and Spirulina). Macronutrient interventions may be delivered in liquid, powder or tablet formulation. In resource‐scare regions where malnutrition is prevalent, food programmes deliver replacement food or foodstuffs in addition to local staple foods in the form of 1) high‐energy ready‐to‐use therapeutic foods, 2) corn‐soya blends, or 3) fortified blended foods, ready‐to‐use foods, high‐energy biscuits and compressed food bars (<a href="./references#CD004536-bbs2-0092" title="http://www.wfp.org/nutrition/special‐nutritional‐products. ">World Food Programme</a>; <a href="./references#CD004536-bbs2-0074" title="KoetheJR , ChiBH , MegazziniKM , HeimburgerDC , StringerJS . Macronutrient supplementation for malnourished HIV‐infected adults: a review of the evidence in resource‐adequate and resource‐constrained settings. Clinical Infectious Diseases2009;49(5):787‐90. ">Koethe 2009</a>). Macronutrient supplements may be fortified with micronutrients in the form of vitamins and trace elements. An existing Cochrane review, revised in 2010, has summarised the effects of micronutrient supplementation in people with HIV/AIDS (<a href="./references#CD004536-bbs2-0073" title="IrlamJH , VisserMM , RollinsNN , SiegfriedN . Micronutrient supplementation in children and adults with HIV infection. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD003650.pub3] ">Irlam 2010</a>). </p> </section> </section> <section id="CD004536-sec-0043"> <h3 class="title" id="CD004536-sec-0043">Why it is important to do this review</h3> <p>People living with HIV are at great risk of nutritional disorders. Adequate nutrition is critical for optimal immune function. Dietary therapy is, therefore, an important adjunct in the clinical care of patients infected with HIV. </p> <p>HIV infection is most prevalent in parts of the world where food security is compromised. Populations at high risk of HIV infection may lack appropriate nourishment prior to infection by HIV. Starvation and undernourishment severely compromises the immune system thereby increasing susceptibility to HIV infection and progression of the disease (<a href="./references#CD004536-bbs2-0065" title="AnabwaniG , NavarioP . Nutrition and HIV/AIDS in sub‐Saharan Africa: an overview. Nutrition2005;21(1):96‐99. ">Anabwani 2005</a>). Poor nutrient status in HIV‐infected individuals is an independent predictor of mortality in both untreated and treated individuals with HIV (<a href="./references#CD004536-bbs2-0084" title="MarazziMC , LiottaG , GermanoP , GuidottiG , AltanAD , CeffaS , LioMM , Nielsen‐SainesK , PalombiL . Excessive early mortality in the first year of treatment in HIV type 1‐infected patients initiating antiretroviral therapy in resource‐limited settings. AIDS Res Hum Retroviruses.2008;24(4):555‐560. ">Marazzi 2008</a>; <a href="./references#CD004536-bbs2-0075" title="KoetheJR , HeimburgerDC . Nutritional aspects of HIV‐associated wasting in sub‐Saharan Africa.. Am J Clin Nutr.2010;91(4):1138S‐1142S. Epub 2010 Feb 10. ">Koethe 2010</a>; <a href="./references#CD004536-bbs2-0079" title="LiuE , SpiegelmanD , SemuH , HawkinsC , ChalamillaG , AveikaA , NyamsangiaS , MehtaS , MtasiwaD , FawziW . Nutritional status and mortality among HIV‐infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis.2011;204(2):282‐290. ">Liu 2011</a>).    </p> <p>The World Health Organization is currently updating the guidelines for nutritional interventions. Current guidelines for HIV‐specific populations are based on an appraisal of the evidence conducted in 2003 and a consultative meeting in 2005. A review of all the evidence conducted on searches as up‐to‐date as feasible, is desirable when informing guidelines. This 2011 review update seeks to provide a comprehensive summary of the current evidence for macronutrient supplementation in HIV‐infected individuals. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004536-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004536-sec-0044"></div> <p>The objective of this review was to evaluate the effectiveness of various macronutrient interventions in reducing morbidity and mortality in adults and children living with HIV infection. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004536-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004536-sec-0045"></div> <section id="CD004536-sec-0046"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004536-sec-0047"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) evaluating the effectiveness of various macronutrient interventions in the management of individuals living with HIV/AIDS were considered. Studies were included regardless of the setting in which they were carried out. </p> </section> <section id="CD004536-sec-0048"> <h4 class="title">Types of participants</h4> <p>Studies involving adults and children with HIV/AIDS were included in the review. Studies involving HIV‐infected pregnant women were excluded from the review. Studies involving participants with TB/HIV co‐infection were included if the randomisation of the participants was stratified according to HIV infection status. </p> </section> <section id="CD004536-sec-0049"> <h4 class="title">Types of interventions</h4> <p><b><i>Experimental</i> </b> </p> <p>In this review, a macronutrient intervention could be any intervention given to provide protein and/or energy, ie through carbohydrates and/or fat, by replacing or supplementing the normal diet (for example, high or low fat/carbohydrate/protein diets). Macronutrient interventions could also include dietary supplements not given specifically to provide energy but rather to test the effectiveness of specific nutritional elements (for example, amino acids, whey protein concentrate and Spirulina). In this instance, only interventions providing 1g or more of the specific macronutrient element were included in the review. Only macronutrient interventions administered orally and for four weeks or longer were included in the review. </p> <p><b><i>Control</i> </b> </p> <p>The control groups could include usual diet, no macronutrient supplementation, dietary counselling or non‐nutritive placebo. </p> <p>Studies assessing the effects of total parenteral or enteral nutritional interventions administered via tube feeding were excluded from this review. Macronutrient interventions fortified with micronutrients were included in the review. However, trials evaluating micronutrient supplements alone in people with HIV infection were excluded, as they form part of an existing Cochrane review (<a href="./references#CD004536-bbs2-0073" title="IrlamJH , VisserMM , RollinsNN , SiegfriedN . Micronutrient supplementation in children and adults with HIV infection. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD003650.pub3] ">Irlam 2010</a>). Studies assessing nutritional interventions for reducing HAART‐related co‐morbidities in HIV‐infected people were also excluded as these studies would form part of another Cochrane protocol (<a href="./references#CD004536-bbs2-0085" title="Marti‐CarvajalA . Pharmacological interventions for treating dyslipidemia in patients with HIV infection. Cochrane Database of Systematic Reviews2011. ">Marti‐Carvajal 2010</a>) </p> <p>Randomised controlled trials comparing the effectiveness of two or more macronutrient interventions (i.e. studies which did not have a control group that received no macronutrient supplementation, dietary counselling or non‐nutritive placebo) in HIV‐infected individuals were not included in review, however, data from these studies was included in <a href="#CD004536-tbl-0002">Table 1</a>. </p> <div class="table" id="CD004536-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of comparative studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bakeine 1997 (Abstract)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Uganda</p> <p>SETTING:</p> <p>Joint Clinical Research Centre, Kampala</p> <p>FOLLOW UP:</p> <p>At days1 and 56 weight, triceps skinfold, serum albumin and CD4 cell count were evalulated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>Early stage (CDC stage I‐III), largely asymptomatic HIV‐infected patients</p> <p>EXCLUSION CRITERIA</p> <p>Number randomised: 22 (7 males, 15 females)</p> <p>Mean age at baseline: 31±12 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In addition to normal diet patients received daily a 4.2 MJ supplement of either Nutrifil (Nutrifil is cow’s‐ milk‐based, is highly digestible and contains a wide range of micronutrients. It consists of 150g protein, 110g fat, 650g carbohydrate/kg) or Cornsoy blend (160g protein, 60g fat, 660g carbohydrate/kg) for 8 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>                                                                Nutrifil‐supplemented group (<i>n</i> 11)                  CSB‐supplemented group (<i>n</i> 11) </p> <p>                                                                                                                                                                            </p> <p>                                                                      Day 1                    Day 56                              Day 1                          Day 56              </p> <p>                                                                Mean         <i>SE</i>            Mean      <i> SE</i>                 Mean             <i> SE</i>             Mean        <i> SE</i> </p> <p>                                                                                                                                                                                     </p> <p>Body weight (kg)                                 53.4           2.9         55.5**     3.0                 60.4                3.3           61.3*        3.5 </p> <p>TSFT (mm)                                           11.6           1.4         14.7**     1.9                 11.8                2.4           13.3*         2.5 </p> <p>Serum albumin (g/L)                           37.6           1.3         41.8**     1.0                 37.2             1.0         40.2*             1.2       </p> <p>CD4/ mm3                                            423            81          400            81               456                  97           328*          45 </p> <p>Significantly different from day 1,  same group:   *<i>P</i> &lt; 0.05,   **<i>P</i> &lt; 0.005, ( paired tests). </p> <p>The mean increase in the Nutrifil group (2.14 (<i>SE</i> 0.6) kg) was greater than that in the CSB group (0.98 (<i>SE</i> 0.5) kg). Increments in TSFT and serum albumin were also seen in both groups with increases again being greater in the Nutrifil group. Mean CD4 cell counts decreased in the CSB group but remained unchanged in the Nutrifil group. Weight change was positively correlated to changes in the CD4 cell count in the Nutrifil group (<i>r</i>  0.66  <i>P</i> &lt; 0.05), but not in the CSB group (<i>r</i> 0.03, NS). Furthermore, five patients (45%) in the Nutrifil group experienced a rise in CD4 cell count at the end of the study, compared with two (18%) in the CSB group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Charlin 2002 (Full text)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Chile</p> <p>SETTING:</p> <p>AIDS wards in the Jose Joaquin Aguirre and San Juan de Dios Hospitals in Santiago, Chile. </p> <p>DURATION OF RECRUITMENT:</p> <p>Not specified</p> <p>DURATION OF TRIAL:</p> <p>September 1994‐August 1995</p> <p>FOLLOW‐UP:</p> <p>At baseline, 45th and 90th day of trial height, weight and skinfold measurements (to determine fat mass and fat free mass) and CD4 and CD8 cell count were assessed. 24 hour urinary ureic nitrogen was determined as well as Resting Energy Expenditure. Nutritional intake was recorded using 24‐hour recall taken on three alternate days before beginning of study and during the supplementation period. Systemic signs and symptoms were recorded each day. </p> <p>ETHICS: <br/> Not reported on in the trial <br/> TRIAL REGISTRATION: <br/> FUNDING: </p> <p>Study supported from a grant from research project FONDECYT 1940507 and collaboration from Davis Laboratories, Braun Co, Chile </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>HIV‐infected outpatients</p> <p>EXCLUSION CRITERIA:</p> <p>Not specified</p> <p>Participants enrolled: 46 <br/> Participants randomised: 46 <br/> Mean age at baseline: 37 ± 12 years <br/> Sex at baseline: 4 females; 42 males <br/> Mean BMI at baseline: 18.5±1.4 kg.m<sup>‐2</sup> (group 1); 18.6±1.2 kg.m<sup>‐2</sup> (group 2) </p> <p>Stage of HIV: 11 patients category A or B; 35 patients category C (AIDS) according to Centre for Disease Control guidelines, 1992 </p> <p>ARV therapy status: 11 patients on zidovudine therapy in group 1; 12 patients on zidovudine therapy in group 2 </p> <p>At baseline energy intake was greater in group 1 (34.2±8.8 kcal/kg/d) than group 2 (27.2±7.5 kcal/kg/d). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1:</p> <p>Patients received polymetric diet during first 45 days then regular food for 45 days. Polymetric diet consisted of powdered drink containing 103kcal, 3.6g protein (sodium and calcium caseinate: 14% contribution to total energy), 13.0g carbohydrates (maltodextrins) and 4g fats (sunflower seed oil and coconut oil) per 10 dl. This formula provides the US‐RDA requirements for adults of vitamins and micronutrients with 200 dl per day. Regular food consisted of cereals, diary products, eggs albumin˜15% of protein contribution to total energy. </p> <p>Group 2:</p> <p>Patients received regular food for 45 days then polymetric diet for 45 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality: 3 patients died in Group 1; 8 patients died in Group 2 in the first 45 days of the trial </p> <p>Significant increase in weight, BMI and fat‐free mass (FFM) was observed in both groups. An increase in fat mass was observed in Group 2. No significant differences were noted in plasma albumin, CD4 and CD8 cell count. Energy intake increased in both groups. with a significant increase noted in group 2 between the 45th day to the 90th day. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Method not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Method not described in report. <br/> Blinding of participants and personnel (performance bias): High risk ‐ Participants could not be blinded as the appearance was different between the supplements. </p> <p>Blinding of outcome assessment (detection bias): Unclear risk ‐ It is not clear if the outcome assessors were blinded. <br/> Incomplete outcome data (attrition bias): 11/46 patients died (24% attrition) <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlebowski 1993 (Abstract)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>USA</p> <p>FOLLOW UP:</p> <p>Parameters evaluated at 0 (baseline), 3, and 6 mo included adherence, weight change, anthropometric measurements, serum biochemical indices, gastrointestinal symptoms, physical performance, and intercurrent health events (including hospitalizations). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>HIV‐infected, early stage, relatively asymptomatic patients</p> <p>EXCLUSION CRITERIA</p> <p>Number randomised: 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Received 2‐3 8 oz cans of ready‐to‐feed peptide‐based enteral formula consisting of 18.7% protein, 65.5% carbohydrate, 15.8% fat and 1.28 kcal/ml per day for 6 months (NEF) </p> <p>CONTROL:</p> <p>Received 2‐3 8oz cans of standard enteral formula consisting of 14% protein, 55% carbohydrate, 31% fat, 1.06 kcal/ml per day for 6 months (SEF). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 patients completed the study. Those supplemented with NEF maintained their body weight significantly (p = 0.04) better, had significantly (p = 0.03) more stable triceps skin‐fold measurements, and had significantly (p = 0.04) lower blood urea nitrogen than patients consuming the SEF supplement. Consumption of the NEF supplement was also associated with significantly reduced hospitalizations during the 3‐ to 6‐mo evaluation period (p = 0.02). The NEF supplement was well tolerated and did not result in untoward clinical effects. These data suggest that supplemental use of an NEF provides superior nutritional management compared with an SEF for patients with early‐stage HIV infection. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attrition rate: 24/80 loss to follow up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comi 1996 (Abstract)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Italy</p> <p>FOLLOW UP:</p> <p>Nutritional status was evaluated by anthropometric parameters, hematological indexes, and by tetrapolar bioelectrical impedance analysis (BIA), before and after one month of diet. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>AIDS patients (CDC stage IV CI)</p> <p>Number randomised: 50 (36 males; 14 females)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group A: treated with normocaloric (35Kcal/kg usual weight), normoproteic (1g/kg usual weight) diet for 1 month; <br/> Group B: treated with an hypercaloric (40Kcal/kg of usual weight), hyperproteic (2g/kg usual weight) dietetic regimen for 1 month. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group A: Statistical significant increase in Body Weight (pre: 59.9±9.9kg; post: 61.2±9.7, p&lt;0.001), BMI (pre: 20.5±3.0, post: 21.0±2.9, p&lt;0.001) and Total Cholesterol (pre:144.3±39.5, post: 162.5±62.8, p&lt;0.04), Triceps skinfold and Mid arm muscle area increased but not significantly. Group B: Significant increase in body weight (pre: 59.1±9.9, post: 60.4±10.4, p&lt;0.001), BMI (pre: 20.3±3.0, post: 20.7±3.0, p&lt;0.001), Tricep skinfold (pre: 6.8±4.1, post: 7.4±4.2, p&lt;0.009), mid arm muscle area (pre: 41.4±11.8, post: 42.9±11.5, p&lt;0.002), HDL Cholesterol (pre: 31.8±10.1, post: 37.8±12.1, p&lt;0.001). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation:</p> <p>Allocation concealment:</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>de Luis 2010</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY</p> <p>Spain</p> <p>SETTING</p> <p>Not reported</p> <p>DURATION OF TRIAL</p> <p>Not reported <br/> FOLLOW UP </p> <p>At baseline and 3 months: prospective serial assessment of nutritional status, nutrient intake (24 hour food recall), GI symptoms, anthropometry, intercurrent health events, blood chemistry, liver function and plasma fatty acids </p> <p>ETHICS</p> <p>Written informed consent received. Ethics and regulatory approval not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA</p> <p> <ul id="CD004536-list-0001"> <li> <p>HIV‐infected patients (30‐60 years old)</p> </li> <li> <p>Previous weight loss (&gt;5% in previous 3 months)</p> </li> <li> <p>Absence of chronic febrile illness</p> </li> <li> <p>Absence of severe GI symptoms (diarrhoea for &gt;30 days or &gt;3 times per day)</p> </li> <li> <p>adequate liver and kidney function</p> </li> <li> <p>Remain on HAART treatment for 3 months prior to and for duration of tria</p> </li> </ul> </p> <p>Number enrolled: 33</p> <p>Number randomised: 30</p> <p>Mean age at baseline:41.6±8.4 years in ENSURE group; 42.1±4.8 years in PROSURE group</p> <p>Mean BMI at baseline:19.2±0.9 kg.m<sup>‐2</sup> in ENSURE group; 18.8±2.2 kg.m<sup>‐2</sup> in PROSURE group </p> <p>All patients receiving HAART therapy</p> <p>CDC class A‐B (%):54.7% in ENSURE group; 55.7% in PROSURE group</p> <p>CDC class C (AIDS, %):53.3% in ENSURE group; 60% in PROSURE group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION</p> <p>2 can of PROSURE per day (236 ml per can) containing:</p> <p> <ul id="CD004536-list-0002"> <li> <p>Caloric density (Kcal/ml): 1.2</p> </li> <li> <p>Protein (g/l): 66 (21.6%)</p> </li> <li> <p>Fat (g/l): 25.6 (18.8%)</p> </li> <li> <p>Carbohydrate (g/l): 183 (59.6%)</p> </li> <li> <p>Dietary fibre (g/l): 20.4</p> </li> <li> <p>n‐3 fatty acids (mg/l): 6.29</p> </li> </ul> </p> <p>Dietary counselling also provided</p> <p>CONTROL</p> <p>2 cans of ENSURE per day (236 ml per day) containing:</p> <p> <ul id="CD004536-list-0003"> <li> <p>Caloric density (Kcal/ml): 1.06</p> </li> <li> <p>Protein (g/l): 37.2 (14%)</p> </li> <li> <p>Fat (g/l): 37.2 (31.5%)</p> </li> <li> <p>Carbohydrate (g/l): 145 (54.5%)</p> </li> <li> <p>Dietary fibre (g/l): 0</p> </li> <li> <p>n‐3 fatty acids (mg/l): 0</p> </li> </ul> </p> <p>Dietary counselling also provided</p> <p>ADHERENCE:</p> <p>Patient reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes were not clearly delineated into primary and secondary. Although reported that study powered to detect 4% change in body weight. Total calorie and protein consumption were similar in both groups at 3 months with a significant increase in each group for both calorie (ENSURE: 18.8% increase; PROSURE: 19% increase) and protein intakes (ENSURE:18.5% increase, PROSURE:18.4% increase). Significant and sustained increase in weight due to increase in fat‐free mass in ENSURE group and increase in both fat‐free mass and fat mass in PROSURE group. No hospitalisations or adverse events reported or observed throughout trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Unclear risk ‐ Not reported for participants and personnel <br/> Blinding of outcome assessment (detection bias): Unclear risk ‐ Not reported for outcome assessors <br/> Incomplete outcome data (attrition bias): Low risk ‐ All randomised participants completed trial <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>de Luis Roman 2001</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Spain</p> <p>SETTING:</p> <p>Not reported</p> <p>DURATION OF TRIAL:</p> <p>Not reported</p> <p>FOLLOW UP:</p> <p>At baseline and 3 months: prospective serial assessment of nutritional status, nutrient intake (24 hour food recall), GI symptoms, anthropometry, intercurrent health events, blood chemistry, liver function and plasma fatty acids </p> <p>ETHICS:</p> <p>Patients provided informed consent (not sure if written or oral). Ethics or regulatory approval not specified in the report </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0004"> <li> <p>HIV‐infected patients aged between 18‐60 years with or without AIDS defining illness</p> </li> <li> <p>Absence of chronic febrile illness</p> </li> <li> <p>Weight stable</p> </li> <li> <p>Absence of severe GI symptoms (diarrhoea for &gt;30 days or &gt;3 times per day)</p> </li> <li> <p>adequate liver and kidney function</p> </li> <li> <p>Remain on HAART treatment for 3 months prior to and for duration of trial</p> </li> </ul> </p> <p>Number enrolled: 91</p> <p>Number randomised: 74</p> <p>Percentage male at baseline: 77.6% in ENSURE group; 78.6% in ADVERA group</p> <p>Mean age at baseline:37.9±10 years in ENSURE group; 38.9±8.8 years in ADVERA group</p> <p>Mean BMI at baseline:22±2.8 kg.m<sup>‐2</sup> in ENSURE group; 21±2.8 kg.m<sup>‐2</sup> in ADVERA group </p> <p>All patients receiving HAART therapy</p> <p>Mean CD4 count at baseline (count/ul): 454±271 in ENSURE group; 561±369 in ADVERA group </p> <p>CDC class A‐B (%):57.2% in ENSURE group; 51.1% in ADVERA group</p> <p>CDC class C (AIDS, %):42.8% in ENSURE group; 48.9% in ADVERA group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION</p> <p>3 can of ADVERA (enterotropic peptide‐based enteral formula with n‐3 fatty acids) per day (236 ml per can) containing: </p> <p> <ul id="CD004536-list-0005"> <li> <p>Caloric density (Kcal/ml): 1.28</p> </li> <li> <p>Protein (g/l): 60 (18.7%)</p> </li> <li> <p>Fat (g/l): 22.8 (15.8%)</p> </li> <li> <p>Carbohydrate (g/l): 215.8 (65.5%)</p> </li> <li> <p>Dietary fibre (g/l): 8.9</p> </li> <li> <p>n‐3 fatty acids (mg/l): 9.46</p> </li> </ul> </p> <p>Dietary counselling also provided</p> <p>CONTROL</p> <p>3 cans of ENSURE per day (236 ml per day) containing:</p> <p> <ul id="CD004536-list-0006"> <li> <p>Caloric density (Kcal/ml): 1.06</p> </li> <li> <p>Protein (g/l): 37.2 (14%)</p> </li> <li> <p>Fat (g/l): 37.2 (31.5%)</p> </li> <li> <p>Carbohydrate (g/l): 145 (54.5%)</p> </li> <li> <p>Dietary fibre (g/l): 0</p> </li> <li> <p>n‐3 fatty acids (mg/l): 0</p> </li> </ul> </p> <p>Dietary counselling also provided</p> <p>ADHERENCE:</p> <p>Patient reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD004536-list-0007"> <li> <p>Treatments with both supplements resulted in a significant and sustained increase in weight (3.2% in ENSURE group and 3.1% in ADVERA group). This increase was mostly due to fat mass (12.8% in ENSURE group and 7.5% in ADVERA group). </p> </li> <li> <p>Total body water and fat‐free mass remained unchanged</p> </li> <li> <p>CD4 counts remained stable in the ENSURE group, while a significant increase was detected in the ADVERA group from baseline to 3 months (576±403 vs. 642±394 cells per mm<sup>3</sup>, P&lt;0.05). At 3 months, the ADVERA group had a significantly higher CD4 count compared with the ENSURE group. </p> </li> <li> <p>The supplemented group had fewer hospitalizations than the standard group, but no statistical differences were found. </p> </li> <li> <p>No side effects to the supplements were reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Unclear risk ‐ Not reported for participants and personnel <br/> Blinding of outcome assessment (detection bias): Unclear risk ‐ Not reported for outcome assessors <br/> Incomplete outcome data (attrition bias): Low risk ‐ All randomised participants completed trial <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gibert 1999</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>USA</p> <p>SETTING:</p> <p>14 administrative units comprising 55 clinics and physician offices</p> <p>DURATION OF RECRUITMENT:</p> <p>Jul 1996 ‐ December 1997</p> <p>DURATION OF TRIAL:</p> <p>Jul 1996 ‐ April 1998 (22 months: end of trial estimated to be four months after last recruitment) </p> <p>FOLLOW‐UP:</p> <p>At baseline, two month and four month visits: height and weight measured with standardized procedures using calibrated scales; body composition calculated using BIA‐101Q analyzer and Body cell mass (BCM) and total body fat (TBF) recorded. </p> <p>At 2 and 4 month visits, 24 hour dietary recall assessed using Minnesota Nutrition Data System NDS‐93 and questionnaire administered regarding aerobic and muscle‐building activities. </p> <p>ETHICS: <br/> Institutional review board approval was obtained at each unit. <br/> TRIAL REGISTRATION: <br/> FUNDING: <br/> National Institute of Allergy and Infectious Disease and Nestle Clinical Nutrition </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0008"> <li> <p>HIV‐infected adults &gt;= 13 years</p> </li> <li> <p>CD4 &lt; 200 cells/mm3</p> </li> <li> <p>Karnofsky scale &gt;= 60</p> </li> <li> <p>Stable weight (loss of no more than loss of 5% body weight recorded in 3 to 6 months prior to trial) </p> </li> <li> <p>Serum creatinine level of &lt;=2.5mg/dL</p> </li> <li> <p>Total bilirubin =&lt; 3mg/dL</p> </li> </ul> </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0009"> <li> <p>Active opportunistic infection</p> </li> <li> <p>Malignancy or Diabetes Mellitus</p> </li> <li> <p>History of phenylketonuria</p> </li> <li> <p>Appetite stimulants</p> </li> <li> <p>Anabolic steroids</p> </li> <li> <p>Caloric supplements</p> </li> <li> <p>Pregnant or breastfeeding</p> </li> <li> <p>BMI &gt;= 29kg/m</p> </li> </ul> </p> <p>Participants enrolled: 536 <br/> Participants randomised: 536 <br/> Mean age at baseline: 40.8 (SD: +/‐ 8.4 years) in the Peptamen intervention group; 39.7 years (SD: +/‐ 8.4 years) in the NuBasics intervention group; 39.9 years (SD: +/‐ 8.2 years) in the control multivitamin group <br/> Sex at baseline: 12.9% women in the Peptamen intervention group; 12.8% women in the NuBasic intervention group; 10.6% in the control group <br/> No significant differences in baseline criteria observed. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Peptamen caloric supplement, each 250ml fluid contained 250kcal comprising:</p> <p> <ul id="CD004536-list-0010"> <li> <p>10g whey protein (16% kcal)</p> </li> <li> <p>9.8g fat with 6.75g medium‐chain triglycerides (33% kcal</p> </li> </ul> </p> <p>The supplementation was a fluid and 250ml was taken twice daily</p> <p>INTERVENTION:</p> <p>NuBasics caloric supplement, each 250ml fluid contained 250kcal comprising:</p> <p> <ul id="CD004536-list-0011"> <li> <p>8.75g whey protein</p> </li> <li> <p>9.2g fat</p> </li> </ul> </p> <p>The supplementation was a fluid, bar or coffee and 500kcal was required daily. <br/> <br/> CONTROL: <br/> A daily multivitamin and mineral supplement. Form not reported. <br/> DURATION: <br/> Four months <br/> CO‐INTERVENTIONS: <br/> None reported. <br/> COMPLIANCE: <br/> Participants reported the amount of supplement consumed in the previous week to visit based on a 24 hour dietary recall. 69% was consumed in the NuBasics group and 62% in the Peptamen group using this method. However, on case‐report post the study, adherence was reported as 82% in the NuBasic group and 65% in the Peptamen group. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This three‐armed trial compared two formulations of caloric supplements: Peptamen comprised peptides and medium‐chain triglycerides (MCT) and NuBasics comprised whole protein and long‐chain triglylcerides (LCT), in patients with stable weights (no more than 5% weight loss in three to six months prior to trial). These supplements were compared with each other and with a control group of multivitamins and mineral supplementation. Both the intervention groups received the same multivitamins and mineral supplementation as the control group. Mortality was low in all three groups: one in the Peptamen group, four in the NuBasics group and three in the control group. Disease progression was also measured. For the combined outcome of disease progression or death, the authors report the raw data. In the Peptamen group, four participants progressed or died, 14 progressed or died in the NuBasics group and 12 progressed or died in the control group. We analysed the difference between the Peptamen and control groups in REVMAN and found that participants in the Peptamen group were not statistically significantly less likely to die or progress than those in the control group (RR = 0.34; 95% CI: 0.11, 1.02; p = 0.05). See Analysis 4.1 <br/> <br/> The trial reports means and standard errors for percentage change for outcomes and not the actual weight change itself. We report the outcomes as reported by the authors in the text. For mean percentage changes in body weight, there were no statistically significant differences between the three groups with a mean % change of 0.8% in the Peptamen group, 1.1% in the NuBasics group and 0.7% in the multivitamin groups. Using analysis of variance the authors report a p value of 0.74 between the groups. Mean percentage change in body cell mass (BCM) at study endpoint was not statistically significant between groups using analysis of variance (p = 0.63). The mean percentage BCM was 0.7% in the Peptamen group, 1.2% in the NuBasics group and 0.6% in the control group. <br/> <br/> Mean daily caloric intake was statistically significantly higher in the Peptamen and NuBasics groups when compared with the multivitamin control group respectively. Participants in the Peptamen group had a mean intake 325 kilocalories more than those in the control group (MD: 325.00; 95% CI: 79.66, 570.34; p = 0.009). See Analysis 4.2. Participants in the NuBasics group had a mean intake 238 kilocalories more than those in the control group (MD: 238; 95% CI: 11.58, 464.42; p = 0.04). See Analysis 4.3. There was no statistically significant difference in intake between the Peptamen and NuBasics groups (MD: 87.00; 95% CI: ‐142.89, 316.89; p = 0.46). See Analysis 4.4. <br/> <br/> More participants in the Peptamen group (22%) discontinued the trial compared with those receiving NuBasics (7%). One third of the participants discontinuing in the Peptamen group did so because of diarrhoea and nausea. In the NuBasics group none stopped due to side effects. In the control group 5% stopped and a quarter of these did so for reasons of nausea, vomiting, diarrhoea or constipation. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias):Unclear risk ‐ Random blocks of permutation of sizes 3 to 6 with equal probability stratified by unit. Actual method not reported <br/> Allocation concealment (selection bias): Low risk ‐ Allocated by telephone to Central Statistical Center <br/> Blinding of participants and personnel (performance bias): High risk ‐ No blinding of participants and not reported for personnel <br/> Blinding of outcome assessment (detection bias): High risk ‐ Measurements were done by investigators using scales so could be influenced by knowledge of treatment assignment <br/> Incomplete outcome data (attrition bias): Low risk ‐ Attrition in Peptamen = 9/178 (5%); in NuBasics = 8/179 (4.5%); in control = 15/179 (8.4%) <br/> Selective reporting (reporting bias)Unclear risk: Protocol not available. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hellerstein 1994 (Abstract)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>USA</p> <p>FOLLOW UP:</p> <p>Nutrient intake, body composition, GI symptoms, nutritional status and AIDS specific surrogate markers were assessed at 6 weeks, 6 months and 12 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with AIDS or HIV‐associated weight loss (13.2±4.2% body wt)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whole protein formula in the form of 2 8oz cans per day for 1 year (WP group)</p> <p>Peptide‐based formula in the form of 2 8oz cans per day for 1 year (PB group)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both formulas were well‐tolerated and there were no adverse effects on GI function or related symptoms. Evaluation of food and formula intake at 6 months revealed an increased intake of calories and protein in both groups. This occurred through supplement intake (500‐600 kcal/day and 17‐28g protein/day) which resulted in some decrease in spontaneous food intake (196‐382 kcal/day and 5.6‐14.45 protein/day). The net increase was approximately 400 kcal/day. REE was elevated compared to normal (110% predicted) at baseline &amp; did not change during supplementation. The response of fat free mass (FFM) at 6 wks was significantly correlated (r2 = ‐0.42, p &lt; 0.01) with baseline hepatic fat synthesis (an index of cytokine presence and metabolic dysregulation). A majority of patients maintained their entrance body weight as only 20% experienced reductions of 2.2 kg or greater. When considering all data from the 1 yr follow up, the risk of a &gt; or = 50% drop from baseline in the CD4 count was 7.4 times greater in the WP than the PB group (p &lt; 0.01). In conclusion, total intake of nutrients increased even after reduction of voluntary food intake was considered. This increased macro and micro nutrient intake resulted in apparent weight maintenance without untoward GI symptom or function. Specific dietary management with the PB formula may provide added clinical benefit based on the CD4 analyses. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mendez 1998</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>USA</p> <p>SETTING:</p> <p>Seven community research sites</p> <p>FOLLOW UP:</p> <p>Weight and body composition by single frequency bioimpedance analysis were measured monthly for 6 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>Clinically‐stable, HIV‐infected subjects with CD4+ lymphocytes below 100 cells/mm3</p> <p>Number randomised: 119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formula containing long chain triglycerides (LCT) vs formula containing medium chain triglycerides (MCT). Subjects were prescribed three cans of coded formulae to take daily as a supplement to their usual diet, for six months. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The two groups were similar at baseline. Dropout rates were high in both groups over the six month follow up. Both groups gained weight, on average, during the study. The LCT group gained significantly more weight than the MCT group (0.63 vs 0.13 kg/month, p = 0.016). In contrast, gains in body cell mass were small and similar in the two groups (0.08 vs 0.06 kg/month, p = 0.655). Subjects who dropped out before the four month follow up were more likely to have lost body cell mass during months 1‐3 than those who continued on study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ndekha 2009 (Full text)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY: <br/> Malawi <br/> SETTING: <br/> Antiretroviral therapy clinic at Queen Elizabeth Central Hospital in Blantyre <br/> DURATION OF RECRUITMENT: <br/> Jan 2006 ‐ Jan 2007 (estimated) <br/> DURATION OF TRIAL: <br/> Jan 2006 ‐ Apr 2007 (16 months) <br/> FOLLOW‐UP: <br/> At baseline, physician examination was conducted, Quality of Life questionnaire was administered and demographic data, clinical status, and anthropometric measurements, including and bioelectrical impedance analysis, were collected. <br/> At 2 weeks, 6 weeks, 10 weeks and 14 weeks clinic visits included all of the above measurements and procedures. A four‐item validated adherence questionnaire was conducted at each visit after enrolment to assess adherence to ART. <br/> Blood samples collected at baseline and 14 weeks. </p> <p>ETHICS: <br/> College of Medicine research and ethics committee, University of Malawi; Human studies committee of Washington School of Medicine; Committee for research on human subjects at University of Witwatersrand <br/> TRIAL REGISTRATION: <br/> Registered on Current Controlled Trials ISRCTN67515515 <br/> FUNDING: <br/> USAID Food and Nutrition Technical Assistance Project of the Academy for Educational Development and AIDS Care Research in Africa </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0012"> <li> <p>HIV‐infected adults &gt; 18 years</p> </li> <li> <p>Met criteria for antiretroviral therapy according to Malawian national HIV treatment guidelines (WHO clinical Stage III or IV or CD4 &lt; 250 cells/mm3) </p> </li> <li> <p>BMI &lt; 18.5</p> </li> </ul> </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0013"> <li> <p>Pregnancy or lactation</p> </li> <li> <p>Participation in another supplementary feeding programme</p> </li> </ul> </p> <p>Participants enrolled: 491 <br/> Participants randomised: 491 <br/> Mea age at baseline: 36 years (SD: +/‐ 11 years) in the intervention group; 36 years (SD: +/‐ 12 years) in the control group <br/> Sex at baseline: 62% women in the intervention group; 58% women in the control group <br/> No significant differences in baseline criteria observed. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Fortified spread 245g/day containing:</p> <p> <ul id="CD004536-list-0014"> <li> <p>35.5g protein</p> </li> <li> <p>91g fat</p> </li> <li> <p>5694kJ energy</p> </li> </ul> </p> <p>Varied micronutrients including vitamins and trace elements</p> <p>The spread was peanut‐based and was provided in 245g plastic bottles and one bottle was consumed daily. </p> <p>CONTROL:</p> <p>Corn‐soy blended flour 374g/day containing:</p> <p> <ul id="CD004536-list-0015"> <li> <p>50g protein</p> </li> <li> <p>26.2g fat</p> </li> <li> <p>5694kJ energy</p> </li> </ul> </p> <p>Varied micronutrients including vitamins and trace elements <br/> The same level of energy was provided in both supplements and was 50% of the daily estimated average energy requirements based on WHO guidelines that take into account that HIV‐infected people require 30% more energy than healthy people. The amounts of micronutrients differed between the supplements but in neither were the amounts in excess of the estimated average requirement. <br/> DURATION: <br/> Taken daily for 14 weeks <br/> COMPLIANCE: <br/> Not clearly reported but in focus groups of 42 participants in the intervention group and 53 in the corn‐soy group following the trial , the supplementation was reported to be highly appreciated and shared with family. Corn‐soy blend was more likely to be shared as required preparation. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants had a BMI &lt; 18.5 at study entry. The trial reported mortality data. Overall 131 participants died with those in the fortified spread being no more likely to die than those in the corn‐soy blend group (RR 1.05; 95% CI: 0.78, 1.41; p = 0.74). See Analysis 7.1. Although 95% Confidence Intervals were reported, no p values were provided. We recalculated the analyses in REVMAN and report these. Participants in the fortified spread group gained significantly more weight than those in the corn‐soy blend group (MD: 1.3kg; 95%CI: 0.52, 2.08; p = 0.001), had a greater gain in fat‐free body mass (MD: 0.70kg; 95% CI: 0.15, 1.25; p = 0.01) and in mid‐upper arm circumference (MD: 0.60cm; 95% CI: 0.27, 0.93; p = 0.0003). See Analysis 7.2; Analysis 7.4; Analysis 7.5. Change in BMI was also statistically significantly greater in the fortified spread group compared with the corn‐soy blend group (MD: 0.6kg; 95% CI: 0.3 to 0.9; p &lt; 0.0001). See Analysis 7.3. <br/> <br/> Change in mean CD4 count at study endpoint was not statistically significantly different between the groups. See Analysis 7.7. The authors report that viral load and quality of life also did not differ significantly between groups. The authors conducted further analyses stratifying the outcomes by diet quality on enrolment and the type of supplement. Neither of the supplements affected any of the three dietary subgroups differently. Adverse effects were not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Method not clearly reported. Reported as blocks of 50 numbers <br/> Allocation concealment (selection bias): Low risk ‐ Allocation done using sealed, unmarked, opaque envelopes which were opened in an area separate from the research and treatment room. Envelopes contained a unique number from 1 to 500 and staff member then matched the number with the food supplement. <br/> Blinding of participants and personnel (performance bias): High risk ‐ Participants could not be blinded as the appearance was different between the supplements. The personnel were blinded. <br/> Blinding of outcome assessment (detection bias): Low risk ‐ The personnel, including clinicians and nutritionist, were blinded <br/> Incomplete outcome data (attrition bias): High risk ‐ For the primary outcome of BMI and fat‐free body mass, attrition was high due to the high number of deaths: Intervention: 89/245 (32.7%); control: 80/246 (32.5%). For other outcomes, such as death, the attrition would have less potential for bias. <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pichard 1998</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY: <br/> Switzerland <br/> SETTING: <br/> Outpatient, University Hospital, Geneva <br/> DURATION OF RECRUITMENT: <br/> Not reported <br/> DURATION OF TRIAL: <br/> Not reported <br/> FOLLOW‐UP: <br/> At enrolment and at monthly visits, a clinical examination was done with weight to nearest 50g, height, and BMI calculated. <br/> At baseline, 3 months, 6 months and 12 months, bloods were taken for total leucocytes, CD4 and CD8, p24 antigen, and beta2 microglobulin. <br/> At baseline, 3 months and 6 months, the French language validated self‐applied questionnaire derived from the Medical Outcome Study 36‐item short form health survey, was administered. <br/> Food intake was monitored by a standard 3‐day calorie count food intake questionnaire. </p> <p>ETHICS: <br/> Ethics Committee of Department of Medicine at Geneva University Hospital <br/> TRIAL REGISTRATION: <br/> Could not locate trial protocol. <br/> FUNDING: <br/> Sponsorship by Sandoz Nutrition, Bern, Switzerland </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0016"> <li> <p>HIV‐infected adults (adult not defined so assumed to be &gt; 18 years)</p> </li> <li> <p>CD4 &gt;= 100 X 106/L</p> </li> </ul> </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0017"> <li> <p>Change in antiretroviral therapy in 8 weeks prior to the trial</p> </li> <li> <p>Symptomatic neuropathy or myopathy</p> </li> <li> <p>Neoplasia</p> </li> <li> <p>Endocrine disorders</p> </li> <li> <p>Diabetes Mellitus</p> </li> <li> <p>Treatment for hypo‐ or hyperthyroidism</p> </li> <li> <p>Renal failure</p> </li> <li> <p>Liver cirrhosis</p> </li> <li> <p>GIT resection</p> </li> <li> <p>Psychiatric disorders</p> </li> <li> <p>Active intravenous use</p> </li> </ul> </p> <p>Participants randomised: 64 <br/> Baseline characteristics only reported for 55 participants who completed the study. <br/> Mean age at baseline: 36.7 years +/‐ SEM: 1.6 years in the Arginine group; 32.6 years +/‐ 1.8 years in the control group <br/> Sex at baseline: 4/27 (14.8%) women in the intervention group; 7/28 (25%) women in the control group <br/> No significant differences in baseline characteristics were observed. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Enriched omega‐3 fatty acid supplementation containing 606kcal comprising:</p> <p> <ul id="CD004536-list-0018"> <li> <p>33g protein (22% of total energy content)</p> </li> <li> <p>26g casein</p> </li> <li> <p>7.4g arginine</p> </li> <li> <p>16.8g fat (25% of total energy content)</p> </li> <li> <p>4g essential fatty acids</p> </li> <li> <p>2.4g omega‐6 fatty acid</p> </li> <li> <p>1.7g omega‐3 fatty acid</p> </li> <li> <p>80.4g carbohydrates (53% of total energy content)</p> </li> <li> <p>10g dietary fibre</p> </li> </ul> </p> <p>The supplementation was taken as two servings daily of 76g powder) for 6 months.</p> <p>CONTROL:</p> <p>Standard supplementation containing 606kcal comprising:</p> <p> <ul id="CD004536-list-0019"> <li> <p>26 protein (17% of total energy content)</p> </li> <li> <p>26g casein</p> </li> <li> <p>16.8g fat (25% of total energy content)</p> </li> <li> <p>2.4g essential fatty acids</p> </li> <li> <p>2.4g omega‐6 fatty acid</p> </li> <li> <p>0.1 omega‐3 fatty acid</p> </li> <li> <p>0.12g alpha‐linoleic acid</p> </li> <li> <p>88.0g carbohydrates (58% of total energy content)</p> </li> <li> <p>10g dietary fibre</p> </li> </ul> </p> <p>The supplementation was taken as two servings daily of 76g powder for 6 months. <br/> COMPLIANCE: <br/> Compliance reported as percentage of patients completing the trial: 70% completed the trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIMARY OUTCOMES:</p> <p>Primary outcomes not clearly reported in the text. Protein intake and weight gain reported prominently. In the abstract main outcome measures listed include: </p> <p> <ul id="CD004536-list-0020"> <li> <p>Disease progression measured by AIDS‐defining events</p> </li> <li> <p>CD4 and CD8 counts</p> </li> <li> <p>Viraemia</p> </li> <li> <p>Tumour necrosis factor soluble receptors</p> </li> <li> <p>Nutritional status determined by anthropometric, bioelectrical impedance and dietetic assessment </p> </li> </ul> </p> <p>SECONDARY OUTCOMES: <br/> Change in fat mass <br/> Total energy intake <br/> ADVERSE EVENTS: <br/> Tolerance and appetite and gastrointestinal symptoms recorded using standard questionnaire. </p> <p>RESULTS:</p> <p>Fifty‐five patients completed the protocol. Compliance with and tolerance of oral nutritional supplement during the 6‐month period was excellent. In both groups of patients the following were found: total energy intake was transiently increased and then returned to baseline level; nitrogen/energy intake ratio was increased throughout the study; gain of body weight and fat mass were approximately 2 and 1kg, respectively, over 6 months, and were similar in both groups. In addition, CD4 and CD8 lymphocyte counts, viraemia, tumour necrosis factor soluble receptors remained statistically unchanged and were similar in both groups. Enrichment of an oral nutritive supplement with arginine and omega‐3 fatty acids did not improve immunological parameters. However, body weight increased in both groups </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Unclear risk ‐ Reported as 'double‐blind' but not stated clearly for participants and personnel <br/> Blinding of outcome assessment (detection bias): Unclear risk ‐ Reported as 'double‐blind' but not stated clearly for outcome assessors <br/> Incomplete outcome data (attrition bias): High risk ‐ Attrition was high: 5/32 (29.1%) in the Arginine group; 4/32 (24.3%) in the standard group <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PrayGod 2011</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Tanzania <br/> SETTING: <br/> Four TB clinics in Mwanza city, under the Tanzanian National TB and Leprosy Programme (NTLP) <br/> DURATION OF TRIAL: </p> <p>April 2006‐March 2009 <br/> FOLLOW‐UP: </p> <p>Weight, arm fat area, arm muscle area and hand grip strength assessed at 2 months and 5 months </p> <p>ETHICS: <br/> Based on guidelines according to Declaration of Helsinki. National Medical Research Coordinating Committee of the National Institue of medical Research in Tanzania and approval from the Danish National Committee on Biomedical Research Ethics. Written informed consent obtained from all patients. <br/> TRIAL REGISTRATION: <br/> ClinicalTrials.gov identifier: NCT00311298 <br/> FUNDING: </p> <p>The Danish Council for Independant Research, Danida and the University of <br/> Copenhagen </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>New or relapse PTB/HIV‐co‐infected patients older than 15 years and residents of Mwanza City </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0021"> <li> <p>Extra‐pulmonary TB</p> </li> <li> <p>pregnancy</p> </li> <li> <p>Terminal illness</p> </li> </ul> </p> <p>Number randomised:377</p> <p>Number included in analyses:166 (2 months); 151 (5 months)</p> <p>Mean age at baseline: 34.7±10.3 years in energy‐protein group; 36.2±9.5 years in control group </p> <p>Sex ratio (M/F) at baseline: 95 males: 94 females in energy‐protein group; 95 males: 93 females in control group </p> <p>Mean BMI at baseline: 18.7±2.9 kg.m<sup>‐2</sup> in energy‐protein group; 18.5±2.8 kg.m<sup>‐2</sup> in control group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Intervention group received 6 daily energy‐protein biscuits for the first 60 days of treatment, of which one contained the additional micronutrients. Energy‐protein biscuit contained 4.5 g protein, 615 kilojoules energy, 120 mg phosphorous, 120 mg calcium, 36 mg magnesium, 70 mg sodium, 150 mg potassium, and traces &lt;1 mg of iron and zinc. Energy‐protein biscuit with additional micronutrients contained all of the above plus 1.5 mg vitamin A, 20 mg thiamin, 20 mg riboflavin, 25 mg vitamin B6, 50 μg vitamin B12, 0.8 mg folic acid, 40 mg niacin, 200 mg vitamin C, 60 mg vitamin E, 5 μg vitamin D, 0.2 mg selenium, 5 mg copper, 30 mg zinc. </p> <p>CONTROL:</p> <p>The control group received one daily energy‐protein biscuit with additional micronutrients.</p> <p>ADHERENCE:</p> <p>Either by direct observation or use of a log book recording intake of supplement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In energy‐protein group: 37/189 lost to follow up and in control group: 35/188 lost to follow up. There were no effects on any outcome at 2 months, but energy–protein supplementation was associated with a 1·3 (95% CI 20·1, 2·8) kg marginally significant gain in handgrip strength at 5 months. At 2 months, there was an interaction between energy–protein supplementation and CD4 count level for weight (P<sub>interaction</sub> =0·03), which was explained by a 1·9 kg (95% CI 0·1, 3·7; P¼0·04) higher weight gain among patients with CD4 counts of 350 cells/ml or higher, and the lack of effect among those who had CD4 counts below 350 cells/ml (20·2 kg; 95% CI 21·3, 0·8; P¼0·66). Similarly, at 5 months, energy–protein supplementation led to a 2·3 (95% CI 0·6, 4·1) kg higher handgrip strength gain among patients with CD4 counts&lt;350 cells/ml, but not in those with high CD4 counts (P<sub>interaction</sub> =0·04). In conclusion, energy–protein supplementation to PTB/HIV‐co‐infected patients had no overall effects on weight and body composition, but was associated with marginally significant gain in handgrip strength. More <br/> research is needed to develop an effective supplement, before it is recommended to TB programmes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of Bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Low risk 'Computer‐generated randomisation sequence, using permuted blocks of ten' <br/> Allocation concealment (selection bias): Low risk 'The allocation sequence was used by designated research staff to sequentially arrange and label supplement packs with identity numbers ranging from 1 to 500. During the study the randomisation sequence and code were kept in a safe cabinet only accessible by designated research staff. Recruitment was done by clinic staff. The same designated research staff not employed at the study clinics assigned an identity number to the recruited patient and sent the corresponding nutritional pack to the respective clinic'. <br/> Blinding (performance bias and detection bias): High risk Blinding was not possible due to the nature of the intervention <br/> Incomplete outcome data (attrition bias): Low risk At 2 and 5 months, 12.2% and 19.1% of patients were lost to follow‐up. However, the proportions lost to follow‐up were similar across the intervention and control arms of the study. <br/> Selective reporting (reporting bias): Unclear risk. Trial protocol not retrieved. Deaths and cure are not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sattler 2008</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY: <br/> USA and Puerto Rico <br/> SETTING: <br/> 15 Adults AIDS Clinical Trials Group (ACTG) ambulatory research sites based at tertiary hospitals <br/> DURATION OF RECRUITMENT: <br/> Feb 1999 ‐ Dec 1999 <br/> DURATION OF TRIAL: <br/> 13 months (estimated from final recruitment month plus12 weeks follow‐up) <br/> FOLLOW‐UP: <br/> At baseline, physician examination and outcome data collected, including anthropometric measurements with weight measured using a calibrated scale. <br/> At 6 weeks, above repeated and three‐day dietary diary administered by dietician. <br/> At 12 weeks, above repeated and three‐day dietary diary administered by dietician. <br/> Routine overnight fasting bloods taken at all three follow‐up visits </p> <p>ETHICS: <br/> Approved by the Instititional Review Board at each ACTG site. <br/> FUNDING: <br/> Funded by National Institute of Allergy and Infectious Diseases through ACTG 01 grant. <br/> Biomune Systems Inc provided whey protein and control supplement </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0022"> <li> <p>HIV‐infected adults</p> </li> <li> <p>Stable weight loss &gt; 3% over course of HIV infection, but no change in weight in two months prior to enrollment </p> </li> <li> <p>HIV RNA concentration &lt;5000 copies/ml</p> </li> <li> <p>HAART or no HAART</p> </li> </ul> </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0023"> <li> <p>Opportunistic infections</p> </li> <li> <p>Malabsorption</p> </li> </ul> </p> <p>Participants enrolled: 66 <br/> Participants randomised: 59 <br/> Median age at baseline: 41 years (range: 31‐ 66) in the intervention group; 41 years (26‐58) in the control group <br/> Sex at baseline: 26:3 men:women in the intervention group; 26:4 men: women in the control group <br/> No significant differences in baseline criteria observed. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>High protein supplement 280kcal serving containing:</p> <p> <ul id="CD004536-list-0024"> <li> <p>40g whey protein</p> </li> <li> <p>20.5g carbohydate</p> </li> <li> <p>4g fat</p> </li> </ul> </p> <p>CONTROL:</p> <p>Isocaloric supplement 280kcal serving containing:</p> <p> <ul id="CD004536-list-0025"> <li> <p>0.6g casein (protein)</p> </li> <li> <p>60.8g carbohydrate</p> </li> <li> <p>4g fat</p> </li> </ul> </p> <p>Control had same texture, appearance and taste as intervention. <br/> DURATION: <br/> Taken orally twice a day between meals for 12 weeks <br/> COMPLIANCE: <br/> Not clearly reported but one participant in intervention group stopped due to disliking the taste </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In Sattler 2008 all analyses were performed using the WiIcoxon rank sum test for non‐normally distributed data. The report also provided means and standard deviations and these were entered into REVMAN for calculations. We report the REVMAN calculations and the Wilcoxon rank sum test data as reported by the authors which are likely to be more accurate if there was a lack of a normal distribution for the outcomes. For daily energy intake, there was no statistically significant difference in the mean change in intake from baseline to week 12 between the whey protein and placebo groups (REVMAN: MD: ‐6.00; 95% CI: ‐637.57, 625.57; p = 0.99). See Analysis 6.1. The authors’ analysis report a non‐significant p = 0.12. For daily protein intake, participants in the whey protein group had a statistically significantly greater intake than the placebo group (REVMAN: MD: 1.17g/kg/day; 95% CI: 0.80, 1.54; p &lt; 0.00001). SeeAnalysis 6.2. This was also significant when analysed using the Wilcoxon rank sum test (reported p &lt; 0.01). <br/> <br/> For mean change in weight, total lean body mass and fat mass from baseline to week 12, there were no statistically significant differences either by REVMAN analysis or reported Wilcoxon rank sum test. See Analysis 6.3; Analysis 6.4; and Analysis 6.5. The authors do not provide final or changes in BMI but conducted an analysis correlating baseline BMI to changes in weight in either group and found no correlation (reported Spearman correlation: whey protein: ‐0.18; p = 0.36; placebo: 0.32; p = 0.12) <br/> <br/> Mean change in triglycerides was statistically significantly lower in the whey protein group compared with placebo at week 12 (MD: ‐55.00; 95% CI: ‐102.62, ‐7.38; p = 0.02). See Analysis 6.6. This was also found to be significant when using the Wilcoxon rank sum test (reported p = 0.03). For mean change in CD4 count the authors conducted a Wilcoxon rank sum test and showed a statistically significant increase in the CD4 count in the whey protein group compared with placebo (reported p = 0.03). In analysis in REVMAN the result was not statistically significant at p = 0.22. See Analysis 6.7. Given that CD4 counts are known to be non‐normally distributed it is likely the authors’ use of Wilcoxon rank sum test is more accurate. <br/> <br/> No adverse effects were reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Low risk ‐ Participants and personnel reported as blinded and control supplement had same texture, taste and appearance as intervention supplement <br/> Blinding of outcome assessment (detection bias): Low risk ‐ Personnel reported as blinded. <br/> Incomplete outcome data (attrition bias): High risk ‐ Attrition was high in the intervention group 12/29 (41%) at 12 weeks follow‐up and less in the control group 6/30 (20%). The observations completed at 6 weeks were carried forward for analysis but the differential follow‐up between the groups is a possible source of bias. <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Suttmann 1996</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY: <br/> Germany <br/> SETTING: <br/> Outpatient clinic, not clearly stated, assume at the Medizinische Hochschule, Hannover <br/> DURATION OF RECRUITMENT: <br/> Not reported <br/> DURATION OF TRIAL: <br/> Not reported but cross‐over trial of 8 months duration per participant <br/> FOLLOW‐UP: <br/> At baseline and at monthly visits for 32 weeks, a clinical examination was done. <br/> Every two months, weekly dietary records were obtained: the nutrient intake was determined by computer analysis of 7‐day diet records <br/> Anthropometry and bioelectrical impedance analysis and bloods were done monthly. </p> <p>ETHICS: <br/> Ethics Committee of Medizinische Hochsculle, Hannover, Germany <br/> TRIAL REGISTRATION: <br/> Could not locate trial protocol. <br/> FUNDING: <br/> Not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0026"> <li> <p>HIV‐infected adults &gt; 18 years</p> </li> <li> <p>Estimated survival &gt; 8 months</p> </li> <li> <p>Platelet count &gt; 50,0000 /µL</p> </li> <li> <p>No malignancies</p> </li> <li> <p>No mycobacteriosis or cytomegalovirus</p> </li> <li> <p>No intravenous drug use</p> </li> <li> <p>No immune‐modulating treatments</p> </li> <li> <p>Stable medication for 1 month prior to study entry</p> </li> </ul> </p> <p>Participants randomised: 10 cross‐over <br/> Baseline characteristics only reported for 55 participants who completed the study. <br/> Mean age at baseline: 32.6 years +/‐ SEM: 1.8 years in the Arginine group; 36.7 years +/‐ 1.6 years in the control group <br/> Sex at baseline: 7/27 (26%) women in the intervention group; 4/28 (14.3%) women in the control group <br/> No signficant differences in baseline characteristics were observed. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Enriched arginine formula containing 500kcal comprising:</p> <p> <ul id="CD004536-list-0027"> <li> <p>27.9g protein</p> </li> <li> <p>21.7g casein</p> </li> <li> <p>6.2g arginine</p> </li> <li> <p>13.9g fat</p> </li> <li> <p>3.2g essential fatty acids</p> </li> <li> <p>1.9g n‐6 fatty acids</p> </li> <li> <p>1.4g n‐3 fatty acids</p> </li> <li> <p>1.8g Linolenic acid</p> </li> <li> <p>67g carbohydrates</p> </li> </ul> </p> <p>The supplementation was taken as a daily liquid formula for 16 weeks and then crossed over to control formula for 16 weeks. </p> <p>CONTROL:</p> <p>Non‐enriched formula containing 500kcal comprising:</p> <p> <ul id="CD004536-list-0028"> <li> <p>21.7g protein</p> </li> <li> <p>21.7g casein</p> </li> <li> <p>13.9g fat</p> </li> <li> <p>3.7g essential fatty acids</p> </li> <li> <p>3.6g n‐6 fatty acids</p> </li> <li> <p>0.1g n‐3 fatty acids</p> </li> <li> <p>3.6g Linolenic acid</p> </li> <li> <p>73.2 carbohydrates</p> </li> </ul> </p> <p>The control supplementation was taken as a daily liquid formula for 16 weeks and then crossed over to the enriched formula for 16 weeks. <br/> COMPLIANCE: <br/> Mean intake of formula reported as 638 +/‐ 117 kcal/day for the intervention and 695 +/‐ 118 kcal/day with no statistically significant differences in intake between groups. (assume this measurement is taken from reported weekly dietary records) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no statistically significant difference in energy intake between the arginine‐enriched formula group and the non‐enriched formula groups (MD: ‐10kcal/day; 95% CI: ‐459.96, 439.96; p = 0.97). See Analysis 2.1. Body weight was significantly increased by a mean of 3.40kg and could be as much as 5.29kg or as little as 1.51kg (MD: 3.4; 95% CI: 1.51, 5.29; p &lt; 0.0004). Authors state that no significant differences between groups for lean body mass and fat mass but the numerical data is not reported. The change in CD4 counts did not differ statistically significantly between the arginine‐enriched formula group and the non‐enriched formula group (MD: ‐50.00; 95% CI: ‐151.73, 51.71; p = 0.34). See Analysis 2.5. Viral load is not reported as an outcome. Adverse effects: a high temperature was reported by two patients (one in arginine‐enriched formula group and one in the non‐enriched formula group), and diarrhoea was reported by two patients (one in the arginine‐enriched formula group and one in the non‐enriched formula control group), but the authors state that the differences observed were not significant between the two periods. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Cross‐over trial but method of randomisation not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Unclear risk ‐ Reported as 'double‐blind' but not clearly specified. <br/> Blinding of outcome assessment (detection bias): Unclear risk ‐ Reported as 'double‐blind' but not clearly specified. <br/> Incomplete outcome data (attrition bias): Low risk ‐ Nil. All participants remained in study <br/> Selective reporting (reporting bias): Unclear risk ‐ Trial protocol not located and cannot exclude selective reporting bias as primary outcomes not stated. </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD004536-sec-0050"> <h4 class="title">Types of outcome measures</h4> <p><i>Primary outcomes</i> </p> <p> <ul id="CD004536-list-0029"> <li> <p>All‐cause mortality</p> </li> <li> <p>Mortality related to HIV infection and other HIV‐related conditions</p> </li> <li> <p>Morbidity (frequency, types, and duration of episodes of opportunistic infections; incidence of AIDS as defined by each trial; hospital admissions; and other types of illnesses related to HIV infection as reported in each study) </p> </li> </ul> </p> <p><i>Secondary outcomes</i> </p> <p> <ul id="CD004536-list-0030"> <li> <p>Disease progression according to WHO (<a href="./references#CD004536-bbs2-0091" title="World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV‐related diseases in adults and children. World Health Organization, Geneva2007. ">WHO 2007</a>) or CDC staging system as recorded in each study </p> </li> <li> <p>Indices of viral load</p> </li> <li> <p>Markers of immune response (absolute CD4+ T‐lymphocyte count and CD4+ percent of total lymphocytes) </p> </li> <li> <p>Nutritional status, including measurements such as body weight, body composition and lean body mass, body mass index (BMI), weight‐for height and linear growth in children </p> </li> <li> <p>Energy expenditure</p> </li> <li> <p>Biochemical markers, such as serum albumin</p> </li> <li> <p>Dietary intake and appetite</p> </li> <li> <p>Functional outcomes such as child development, quality of life and level of physical activity </p> </li> </ul> </p> <p>If studies reported on additional outcomes not listed above we also reported the data for these outcomes in the review. Adverse events were recorded when these were provided. </p> </section> </section> <section id="CD004536-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>See: Cochrane HIV/AIDS Group methods used in reviews.</p> <p>See: Collaborative Review Group search strategy.</p> <p>A comprehensive, unbiased search strategy was developed to ensure that as many relevant studies as possible were screened for inclusion in the review. An attempt was made to identify all relevant studies, regardless of language or publication status (published or unpublished, in press or in progress). </p> <section id="CD004536-sec-0052"> <h4 class="title">Electronic searches</h4> <p> <ul id="CD004536-list-0031"> <li> <p>Journal and trial databases</p> </li> </ul> </p> <p>MEDLINE</p> <p>A search of MEDLINE was conducted in February 2010 limited from January 2006 to January 2010 as the original review published review in 2007 included searches prior to and including 2006. We ran a final search on 24 August 2011 to ensure that the most recent trial reports were identified using the strategy outlined in <a href="./appendices#CD004536-sec-0110">Appendix 2</a>: PUBMED search strategy. </p> <p><i>EMBASE</i> </p> <p>The searches were conducted in February 2010 and a final revised search was conducted on the 26 August 2011 using the strategy outlined in <a href="./appendices#CD004536-sec-0111">Appendix 3</a>: EMBASE search strategy </p> <p><i>Cochrane Central Register of Controlled Trials (CENTRAL)</i> <br/> A search of the CENTRAL database of <i>The Cochrane Library</i> (2010), was conducted in February 2010 and a final revised search of Issue 3 <i>The Cochrane Library</i> (2011)<i>,</i> on 26 August 2011 using the strategy in <a href="./appendices#CD004536-sec-0112">Appendix 4</a>: Cochrane Library search strategy.  CENTRAL provides records marked either as <b>RCTs</b> or <b>Systematic Reviews</b>. </p> <p><i>LILACS (</i><a href="http://lilacs.bvsalud.org/en/" target="_blank">http://lilacs.bvsalud.org/en/</a> ) </p> <p>LILACS is an index of scientific and technical literature of Latin America and the Caribbean. We searched this database on 8 February 2012 using the following search terms: <b>(HIV OR HIV/AIDS) AND (nutrition OR nutritional OR nutrient*)</b> [all fields] </p> <p> <ul id="CD004536-list-0032"> <li> <p><b>Conference databases</b> </p> </li> </ul> </p> <p>A search of the National Library of Medicine GATEWAY database which contains abstracts from the major HIV/AIDS conferences was done on 5 February 2010. However, no updated search of conference abstracts was done in 2011 as NLM Gateway is no longer maintained and updated. </p> <p> <ul id="CD004536-list-0033"> <li> <p><b>Trial Registers</b> </p> </li> </ul> </p> <p>The trials registry <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> was searched on 16 August 2011 using the search string:  </p> <p>(nutrition therapy OR fortified food OR energy intake OR dietary fat OR dietary protein OR dietary carbohydrate OR macronutrient OR spirulina OR supplement OR amino acid OR fatty acid OR oil) AND HIV | Interventional Studies | </p> <p>The search was limited to 1980 to ensure coverage throughout the period HIV has been documented. </p> </section> <section id="CD004536-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We were in close contact with individual researchers working in the field, and policymakers based in inter‐governmental organizations. <b> </b>We also checked the reference lists of all studies identified by the above methods and examined any systematic reviews, meta‐analyses, or clinical guidelines we identified during the search process for references. </p> </section> </section> <section id="CD004536-sec-0054"> <h3 class="title" id="CD004536-sec-0054">Data collection and analysis</h3> <section id="CD004536-sec-0055"> <h4 class="title">Selection of studies</h4> <p>NS and LN read the titles, abstracts and descriptor terms of all downloaded material from the electronic searches to identify potentially eligible reports. Full text articles were obtained for all citations identified as potentially eligible and NS and LN inspected these to establish the relevance of the article according to the pre‐specified criteria. Where there was any uncertainty as to the eligibility of the record, the full article was obtained. </p> <p>NS and LN applied the inclusion criteria with studies reviewed for relevance based on study design, types of participants, interventions and outcome measures. All studies not meeting the inclusion criteria were excluded and the reasons for exclusion were stated in the table “Characteristics of Excluded Studies.” </p> </section> <section id="CD004536-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>NS, LG, SM and MV independently extracted data using a standardised electronic data extraction form. The following characteristics were extracted from each included trial: </p> <p> <ul id="CD004536-list-0034"> <li> <p>Administrative details: Trial identification number; author(s); published or unpublished; year of publication; number of studies included in paper; year in which study was conducted; details of other relevant papers cited; </p> </li> <li> <p>Details of the study: study design (Cochrane review, non‐Cochrane systematic review, RCT); type, duration and completeness of follow‐up; country and location of study (e.g. higher‐income vs. lower‐income country); informed consent and ethics approval; </p> </li> <li> <p>Details of participants: presence of malnutrition, age, disease progression according to CD4 count or staging by WHO clinical stages, setting, sample size, relevant baseline characteristics including CD4 count and viral load; </p> </li> <li> <p>Details of intervention and control group: type of supplements of macronutrient(s); dosage of macronutrient(s); form and formulation of macronutrient(s), additional co‐interventions (such as ART, TB treatment or other management of opportunistic infections); fortification with micronutrients </p> </li> <li> <p>Details of outcomes: all pre‐specified outcomes and any additional outcomes reported in the study; adverse events and toxicity. </p> </li> <li> <p>Details of quality assessment: type of quality assessment including use of the Risk of Bias tool. </p> </li> <li> <p>Details of data analysis: numbers and reported statistics for each reported outcome</p> </li> </ul> </p> <p>Where trials were reported in more than one reference, all the trial reports were used to extract data as comprehensively as possible. Discrepancies regarding extracted data were resolved by discussion and, if necessary, referred to an additional reviewer (JV). </p> </section> <section id="CD004536-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The components of each included trial were examined for risk of bias using a standard form. This included information on the sequence generation, allocation concealment, masking (participants, personnel and outcome assessor), incomplete outcome data, selective outcome reporting and other sources of bias. The methodological components of the trials were assessed and classified as adequate, inadequate or unclear as per the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD004536-bbs2-0071" title="Higgins , J.P , Altman . D.G . Assessing Risk of Bias in Included Studies. In: J. P.Higgins , S.Green editor(s). Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Chichester, UK: John Wiley &amp; Sons, Ltd, 2008. doi: 10.1002/9780470712184.ch8. ">Higgins 2008</a>). </p> <p><b>Sequence generation</b> </p> <p>Low risk: investigators described a random component in the sequence generation process such as the use of random number table, coin tossing, cards or envelops shuffling etc </p> <p>High risk: investigators described a non‐random component in the sequence generation process such as the use of odd or even date of birth, algorithm based on the day/date of birth, hospital or clinic record number </p> <p>Unclear: insufficient information to permit judgment of the sequence generation process</p> <p><b>Allocation concealment</b> </p> <p>Low risk: participants and the investigators enrolling participants cannot foresee assignment, e.g. central allocation; or sequentially numbered, opaque, sealed envelopes. </p> <p>High risk: participants and investigators enrolling participants can foresee upcoming assignment, e.g. an open random allocation schedule (e.g. a list of random numbers); or envelopes were unsealed or non‐­opaque or not sequentially numbered </p> <p>Unclear: insufficient information to permit judgment of the allocation concealment or the method not described </p> <p><b>Masking</b> </p> <p>Low risk: blinding of the participants, key study personnel and outcome assessor, and unlikely that the blinding could have been broken. Or lack of blinding unlikely to introduce bias. No blinding in the situation where non‐blinding is not likely to introduce bias. </p> <p>High risk: no blinding, incomplete blinding and the outcome is likely to be influenced by lack of blinding </p> <p>Unclear: insufficient information to permit judgment of adequacy or otherwise of the blinding </p> <p><b>Incomplete outcome data</b> </p> <p>Low risk: no missing outcome data, reasons for missing outcome data unlikely to be related to true outcome, or missing outcome data balanced in number across groups </p> <p>High risk: reason for missing outcome data likely to be related to true outcome, with either imbalance in number across groups or reasons for missing data </p> <p>Unclear: insufficient reporting of attrition or exclusions</p> <p><i>To calculate attrition per group the denominators according to the intention‐to‐treat principle was used: participants were maintained in the groups into which they were randomized and the overall potential number of participants who could produce an outcome was used as the denominator.</i> </p> <p><b>Selective Reporting</b> </p> <p>Low risk: a protocol is available which clearly states the primary outcome as the same as in the final trial report </p> <p>High risk: the primary outcome differs between the protocol and final trial report</p> <p>Unclear: no trial protocol is available or there is insufficient reporting to determine if selective reporting is present </p> <p><b>Other forms of bias</b> </p> <p>Low risk: there is no evidence of bias from other sources</p> <p>High risk: there is potential bias present from other sources (e.g. early stopping of trial, fraudulent activity, extreme baseline imbalance or bias related to specific study design) </p> <p>Unclear: insufficient information to permit judgment of adequacy or otherwise of other forms of bias </p> </section> <section id="CD004536-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5.1 to calculate the risk ratio (RR) for dichotomous data, and the weighted mean difference (WMD) for continuous data, with 95% confidence intervals and we report these results below. Where this was not possible due to missing primary data, we report only the results as presented in the published studies. When units of measurement differed between trials we chose to use the SI unit and appropriate conversions were made. </p> </section> <section id="CD004536-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>Where data was missing or unclear, we planned to contact authors where this was possible to do so. When percentages were provided without denominators these were back‐calculated. If only standard errors or 95% confidence intervals were reported for means and no standard deviations, the standard deviations were calculated as follows: </p> <p>SD = SEM x Square root of sample size</p> </section> <section id="CD004536-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>RCTs were first assessed for clinical heterogeneity by examining variability in the participants, interventions and outcomes. Where it was clinically meaningful to combine studies, we conducted a meta‐analysis using the random effects model as we anticipated heterogeneity. We further assessed statistical heterogeneity in the meta‐analysis study results using the Chi‐square test for heterogeneity with a 10% level of significance as the cut‐off. The impact of statistical heterogeneity was quantified using the I<sup>2</sup> statistic (<a href="./references#CD004536-bbs2-0070" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Stat Med2002;21(11):1539‐1558. ">Higgins 2002</a>). We used the following guidelines for the interpretation of the I<sup>2</sup> values (Higgins 2011): </p> <p>0% to 40%: might not be important;</p> <p>30% to 60%: may represent moderate heterogeneity;</p> <p>50% to 90%: may represent substantial heterogeneity;</p> <p>75% to 100%: considerable heterogeneity.</p> </section> <section id="CD004536-sec-0061"> <h4 class="title">Data synthesis</h4> <p>Where trials were sufficiently homogenous we combined the results of the trials using the random effects model as we anticipated some heterogeneity. Importantly, for changes in mean measurements, we combined the results if a mean change from baseline to end‐point was recorded or if a final mean at the end‐point of the study was recorded as described in the <i>Cochrane Review Authors’ Handbook</i>. When measurement time points and lengths of follow up differed between studies we combined these when we thought this was meaningful. Where appropriate we categorised studies into length of follow‐up from less than 3 months (short term follow‐up), 3 to 6 months (medium term follow‐up) and 6‐12 months (long term follow‐up). </p> </section> <section id="CD004536-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The pre‐specified sub‐groups to investigate for possible sources of heterogeneity across studies were: </p> <p> <ol id="CD004536-list-0035"> <li> <p>By disease progression: CD4&lt; 200 vs. CD4 &lt;350 vs. CD4 &gt;350</p> </li> <li> <p>By disease progression: WHO HIV clinical stage 1‐4 or CDC Stages 1‐3</p> </li> <li> <p>By ART status: on ART vs. not eligible for ART vs. eligible but not on ART</p> </li> <li> <p>By age: 0‐14 years of age vs. 14‐19 years of age vs. 20 years and older</p> </li> </ol> </p> <p>None of the included trials presented data in a format that allowed extraction of the above sub‐groups, therefore we did not conduct sub‐group analyses. </p> <section id="CD004536-sec-0063"> <h5 class="title">GRADE assessments</h5> <p>GRADEPro was used to create Summary of Findings tables for meta‐analyses using the pre‐specified outcomes. In determining the level of evidence for each outcome, both the efficacy results and the assessment of the risk of bias was integrated into a final assessment of the level of evidence and full details of the decision provided. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004536-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004536-sec-0064"></div> <section id="CD004536-sec-0065"> <h3 class="title">Description of studies</h3> <section id="CD004536-sec-0066"> <h4 class="title">Results of the search</h4> <section id="CD004536-sec-0067"> <h5 class="title">Electronic database</h5> <section id="CD004536-sec-0068"> <h6 class="title">2010 Search of electronic journal and trial databases</h6> <p>The 2010 PUBMED search yielded 897 records of which 32 were identified as potentially eligible studies and the full texts obtained. </p> <p>The 2010 EMBASE search yielded 528 records of which 18 were identified as potentially eligible and the full texts obtained. </p> <p>The CLIB search yielded 333 records marked as RCT records of which 21 were identified as potentially eligible and the full texts obtained. </p> </section> <section id="CD004536-sec-0069"> <h6 class="title">2011 Search of electronic journal and trial databases</h6> <p>The 2011 searches of PUBMED yielded 265 records, of EMBASE 152 records and of CLIB 42 records. These were de‐duplicated electronically using PROCITE reference management software and 67 duplicate records were removed prior to manual checking. </p> </section> <section id="CD004536-sec-0070"> <h6 class="title">Conference databases</h6> <p>The NLM GATEWAY search yielded 1503 records of which 89 were coded as Meeting Abstracts. We identified two of these abstract records for further assessment. </p> </section> <section id="CD004536-sec-0071"> <h6 class="title">Trials Registries</h6> <p>The 2011 search of <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> yielded 212 studies of which 28 were identified for further assessment. </p> <p><b>Other sources</b> </p> <p>One included study was identified through discussion with an expert in the field. A further study was identified through the search conducted for the review entitled: Micronutient supplementation in children and adults with HIV infection. This study has been placed in the Studies awaiting assessment category. </p> <p>A total of 33 full‐text articles were obtained. We conducted eligibility assessments on each of these and identified a total of 6 references reporting on 6 RCTs eligible for inclusion. The reasons for exclusion for 25 studies are detailed in <a href="#CD004536-fig-0001">Figure 1</a>. Two studies were categorised as awaiting assessment (see: <a href="./references#CD004536-bbs1-0003" title="">Studies awaiting classification</a>) and once further details are obtained, these studies may become eligible. </p> <div class="figure" id="CD004536-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004536-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> </section> </section> <section id="CD004536-sec-0072"> <h4 class="title">Included studies</h4> <p>We identified a total of six new RCTs to be included in the review in addition to the eight RCTs already included in the review, making a total of 14 RCTs. Full details for each of the trials are reported in the table: <a href="./references#CD004536-sec-0121" title="">Characteristics of included studies</a>. </p> <p><b>Trial locations</b> </p> <p>Seven studies were conducted in high‐income countries. Four studies were conducted in the USA (<a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a>; <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a>; <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a>; <a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a>), two in Switzerland (<a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>; <a href="./references#CD004536-bbs2-0005" title="KarsegardVL , RagusoCA , GentonL , HirschelB , PichardC . L‐Ornithine alpha‐Ketoglutarate in HIV infection: Effects on muscle, gastrointestinal and immune functions. Nutrition2004;20:515‐520. ">Karsegard 2004</a>) and one in Germany (<a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>). Four studies were conducted in African countries. One in South Africa (<a href="./references#CD004536-bbs2-0009" title="RollinsNC , van denBroeckJ , KindraG , PentM , KasambiraT , BennishML . The effect of nutritional support on weight gain of HIV‐infected children with prolonged diarrhoea. Acta Paediatrica2007;96:62‐68. ">Rollins 2007</a>), one in Kenya (<a href="./references#CD004536-bbs2-0004" title="CastlemanT , MwadimeR , et al. Randomised controlled trial of the impact of supplementary food on malnourished adult ART clients and adult pre‐ART clients in Kenya. Final reportJune 2011. ">FANTA‐KEMRI study 2011</a>), one in Burkina Faso (<a href="./references#CD004536-bbs2-0012" title="SimporeJ , ZongoF , KaboreF , DansouD , BereA , NikiemaJ , PignatelliS , BiondiD , RubertoG , MusumeciS . Nutrition rehabilitation of HIV‐infected and HIV‐negative undernourished children utilizing Spirulina. Annuls of Nutrition and Metabolism2005;49:373‐380. ">Simpore 2005</a>), one in Central African Republic (<a href="./references#CD004536-bbs2-0014" title="YamaniE , Kaba‐MebriJ , MoualaC , GresenguetG , ReyJL . Use of spirulina supplement for nutritional management of HIV‐infected patients: study in Bangui, Central African Republic. Medecine Tropicale2009;69(1):66‐70. ">Yamani 2010</a>). One trial was conducted in Brazil (<a href="./references#CD004536-bbs2-0007" title="MorenoYF , SgarbieriVC , daSilvaMN , ToroAADC , VilelaMMS . Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. Journal of Tropical Pediatrics2005;52(1):34‐38. ">Moreno 2005</a>) and another in India (<a href="./references#CD004536-bbs2-0013" title="SudarsanamTD , JohnJ , KangG , MahendriV , GerriorJ , FranciosaM , et al. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV‐tuberculosis coinfection receiving directly observed short‐course chemotherapy for tuberculosis. Tropical medicine &amp; international health : TM &amp; IH2011;16(6):699‐706. [PUBMED: 21418447] ">Sudarsanam 2011</a>). It is not clear where the study by de Luis 2003 (<a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>) was conducted, although based on the address of the corresponding author it appears to be Spain. In general the trials were conducted in the out‐patient (ambulatory) setting. </p> <p><b>Trial participants</b> </p> <p>A total of 1725 adults and 271 children were included across the trials. All participants were infected with HIV. In six trials at least half or all of the participants received antiretroviral therapy (ART). In three of the four African studies none of the participants received ART. In seven studies the majority (&gt;50%) or all participants were CDC category C (AIDS) or WHO Stage III/IV. More men participated in trials than women. Trials evaluated interventions in participants from diverse populations including those with normal weight, those with stable weight loss, and those with malnutrition. In one trial participants were TB/HIV co‐infected (<a href="./references#CD004536-bbs2-0013" title="SudarsanamTD , JohnJ , KangG , MahendriV , GerriorJ , FranciosaM , et al. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV‐tuberculosis coinfection receiving directly observed short‐course chemotherapy for tuberculosis. Tropical medicine &amp; international health : TM &amp; IH2011;16(6):699‐706. [PUBMED: 21418447] ">Sudarsanam 2011</a>). In the remaining trials all participants were free of confirmed secondary infections or other signs and symptoms of infection, such as fever, chills, or persistent diarrhoea upon enrollment into the study. No trials were identified in pregnant or lactating women although two studies awaiting assessment may provide data on this population group when final results are available (<a href="./references#CD004536-bbs2-0058" title="KindraG , CoutsoudisA , EspositoF . Effect of nutritional supplementation of breastfeeding HIV positive mothers onmaternal and child health: findings from a randomized controlled clinical trial. BMC Public Health2011;11:946. ">Kindra 2011</a>; <a href="./references#CD004536-bbs2-0059" title="van derHorstC , ChaselaC , AhmedY , HoffmanI , HosseinipourM , KnightR , et al. Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemporary clinical trials2009;30(1):24‐33. [PUBMED: 18805510] ">van der Horst 2009</a>). </p> <p><b>Trial interventions and comparison groups</b> </p> <p>The interventions can be broadly classified as follows:</p> <section id="CD004536-sec-0073"> <h5 class="title">ADULTS</h5> <section id="CD004536-sec-0074"> <h6 class="title">Macronutrient supplementation fortified with micronutrients given to provide protein and/or energy by replacing or supplementing usual diet plus nutrition counselling versus nutrition counselling or standard care </h6> <section id="CD004536-sec-0075"> <p><b>Macronutrient formulas fortified with micronutrients plus nutrition counselling versus nutrition counselling alone in participants with and without weight loss (five trials)</b></p> <p> <ul id="CD004536-list-0036"> <li> <p><i>Four trials in participants with &gt; 5% weight loss:</i> </p> </li> </ul> <ol id="CD004536-list-0037"> <li> <p>Liquid supplement containing 600 kcal/day, 17% protein (whey), 59% carbohydrates, 26% fat, electrolytes, trace elements and micronutrients plus nutrition counselling versus nutrition counselling for 12 weeks (<a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>). </p> </li> <li> <p>Liquid supplement containing 795 kcal/day, 14% protein, 54% carbohydrates, 32% fat, electrolytes, trace elements and micronutrients (ENSURE<sup>®</sup>) plus nutrition counselling versus nutrition counselling for 12 weeks (<a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>). </p> </li> <li> <p>Specialized medium chain triglyceride (MCT) formula to provide additional 960 kcal/day over and above usual diet (Lipisorb® Liquid Nutrition: 17% protein, 48% carbohydrates, 35% fat) plus nutrition counselling versus nutrition counselling for 6 weeks (<a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a>). </p> </li> <li> <p>Range of fortified oral supplements providing 600 kcal/day in addition to usual diet plus nutrition counselling versus nutrition counselling for 8 weeks (<a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>) </p> </li> </ol> <ul id="CD004536-list-0038"> <li> <p><i>One trial in participants with normal body weight assumed:</i> </p> </li> </ul> <ol id="CD004536-list-0039"> <li> <p>1‐2 cans per day of standard oral formula (Ensure Plus®: 355 calories per can, 15% protein, 53% carbohydrates, 32% fat) plus nutrition counselling versus 1‐2 cans per day of immune‐enhancing oral formula (Advera®: 303 calories, 19% protein, 65% carbohydrates, 16% fat) plus nutrition counselling versus nutrition counselling for 1 year (<a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a>). </p> </li> </ol> </p> </section> <section id="CD004536-sec-0076"> <p><b>Supplementary food fortified with micronutrients plus nutrition counselling vs nutritional counselling alone in malnourished participants (two trials)</b></p> <p> <ul id="CD004536-list-0040"> <li> <p><i>One trial in participants either initiating ART or not yet eligible for ART:</i> </p> </li> </ul> <ol id="CD004536-list-0041"> <li> <p>ART (BMI&lt;18.5 kg/m<sup>2</sup>) and pre‐ART participants received either 300g per day of fortified blended food for 6 months plus nutrition counselling for 12 months or nutrition counselling alone for 12 months (<a href="./references#CD004536-bbs2-0004" title="CastlemanT , MwadimeR , et al. Randomised controlled trial of the impact of supplementary food on malnourished adult ART clients and adult pre‐ART clients in Kenya. Final reportJune 2011. ">FANTA‐KEMRI study 2011</a>) </p> </li> </ol> <ul id="CD004536-list-0042"> <li> <p><i>One trial in participants with TB/HIV co‐infection:</i> </p> </li> </ul> <ol id="CD004536-list-0043"> <li> <p>A locally prepared cereal‐lentil mixture providing 930 kcal/day plus multivitamin micronutrient supplement plus nutrition counselling versus nutrition counselling alone for 6 months (<a href="./references#CD004536-bbs2-0013" title="SudarsanamTD , JohnJ , KangG , MahendriV , GerriorJ , FranciosaM , et al. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV‐tuberculosis coinfection receiving directly observed short‐course chemotherapy for tuberculosis. Tropical medicine &amp; international health : TM &amp; IH2011;16(6):699‐706. [PUBMED: 21418447] ">Sudarsanam 2011</a>). </p> </li> </ol> </p> </section> </section> <section id="CD004536-sec-0077"> <h6 class="title">Specific macronutrient supplements versus placebo, no supplement or usual diet</h6> <p> <ul id="CD004536-list-0044"> <li> <p><i>Two trials in participants with weight loss or low BMI</i> </p> </li> </ul> <ol id="CD004536-list-0045"> <li> <p>Participants received either amino acid mixture containing 14g arginine (free base), 14g glutamine and 3g β‐hydroxy‐β‐methylbutyrate (HMB, calcium salt) plus citric acid (ph 4.5) or isocaloric placebo of bulk maltodextrin for 8 week(<a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a>) </p> </li> <li> <p>ART naive participants received either 10g per day Spirulina or 10g per day placebo of green clay for 6 months (<a href="./references#CD004536-bbs2-0014" title="YamaniE , Kaba‐MebriJ , MoualaC , GresenguetG , ReyJL . Use of spirulina supplement for nutritional management of HIV‐infected patients: study in Bangui, Central African Republic. Medecine Tropicale2009;69(1):66‐70. ">Yamani 2010</a>) </p> </li> </ol> <ul id="CD004536-list-0046"> <li> <p><i>Two trials in participants with normal or assumed normal weight</i> </p> </li> </ul> <ol id="CD004536-list-0047"> <li> <p>10g per day of L‐ornithine alpha‐ketoglutarate (OKG, 1.3g of nitrogen) and nutritional counselling versus isonitrogenous placebo plus nutrition counselling for 12 weeks (<a href="./references#CD004536-bbs2-0005" title="KarsegardVL , RagusoCA , GentonL , HirschelB , PichardC . L‐Ornithine alpha‐Ketoglutarate in HIV infection: Effects on muscle, gastrointestinal and immune functions. Nutrition2004;20:515‐520. ">Karsegard 2004</a>) </p> </li> <li> <p>Daily vitamin and mineral preparation plus L‐glutamine (GLN) amino acid (400g/day) plus antioxidant nutrients (ascorbic acid 800mg/d, α‐tocopherol 500 IU/d, β‐carotene 27000IU/d, selenium 280ug/d and N‐acetyl cysteine 2400mg/d) plus weekly nutrition counselling versus placebo of glycine plus weekly nutrition counselling for 12 weeks (<a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a>) </p> </li> </ol> </p> </section> </section> <section id="CD004536-sec-0078"> <h5 class="title">CHILDREN</h5> <section id="CD004536-sec-0079"> <h6 class="title">Macronutrient supplements fortified with micronutrients given to provide protein and/or energy by replacing or supplementing usual diet versus no supplement or standard care </h6> <p> <ul id="CD004536-list-0048"> <li> <p><i>One trial in children with prolonged diarrhoea:</i> </p> </li> </ul> </p> <p><b>Enhanced diet:</b> casein maltodextrin‐based milk formula (AL110) until diarrhoea resolved and appetite re‐established, thereafter, amount of milk formula modified to provide at least 150 kcal/kg/day containing ˜4.0–5.5 g protein/kg/day and 15% of calories as protein versus <b>standard nutrition support:</b> casein maltodextrin‐based milk formula with 67 kcal/100mL offered at least four times per day and a maize porridge/pureed vegetable/oil diet with fermented milk offered at least four times per day. This diet provided at least 100‐110 kcal/kg/day containing ˜2.2g protein/kg/day (9.5% of calories as protein) for 6 months (<a href="./references#CD004536-bbs2-0009" title="RollinsNC , van denBroeckJ , KindraG , PentM , KasambiraT , BennishML . The effect of nutritional support on weight gain of HIV‐infected children with prolonged diarrhoea. Acta Paediatrica2007;96:62‐68. ">Rollins 2007</a>). </p> </section> <section id="CD004536-sec-0080"> <h6 class="title">Specific macronutrient supplements versus placebo, no supplement or usual diet</h6> <p> <ul id="CD004536-list-0049"> <li> <p><i>One trial in children with rapidly progressive HIV infection</i> </p> </li> </ul> </p> <p>Whey protein concentrate versus placebo of maltodextrin for 4 months (<a href="./references#CD004536-bbs2-0007" title="MorenoYF , SgarbieriVC , daSilvaMN , ToroAADC , VilelaMMS . Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. Journal of Tropical Pediatrics2005;52(1):34‐38. ">Moreno 2005</a>). </p> <p> <ul id="CD004536-list-0050"> <li> <p><i>One trial in undernourished children</i> </p> </li> </ul> </p> <p>Spirulina supplement plus traditional meals (millet, vegetables and fruit) versus traditional meals for 8 weeks (<a href="./references#CD004536-bbs2-0012" title="SimporeJ , ZongoF , KaboreF , DansouD , BereA , NikiemaJ , PignatelliS , BiondiD , RubertoG , MusumeciS . Nutrition rehabilitation of HIV‐infected and HIV‐negative undernourished children utilizing Spirulina. Annuls of Nutrition and Metabolism2005;49:373‐380. ">Simpore 2005</a>). </p> <p><b>Trial outcomes</b> </p> <p>None of the studies included in this review specifically aimed to assess the effects of macronutrient interventions on the all‐cause or HIV‐related mortality and/or morbidity we pre‐specified as primary outcomes. Proxies of these outcomes, such as body weight, body composition, viral load, CD4 count, energy intake and quality of life were measured. Outcomes were not consistently reported across trials with some reports conducting analyses with means (normal distribution) and others reporting medians (non‐normal distribution) for the same outcomes. In general, outcomes measured anthropometric and immunologic parameters rather than clinical symptoms. Although most trials reported on BMI in the baseline characteristics, few reported on it as an outcome of the trial. </p> <p><b>Trial Methods</b> </p> <p>Trials were small with sample sizes ranging from 18 to 1057 with a mean sample size of 143. Follow‐up ranged from six weeks to 12 months with more than half (8 out of 14 trials) including a follow‐up of 12 weeks or less. </p> </section> </section> </section> </section> <section id="CD004536-sec-0081"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD004536-sec-0082"> <h4 class="title">Allocation</h4> <section id="CD004536-sec-0083"> <h5 class="title">Random generation</h5> <p>Risk due to bias arising from the method of generation of the allocation sequence was low in six studies (<a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a>; <a href="./references#CD004536-bbs2-0004" title="CastlemanT , MwadimeR , et al. Randomised controlled trial of the impact of supplementary food on malnourished adult ART clients and adult pre‐ART clients in Kenya. Final reportJune 2011. ">FANTA‐KEMRI study 2011</a>; <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a>; <a href="./references#CD004536-bbs2-0009" title="RollinsNC , van denBroeckJ , KindraG , PentM , KasambiraT , BennishML . The effect of nutritional support on weight gain of HIV‐infected children with prolonged diarrhoea. Acta Paediatrica2007;96:62‐68. ">Rollins 2007</a>; <a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a>; <a href="./references#CD004536-bbs2-0013" title="SudarsanamTD , JohnJ , KangG , MahendriV , GerriorJ , FranciosaM , et al. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV‐tuberculosis coinfection receiving directly observed short‐course chemotherapy for tuberculosis. Tropical medicine &amp; international health : TM &amp; IH2011;16(6):699‐706. [PUBMED: 21418447] ">Sudarsanam 2011</a>). Five of the studies reported generating the sequence by computer and for the one study we obtained this information directly from the authors. The remaining nine studies did not report how the randomisation sequence was generated so the risk of bias was rated as unclear in these studies (See: <a href="#CD004536-fig-0002">Figure 2</a>; <a href="#CD004536-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD004536-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004536-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004536-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004536-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD004536-sec-0084"> <h5 class="title">Allocation concealment</h5> <p>Risk due to bias arising from the method of allocation concealment was rated as low in four studies (<a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a>; <a href="./references#CD004536-bbs2-0004" title="CastlemanT , MwadimeR , et al. Randomised controlled trial of the impact of supplementary food on malnourished adult ART clients and adult pre‐ART clients in Kenya. Final reportJune 2011. ">FANTA‐KEMRI study 2011</a>; <a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>; <a href="./references#CD004536-bbs2-0013" title="SudarsanamTD , JohnJ , KangG , MahendriV , GerriorJ , FranciosaM , et al. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV‐tuberculosis coinfection receiving directly observed short‐course chemotherapy for tuberculosis. Tropical medicine &amp; international health : TM &amp; IH2011;16(6):699‐706. [PUBMED: 21418447] ">Sudarsanam 2011</a>). The reported methods included central co‐ordination of the allocation and use of sealed, unmarked, opaque envelopes. Allocation concealment was not reported in the remaining ten studies so the risk of bias was rated as unclear for those (See: <a href="#CD004536-fig-0002">Figure 2</a>; <a href="#CD004536-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD004536-sec-0085"> <h4 class="title">Blinding</h4> <section id="CD004536-sec-0086"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Risk of bias arising from lack of blinding of participants and personnel was rated as low for three studies all of which reported using a placebo which was identical in appearance to the intervention (<a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a>; <a href="./references#CD004536-bbs2-0005" title="KarsegardVL , RagusoCA , GentonL , HirschelB , PichardC . L‐Ornithine alpha‐Ketoglutarate in HIV infection: Effects on muscle, gastrointestinal and immune functions. Nutrition2004;20:515‐520. ">Karsegard 2004</a>; <a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a>). In two trials is was unclear if the participants or personnel were blinded (<a href="./references#CD004536-bbs2-0007" title="MorenoYF , SgarbieriVC , daSilvaMN , ToroAADC , VilelaMMS . Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. Journal of Tropical Pediatrics2005;52(1):34‐38. ">Moreno 2005</a>; <a href="./references#CD004536-bbs2-0014" title="YamaniE , Kaba‐MebriJ , MoualaC , GresenguetG , ReyJL . Use of spirulina supplement for nutritional management of HIV‐infected patients: study in Bangui, Central African Republic. Medecine Tropicale2009;69(1):66‐70. ">Yamani 2010</a>). The remaining 9 trials all used controls which were not identical to the intervention or the intervention was such that it was not possible to blind the participants and personnel. The risk arising from this was rated as high for all 9 trials (See: <a href="#CD004536-fig-0002">Figure 2</a>; <a href="#CD004536-fig-0003">Figure 3</a>). </p> </section> <section id="CD004536-sec-0087"> <h5 class="title">Blinding of outcome assessors (detection bias)</h5> <p>In two trials outcome assessment was clearly reported as blinded, or confirmed with the authors to be so, and detection bias was thus rated as low (<a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a>; <a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a>). Blinding was unclear in 11 trials and the risk of detection bias was rated as unclear. In one trial detection bias was rated as high, as it was stated in the report that no steps were taken to blind the outcome assessors to the treatment assignments (<a href="./references#CD004536-bbs2-0013" title="SudarsanamTD , JohnJ , KangG , MahendriV , GerriorJ , FranciosaM , et al. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV‐tuberculosis coinfection receiving directly observed short‐course chemotherapy for tuberculosis. Tropical medicine &amp; international health : TM &amp; IH2011;16(6):699‐706. [PUBMED: 21418447] ">Sudarsanam 2011</a>)(See: <a href="#CD004536-fig-0002">Figure 2</a>; <a href="#CD004536-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD004536-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of attrition bias was rated as low in three trials (<a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>; <a href="./references#CD004536-bbs2-0012" title="SimporeJ , ZongoF , KaboreF , DansouD , BereA , NikiemaJ , PignatelliS , BiondiD , RubertoG , MusumeciS . Nutrition rehabilitation of HIV‐infected and HIV‐negative undernourished children utilizing Spirulina. Annuls of Nutrition and Metabolism2005;49:373‐380. ">Simpore 2005</a>; <a href="./references#CD004536-bbs2-0013" title="SudarsanamTD , JohnJ , KangG , MahendriV , GerriorJ , FranciosaM , et al. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV‐tuberculosis coinfection receiving directly observed short‐course chemotherapy for tuberculosis. Tropical medicine &amp; international health : TM &amp; IH2011;16(6):699‐706. [PUBMED: 21418447] ">Sudarsanam 2011</a>). Risk of attrition bias was rated as high in nine trials in which attrition was greater than 10% overall and/or differentially distributed between the intervention and control groups (<a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a>; <a href="./references#CD004536-bbs2-0004" title="CastlemanT , MwadimeR , et al. Randomised controlled trial of the impact of supplementary food on malnourished adult ART clients and adult pre‐ART clients in Kenya. Final reportJune 2011. ">FANTA‐KEMRI study 2011</a>; <a href="./references#CD004536-bbs2-0005" title="KarsegardVL , RagusoCA , GentonL , HirschelB , PichardC . L‐Ornithine alpha‐Ketoglutarate in HIV infection: Effects on muscle, gastrointestinal and immune functions. Nutrition2004;20:515‐520. ">Karsegard 2004</a>; <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a>; <a href="./references#CD004536-bbs2-0007" title="MorenoYF , SgarbieriVC , daSilvaMN , ToroAADC , VilelaMMS . Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. Journal of Tropical Pediatrics2005;52(1):34‐38. ">Moreno 2005</a>; <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a>; <a href="./references#CD004536-bbs2-0009" title="RollinsNC , van denBroeckJ , KindraG , PentM , KasambiraT , BennishML . The effect of nutritional support on weight gain of HIV‐infected children with prolonged diarrhoea. Acta Paediatrica2007;96:62‐68. ">Rollins 2007</a>; <a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a>; <a href="./references#CD004536-bbs2-0014" title="YamaniE , Kaba‐MebriJ , MoualaC , GresenguetG , ReyJL . Use of spirulina supplement for nutritional management of HIV‐infected patients: study in Bangui, Central African Republic. Medecine Tropicale2009;69(1):66‐70. ">Yamani 2010</a>). Risk of attrition bias was unclear in the remaining two trials. In Schwenk 1999 overall attrition was moderate at 10%(5/50) but was differentially distributed between groups at 8% (2/26) in the intervention group and 13% (3/24) in the control group (<a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>). In Berneis 2000 overall attrition was high (16.7%) and no further information regarding group assignment is provided (<a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>)(See: <a href="#CD004536-fig-0002">Figure 2</a>; <a href="#CD004536-fig-0003">Figure 3</a>). </p> </section> <section id="CD004536-sec-0089"> <h4 class="title">Selective reporting</h4> <p>The trial protocols were not obtained for any of the trials and therefore the risk of bias due to selective reporting of outcomes was rated as unclear for all the trials (See: <a href="#CD004536-fig-0002">Figure 2</a>; <a href="#CD004536-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD004536-sec-0090"> <h3 class="title" id="CD004536-sec-0090">Effects of interventions</h3> <p>See: <a href="./full#CD004536-tbl-0001"><b>Summary of findings for the main comparison</b> Balanced nutritional supplement compared to counselling or nutritional placebo in patients with weight loss for reducing morbidity and mortality in people with HIV</a> </p> <p>We present the results of the trials conducted in adults followed by the results of the trials conducted in children. Where it was possible to combine the results of outcomes in a meta‐analysis, we report on the meta‐analysis of these outcomes. When meta‐analysis was not possible, we provide reasons for this and report the results for each trial. </p> <section id="CD004536-sec-0091"> <h4 class="title">ADULTS</h4> </section> <section id="CD004536-sec-0092"> <h4 class="title">Macronutrient interventions, fortified with micronutrients, given to provide protein and/or energy by replacing or supplementing usual diet plus nutrition counselling versus nutrition counselling alone or standard care </h4> <p><b><i>MACRONUTRIENT FORMULAS FORTIFIED WITH MICRONUTRIENTS PLUS NUTRITION COUNSELLING VERSUS NUTRITION COUNSELLING ALONE IN PARTICIPANTS WITH AND WITHOUT WEIGHT LOSS</i> </b> </p> <p>Five trials assessed the effects of macronutrient supplements given to provide protein and/or energy in conjunction with nutrition counselling compared to nutrition counselling alone in adequately nourished participant with or without weight loss (<a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>; <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>; <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a>; <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a>; <a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>). All the interventions included micronutrients in varied percentages of the Recommended Daily Allowance (details from product web sites). This may be a possible confounder in the outcomes of these studies, as one cannot distinguish between the effect of the increased energy supply or that of the vitamins and minerals. Excluding the <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> trial, all the participants entered the trials with a loss of body weight of more than 5% or a reduction in their BMI in the previous 6 months. As <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> was a three‐armed trial we report the comparisons between each of the two intervention groups and the control group.   </p> <p> <ul id="CD004536-list-0051"> <li> <p><b><i>Clinical symptoms</i> </b> </p> </li> </ul> </p> <p>Only <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> reported on clinical symptoms but did not define the symptoms nor provide numerical data. The authors report that there were no significant differences between reported clinical symptoms among the two intervention groups and the nutritional counselling control group. </p> <p> <ul id="CD004536-list-0052"> <li> <p><b><i>Energy intake</i> </b> </p> </li> </ul> </p> <p>Meta‐analysis of three trials (N = 131; <a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>; <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>; <a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>) comparing balanced nutritional supplements (consisting of 50‐60% carbohydrate, 15‐30% protein and 20‐30% fat aimed at improving energy intake by 600‐960 kcal/day) with no nutritional supplements, showed significantly increased energy intake by 394kcal/day in the intervention arm (Mean Difference: 393.57kcal/day; 95%CI: 224.66, 562.47; p &lt; 0.00001). See <a href="./references#CD004536-fig-0005" title="">Analysis 1.1</a>. The increase was statistically significant and could be as much as an increase of 562 kcal/day or as little as 225 kcal/day. There was little statistical heterogeneity between the trial results (Ҳ<sup>2</sup> = 2.75; df = 2; p = 0.25) with the heterogeneity quantified by an I<sup>2</sup> of 27%. </p> <p>Although no p values were presented, <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> reported no statistically significant differences in energy intake between the groups at any of the study visits. We calculated the mean difference, 95% CI and level of significance for energy intake at 12 months between each group. At 12 months there was no statistically significant difference in the mean energy intake between a) the Ensure Plus group (2236kcal/day, SD 1045) and the control group (1855 kcal/day, SD 991; mean difference: 381 kcal/day; 95%CI: ‐218.92,980.92; p=0.22); b) the Advera (Immune‐enhancing formula) group (2461 kcal/day, SD 1019) and the control group (1855 kcal/day, SD 991; mean difference: 606 kcal/day; 95%CI: ‐17.30,1229.30; p=0.06); and c) the Ensure Plus group (2236kcal/day, SD 1045) and the Advera group (2461 kcal/day, SD 1019; mean difference:‐225; 95%CI:‐817.69, 367.69; p=0.46). </p> <p><a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a> do not provide the numerical energy intake data but report that 56% of the group receiving the specialized MCT formula and 50% of the control group (nutritional counselling) achieved 80% or more of the energy target, defined as 960kcal/day greater than estimated total energy expenditure (p=0.56). </p> <p> <ul id="CD004536-list-0053"> <li> <p><b><i>Protein intake</i> </b> </p> </li> </ul> </p> <p>Meta‐analysis of two trials (N = 81; <a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>; <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>) showed supplementation with a liquid formula providing an additional 600‐795 kcal/day and consisting of 14‐17% protein, 55‐60% carbohydrates and 26‐32% fat, significantly increased daily protein intake compared with no supplements (Mean Difference: 23.25g/day; 95% CI: 12.68, 34.01; p &lt; 0.00001). See <a href="./references#CD004536-fig-0006" title="">Analysis 1.2</a>. There was no statistical heterogeneity between results (Ҳ<sup>2</sup> = 0.09; df = 1; p = 0.77) with the heterogeneity quantified by an I<sup>2</sup> of 0%. </p> <p><a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a>; <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a> and <a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a> did not report protein intake. </p> <p> <ul id="CD004536-list-0054"> <li> <p><b><i>BMI</i> </b> </p> </li> </ul> </p> <p>One trial reported on BMI at baseline and at 6 and 12 months (<a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a>). <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a> did not provide data for BMI as an outcome despite recording the method of analysis used for it. In <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> mean BMI at 12 months did not differ statistically significantly between the Ensure Plus group (Mean BMI: 24, SD 4 kg/m<sup>2</sup>) and the control group (Mean BMI: 27, SD 7 kg/m<sup>2</sup>; Mean Difference: ‐3, 95%CI: ‐6.5, 0.5; p=0.07); between the Advera group (Mean BMI: 26, SD 5 kg/m<sup>2</sup>) and the control group (Mean BMI: 27, SD 7 kg/m<sup>2</sup>; Mean Difference: ‐1, 95%CI: ‐4.8, 2.8; p=0.6) or between the Ensure Plus group (Mean BMI: 24, SD 4 kg/m<sup>2</sup>) and the Advera group (Mean BMI: 26, SD 5 kg/m<sup>2</sup>; Mean Difference: 2, 95%CI: 0.79, 4.79; p=0.17). Mean difference and p values were calculated in Review Manager.   </p> <p> <ul id="CD004536-list-0055"> <li> <p><b><i>Body weight</i> </b> </p> </li> </ul> </p> <p>A meta‐analysis of 4 trials (N=233; <a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>; <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>; <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a>; <a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>) found no statistically significant difference in body weight between the supplemented group and those receiving nutrition counselling alone (Mean Difference: ‐0.17; 95% CI: ‐1.10, 0.75; p = 0.72). See <a href="./references#CD004536-fig-0007" title="">Analysis 1.3</a>. Statistical heterogeneity was quantified at 9% by the I<sup>2</sup> and was not statistically significant (Ҳ<sup>2</sup> = 3.30; df = 3; p = 0.35). For this outcome we combined both mean change from baseline to end‐point data and actual mean body weight at the end‐point of the study. <a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a> reported that body weight did not change significantly from baseline in either group after 12 weeks and there was no significant difference between the groups at the study endpoint. After 6 weeks <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a> found no significant difference in body weight between the group receiving nutrition counselling and supplementation with a specialised MCT formula and those receiving nutrition counselling alone. <a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a> reported a similar increase in body weight in both groups after 8 weeks. <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a> was the only study to report a significant change in body weight in the supplemented group. Following 3 months of supplementation, <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a> reported a 2.75% (p&lt;0.05) increase in body weight in the Ensure® group, with the weight gain mainly due to an increase in fat mass. </p> <p><a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> reported no statistically significant differences in body weight between the groups after 12 months, but did not present the p values. Using Review Manager we calculated the mean difference, 95%CI and p values between the groups at 12 months. At 12 months the mean body weight for the Ensure Plus group was 72kg (SD 17) while the mean body weight in the control group was 78kg (SD 23; mean difference: ‐6.0; 95%CI:‐18.23, 6.23; p=0.32). The mean body weight for the Advera group (mean body weight=78kg, SD 13) and the control group (mean body weight=78kg, SD 23) were practically identical (Mean difference was 0, 95%CI: ‐11.74,11.74; p=1). Even though there was a 6 kg difference in mean body weight between the Ensure Plus group and the Advera group at 12 months this difference was not significant (Mean difference: 6; 95%CI: ‐2.57, 14.58; p=0.19). </p> <p> <ul id="CD004536-list-0056"> <li> <p><b><i>Fat mass</i> </b> </p> </li> </ul> </p> <p>A meta‐analysis of four trials (N = 233; <a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>; <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>; <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a>; <a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>) showed no statistically significant difference in fat mass, measured as a percentage of total body weight, between the supplemented and non‐supplemented groups (mean difference: ‐1.14%; 95% CI: ‐2.58, 0.29; p = 0.12). See <a href="./references#CD004536-fig-0008" title="">Analysis 1.4</a>. There was no statistical heterogeneity between results (Ҳ<sup>2</sup> = 1.34; df = 3; p = 0.72) with the heterogeneity quantified by an I<sup>2</sup> of 0%. </p> <p>In <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> body fat mass was presented in kg/m<sup>2</sup>. At 12 months the mean body fat mass in the Ensure Plus and in the Advera group was 9kgm<sup>2</sup>(SD 2), and in the control group it was 9kg/m<sup>2</sup>(SD 1). The authors report that there were no statistically significant differences between the groups but do not report the p values. Using Review Manager we calculated the following p values between the three groups at 12 months: mean fat mass in the Ensure Plus group versus the control group, p=1.0; mean fat mass in the Advera group compared to the control, p=1.0; mean fat value in the Ensure Plus group compared to the Advera group, p=1.0. </p> <p> <ul id="CD004536-list-0057"> <li> <p><b><i>Fat free mass</i> </b> </p> </li> </ul> </p> <p>In a meta‐analysis of three trials (N = 218; <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>; <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a>; <a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a>) there was no statistically significant difference in fat free mass between the supplemented and the non‐supplemented groups (MD: ‐0.37; 95% CI: ‐2.77, 2.03; p = 0.78). See <a href="./references#CD004536-fig-0009" title="">Analysis 1.5</a>. Statistical heterogeneity between results was not significant (Ҳ<sup>2</sup> = 4.77; df = 2; p = 0.09) but was high with the heterogeneity quantified by an I<sup>2</sup> of 58%. </p> <p>Fat free mass was not reported in <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> or in <a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>. </p> <p> <ul id="CD004536-list-0058"> <li> <p><b><i>CD4 cell count</i> </b> </p> </li> </ul> </p> <p>A meta‐analysis of the two trials which reported on this outcome (N = 81; <a href="./references#CD004536-bbs2-0001" title="BerneisK , BattegayS , BassettiS , NueschR , LeisibachA , BilzS , KellerU . Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV‐infected patients. European Journal of Clinical Investigation2000;30(1):87‐94. ">Berneis 2000</a>; <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>) showed no statistically significant difference in CD4 cell count between the supplemented and the non‐supplemented groups (Mean Difference: ‐114.48; 95%CI: ‐233.20, 4.23; p = 0.06). See <a href="./references#CD004536-fig-0010" title="">Analysis 1.6</a>. Heterogeneity was not significant (Ҳ<sup>2</sup> = 0.13; df = 1; p = 0.72) with the heterogeneity quantified by an I<sup>2</sup> of 0%. </p> <p><a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> reported no significant difference in mean CD4 cell counts between the three groups at any of the time points. At 12 months the mean CD4 cell count in the Ensure Plus group was 471 cells/mm<sup>3</sup> (SD 175), compared to the mean CD4 cell count in the Advera group (459 cells/mm<sup>3</sup>, SD 198; mean difference: 12; 95%CI: ‐96.15, 120.15; p=0.82) and the mean CD4 cell count in the control group (437 cells/mm<sup>3</sup>, SD 182; mean difference: 34; 95%CI: ‐71.93, 139.93; p=0.5). There was also no significant difference in the mean CD4 cell count between the Advera and the control group (459 cells/mm<sup>3</sup>, SD 198 vs 437 cells/mm<sup>3</sup>, SD 182; mean difference: ‐22; 95%CI: ‐139.76, 95.76; p=0.72) at 12 months. </p> <p><a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a> reports that there was no significant change observed in CD4 counts between the groups (no data provided). </p> <p><a href="./references#CD004536-bbs2-0010" title="SchwenkA , SteuckH , KremerG . Oral supplements as adjunctive treatment to nutritional counselling in malnourished HIV‐infected patients: randomised controlled trial. Clinical Nutrition1999;18(6):371‐374. ">Schwenk 1999</a> did not report on CD4 counts. </p> <p> <ul id="CD004536-list-0059"> <li> <p><b><i>Viral load</i> </b> </p> </li> </ul> </p> <p>Only one of the five trials (<a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a>) reported on the change in viral load over the course of the trial. After 12 weeks no statistically significant difference was noted in HIV viral load (log<sub>10</sub>copies/ml) between the supplemented and non‐supplemented groups (N=66 participants; Mean Difference: ‐3.71 log<sub>10</sub>copies/ml; 95% CI: ‐12.16, 4.74; p = 0.39) in this study. </p> <p> <ul id="CD004536-list-0060"> <li> <p><b><i>Adverse effects</i> </b> </p> </li> </ul> </p> <p>Adverse effects were poorly reported and in general, were related to tolerance rather than adverse effects. <a href="./references#CD004536-bbs2-0006" title="KeithleyJK , SwansonB , ZellerJM , ShaBE , CohenM , HershowR , et al. Comparison of standard and immune‐enhancing oral formulas in asymptomatic HIV‐infected persons: a multicenter randomized controlled clinical trial. Journal of Parenteral and Enteral Nutrition2002;26(1):6‐14. ">Keithley 2002</a> reports that no significant differences were found in acceptance and tolerance of the formulas. <a href="./references#CD004536-bbs2-0008" title="RabeneckL , PalmerA , KnowlesJB , SeidehamelRJ , HarrisCL , MerkelKL , RisserJMH , AkrabawiSS . A randomised controlled trial evaluating nutrition counselling with or without supplementation in malnourished HIV‐infected patients. Journal of American Dietary Association1998;98:434‐438. ">Rabeneck 1998</a> noted that one participant discontinued the supplement due to nausea and epigastric pain and one discontinued as he did not like the taste of the supplement. </p> <p><b><i>SUPPLEMENTARY FOOD FORTIFIED WITH MICRONUTRIENTS PLUS NUTRITION COUNSELLING VS NUTRITIONAL COUNSELLING ALONE IN MALNOURISHED PARTICIPANTS</i> </b> </p> <p>A study conducted in Kenya evaluated the impact of supplementary food on nutritional and clinical status, treatment progress and quality of life of malnourished HIV‐infected adults on ART and pre‐ART (i.e. HIV‐infected adults who did not qualify for ART according to the Kenyan National HIV treatment protocol. ART was only provided to HIV‐infected adults who met the WHO Stage IV disease criteria, or who had a CD4 count &lt;200 cells/µl <a href="./references#CD004536-bbs2-0004" title="CastlemanT , MwadimeR , et al. Randomised controlled trial of the impact of supplementary food on malnourished adult ART clients and adult pre‐ART clients in Kenya. Final reportJune 2011. ">FANTA‐KEMRI study 2011</a>). This trial pre‐dated the recommendation to commence ART at CD4 counts less than 350 cells/µl. The food products were distributed monthly, for six months or until subjects reach the exit criterion of BMI = 23 kg/m<sup>2</sup>, whichever occurred first, and participants were followed up for a year. The food product was a blend of maize, soya, vegetable oil, sugar, whey protein concentrate, and micronutient pre‐mix. The food was provided in 300 gram packets and provided 1320 kcal/day energy and 48 g/day protein. At the time of the study, the cost of the food product was approximately $1/kg, or $0.30/300g dose, or $0.23/1,000 kcal. All patients in the study received nutrition counselling according to national protocols and using counselling materials and job aids provided by NASCOP.  The nutrition counseling was usually carried out by a trained nutritionist or dietician and focused on supporting the client in appropriate weight gain and management of diet‐related symptoms and food‐drug interactions.  </p> <p> <ul id="CD004536-list-0061"> <li> <p><b><i>Body weight, change in body weight, BMI and % lean body mass</i> </b> </p> </li> </ul> </p> <p>The authors noted that at baseline pre‐ART participants had higher weight and BMI compared to the ART participants. Throughout the trial pre‐ART participants gained less weight each month than the ART participants. </p> <p>Amongst participants receiving ART there was no significant difference in mean body weight at any of the time points between the supplement and no supplement group (See <a href="./references#CD004536-fig-0012" title="">Analysis 2.1</a>. However, in the first 3 months of the trial the supplement group appeared to gain weight more rapidly than the no supplement group, as they had a significantly greater change in body weight gain compared to the no supplement group at these time points. After this time point the change in body weight was not significantly different between the groups (See <a href="./references#CD004536-fig-0013" title="">Analysis 2.2</a>). Mean BMI and change in BMI in the supplement group was significantly higher in the first 3 months compared to the no supplement group (See <a href="./references#CD004536-fig-0014" title="">Analysis 2.3</a>). After 3 months there was no significant difference in weight gain, BMI or BMI gain between the supplement and no supplement groups in the participants receiving ART. </p> <p>Amongst participants not receiving ART, at 3 months (p=0.0027) and 6 months (p=0.001), the supplement group had a significantly greater mean body weight than the no supplement group (See <a href="./references#CD004536-fig-0012" title="">Analysis 2.1</a>). In the first 4 months of the trial and at the 6 month and 9 month time point, the supplement group had a significantly greater body weight gain compared with the no supplement group (See <a href="./references#CD004536-fig-0013" title="">Analysis 2.2</a>). In the first 3 months of the trial and in month 6, 7 and 9, mean BMI in the supplement group was significantly greater than in the no supplement group (See <a href="./references#CD004536-fig-0014" title="">Analysis 2.3</a>). In the first 4 months of the trial and months 6, 7, 8 and 9 the supplement group exhibited a significantly greater gain in BMI than the no supplement group. </p> <p>There was no significant difference in % lean body mass or changes in % lean body mass between the supplement and no supplement group at any time point for both the ART arm and the pre‐ART arm (See <a href="./references#CD004536-fig-0015" title="">Analysis 2.4</a>). </p> <p> <ul id="CD004536-list-0062"> <li> <p><b><i>Clinical and immunological outcomes</i> </b> </p> </li> </ul> </p> <p>There was no significant difference in mean CD4 cell count between the supplement and no supplement group at any time point for both the ART arm and the pre‐ART arm. However, in the pre‐ART arm, at 3 months, the mean CD4 cell count in the supplement group increased by 7.4±123.5 and the mean CD4 cell count in the no supplement group decreased by 32.59±103.5 (p=0.01, authors own data). </p> <p>Supplemented ART participants had significantly higher increase in hemoglobin levels at month 3 compared to the no supplement group (change in hemoglobin: 1.23±2.3 in supplement group vs 0.69±2.4 in the no supplement group, p=0.05). Supplemented pre‐ART participants had a significantly higher increase in hemoglobin levels at 3 (0.93±2.7 in the supplement group vs 0.01±2.3 in the no supplement group; p=0.01) and 6 months (0.78±3.1 in the supplement group vs ‐0.18±0.6 in the no supplement group; p=0.05) compared to the no supplement group. </p> <p>The authors only present the 3 month values for changes in serum albumin. Based on this data there was no difference in changes in serum albumin at this time point between the supplement and no supplement groups for either arms of the study. </p> <p> <ul id="CD004536-list-0063"> <li> <p><b><i>Quality of life</i> </b> </p> </li> </ul> </p> <p>The authors report that most of the changes in quality of life occurred during the initial months of the study. The majority of the ART and pre‐ART participants experienced improvements in perceived health or their perceived health remained good, in both supplement and no supplement groups. The authors report that pre‐ART participants receiving supplementary food on average experienced significantly greater improvement and less of a decline in perceived health than those not receiving food.  These differences did not persist over longer periods of follow‐up.  Among ART participants, the difference in changes in perceived health between those receiving food and those not receiving food was smaller and not statistically significant (data presented graphically). </p> <p>In the report, quality of life was also measured by the number of days per month that subjects reported having had poor physical health during the first three months. The authors report that among pre‐ART participants, those receiving food had fewer poor health days than those not receiving food, and the differences were significant during the first and second months, but not subsequently.  Among ART participants, the difference was significant in the second month only (data presented graphically).  <b><i> </i> </b> </p> <p> <ul id="CD004536-list-0064"> <li> <p><b><i>Attrition</i> </b> </p> </li> </ul> </p> <p>Attrition, defined as discontinuation of care and treatment at the health facility for any reason, including death, loss‐to‐follow‐up, or relocation was high in all groups. Authors report that the highest rate of attrition occurred during the first month of the study: with an attrition rate of 26% in the ART arm and 24% in the pre‐ART arm.  By the third month of follow‐up, 37% and 39% of participants in the food and no‐food groups of the ART arm and 37% and 48% of the food and no‐food groups in the pre‐ART arm respectively had been lost from the study. The difference in attrition between the food and no‐food groups in the pre‐ART arm was significant (p=.039), and the difference between the groups in the ART arm was not significant (data reported by author). </p> <p>In the ART arm, the mean durations that participants were retained in the study were 6.3 months and 5.9 months for the food and no‐food groups respectively. In the pre‐ART arm the mean durations that subjects were retained in the study were 5.9 and 5.4 months for the food and no‐food groups respectively (author's results).  </p> <p>The above data is from an unpublished report prepared by the study coordinators (See <a href="./references#CD004536-bbs2-0004" title="CastlemanT , MwadimeR , et al. Randomised controlled trial of the impact of supplementary food on malnourished adult ART clients and adult pre‐ART clients in Kenya. Final reportJune 2011. ">FANTA‐KEMRI study 2011</a>). The report does not include data on all of the measured outcomes, such as adherence to ART, survival, number of severe clinical events (defined as the sum of hospitalizations and deaths) and number of non‐severe clinical events (defined as the number of new opportunistic infections and new symptoms for which medication is required). </p> <p>In a study conducted in India (<a href="./references#CD004536-bbs2-0013" title="SudarsanamTD , JohnJ , KangG , MahendriV , GerriorJ , FranciosaM , et al. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV‐tuberculosis coinfection receiving directly observed short‐course chemotherapy for tuberculosis. Tropical medicine &amp; international health : TM &amp; IH2011;16(6):699‐706. [PUBMED: 21418447] ">Sudarsanam 2011</a>) participants with pulmonary tuberculosis, with and without HIV co‐infection, and a BMI &lt;19 kg/m² were randomised to receive a cereal‐lentil mixture, micronutrient supplement plus standard care versus standard care alone. The supplement consisted of three daily servings of a cereal and lentil mixture (providing 930 kcal and 31.5 g protein) and a once a day multivitamin tablet. Patients were given a months supply of supplement at a time. TB/HIV‐coinfected individuals were treated for TB but did not receive ART, as per protocol in India at the time. Despite randomisation the supplemented group had poorer initial nutritional status as measured by most parameters. </p> <p>There was no significant difference in risk of death at 6 months (22 TB/HIV participants: RR: 2.14, 95% CI: 0.10, 47.38), cure rate at 6 months (22 TB/HIV participants: RR: 1.38, 95% CI: 0.46, 4.14) and treatment failure before 6 months (22 TB/HIV participants: RR: 0.69, 95% CI: 0.12, 4.05) between the two groups. (Data and information retrieved from recently updated Cochrane review: Nutritional supplements for people being treated for active tuberculosis <a href="./references#CD004536-bbs2-0088" title="SinclairD , AbbaK , GroblerL , SudarsanamTD . Nutritional supplements for people being treated for active tuberculosis. Cochrane Database of Systematic Reviews2011, Issue 11 DOI: 10.1002/14651858.CD006086.pub3. ">Sinclair 2011</a>). </p> <p>At the end of the trial there was no significant difference in mean CD4 cell count (See Analysis 5.2: 221±142 cell count.mm<sup>‐3</sup> in supplemented group vs 249±387 cell count.mm<sup>‐3</sup> in no supplement group, SMD: ‐0.10 95% CI: ‐0.95, 0.75) and median viral load (845819 HIV viral load.ml<sup>‐1</sup> in supplemented group vs 1435700 HIV viral load.ml<sup>‐1</sup> in no supplement group) between the two groups in the TB/HIV‐coinfected individuals. </p> <p>Although supplementation resulted in a significant increase in daily caloric (11.15±882.2 in supplement group vs ‐375.42±893.2 kcal in no supplement group, p=0.05), protein (4.6±29.2g in supplement group vs ‐9.85±25.9 g in no supplement group, p=0.019) and fat (2.86±18.9 g in supplement group vs ‐10.78±17.1 g in no supplement group, p=0.009) intakes, compared to the no supplement group, changes in lean body mass and fat mass in both groups were similar at the end of the trial (change in lean body mass: 2.37±4.97 kg in supplement groups vs 2.40±6.3 kg in no supplement group, p=0.479; change in fat mass: 1.72±4.8 kg in supplement groups vs 1.1±5.4 kg in no supplement group, p=0.573). Data for mean weight are only presented graphically. Authors reported no difference in mean weight changes between the two groups throughout the study. These results are for all the participants, both TB and TB/HIV participants. We have requested information for the TB/HIV participants alone but have not yet received it from the author. </p> </section> <section id="CD004536-sec-0093"> <h4 class="title">Specific macronutrient supplements versus placebo, no supplements or usual diet</h4> <p>Four trials assessed specific supplements compared either with a placebo or traditional meals in adults (<a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a>; <a href="./references#CD004536-bbs2-0005" title="KarsegardVL , RagusoCA , GentonL , HirschelB , PichardC . L‐Ornithine alpha‐Ketoglutarate in HIV infection: Effects on muscle, gastrointestinal and immune functions. Nutrition2004;20:515‐520. ">Karsegard 2004</a>; <a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a>; <a href="./references#CD004536-bbs2-0014" title="YamaniE , Kaba‐MebriJ , MoualaC , GresenguetG , ReyJL . Use of spirulina supplement for nutritional management of HIV‐infected patients: study in Bangui, Central African Republic. Medecine Tropicale2009;69(1):66‐70. ">Yamani 2010</a>). Two trials were conducted in participants with weight loss or low BMI (<a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a>; <a href="./references#CD004536-bbs2-0014" title="YamaniE , Kaba‐MebriJ , MoualaC , GresenguetG , ReyJL . Use of spirulina supplement for nutritional management of HIV‐infected patients: study in Bangui, Central African Republic. Medecine Tropicale2009;69(1):66‐70. ">Yamani 2010</a>). Two trials were conducted in participants with normal or assumed normal weight (<a href="./references#CD004536-bbs2-0005" title="KarsegardVL , RagusoCA , GentonL , HirschelB , PichardC . L‐Ornithine alpha‐Ketoglutarate in HIV infection: Effects on muscle, gastrointestinal and immune functions. Nutrition2004;20:515‐520. ">Karsegard 2004</a>; <a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a>). </p> <p><b><i>ARGININE, GLUTAMINE AND B‐HYDROXY‐B‐METHYLBUTYRATE</i> </b> </p> <p><a href="./references#CD004536-bbs2-0002" title="ClarkRH , FelekeG , DinM , YasminT , SinghG , KhanFA , RathmacherJA . Nutritional treatment for Acquired Immunodeficiency Virus‐associated wasting using B‐hydroxy B‐methylbutyrate, glutamine and arginine: a randomised, double‐blind, placebo‐controlled study. Journal of Parenteral and Enteral Nutrition2000;24:133‐139. ">Clark 2000</a> compared the effects of an amino acid mixture containing 14g arginine (free base), 14g glutamine, 3g ß‐hydroxy‐ß‐methylbutyrate (HMB, calcium salt) and citric acid (ph 4.5) with maltodextrin control formulation in participants with unintentional weight loss of 5% or more in the past 3 months who were on ART. After 8 weeks the arginine group gained significantly greater body weight than the control group (MD: 2.63 95% CI: 0.72, 4.54). See <a href="./references#CD004536-fig-0016" title="">Analysis 3.1</a>. There was no significant difference in change in fat mass between the two groups (MD: ‐0.64 g; 95% CI: ‐2.69, 1.41; p = 0.54). See <a href="./references#CD004536-fig-0017" title="">Analysis 3.2</a>. The increase in fat‐free mass was statistically significantly greater in the arginine group compared with controls (MD: 3.25kg; 95% CI: 1.25 to 5.25; p = 0.001). See <a href="./references#CD004536-fig-0018" title="">Analysis 3.3</a>. CD4 count in the arginine group was reported to increase but not statistically significantly so (p = 0.10). Viral load was reported to decrease statistically significantly (p = 0.007) in the arginine group but actual data for the study endpoint is not presented. Energy intake was not reported on in this study. </p> <p><b><i>SPIRULINA</i> </b> </p> <p>The trial by <a href="./references#CD004536-bbs2-0014" title="YamaniE , Kaba‐MebriJ , MoualaC , GresenguetG , ReyJL . Use of spirulina supplement for nutritional management of HIV‐infected patients: study in Bangui, Central African Republic. Medecine Tropicale2009;69(1):66‐70. ">Yamani 2010</a> was conducted in ARV naive adults from the Central African Republic. A total of 160 patients were included in the trial. Patients in the spirulina group (N=79) received 10g spirulina per day and participants in the placebo group (N=81) received green clay. Each week all participants received food packages from the World Food Program consisting of 14g maize flour, 500g mixture of maize and soya bean, 2kg garden peas, 500g sugar, 150g iodized salt and 500ml oil. </p> <p>During the 6 month follow‐up, 16 patients died and 16 patients were lost to follow up. There was no significant difference in the distribution of lost cases or deaths between the two groups (Spirulina group: 6 deaths and 6 lost to follow‐up vs placebo group: 10 deaths and 10 lost to follow‐up (p=0.8). </p> <p>The authors report a statistically significant gain in weight from baseline in each group after 6 months. There was no significant difference in weight gain between the two groups over this time period. Arm circumference also increased significantly in each group, without significant difference between both the groups. </p> <p>At 3 months the authors reported a significant decrease in mean Karnofsky score in the placebo group versus the spirulina group (p=0.0045). Thereafter the mean Karnofsky score in the placebo group increased to a value similar to that of the spirulina group. </p> <p>The authors reported a lower number of pneumonia cases in the spirulina group versus the placebo group at 6 months (p=0.01, number of pneumonia cases in each group not presented. Specific information has been requested from author).  </p> <p>After 6 months CD4 count increased in both groups. This increase was not significant and there was no difference in CD4 count between the two groups at the end of the trial. Hemoglobin values decreased in both groups between months 0 and 6, with no significant difference between spirulina and placebo groups. </p> <p>In both groups serum protein concentration increased in the first 3 months and then decreased in the following 3 months. There was a significant increase in serum protein (g/L) in the spirulina group between months 0‐3 (p value not shown) and months 0‐6 (p=0.0001). At 3 months (p=0.01) and 6 months (p=0.00001) serum protein concentrations were significantly higher in the spirulina group compared to the placebo group. In both groups, serum creatinine levels decreased at month 3 and then increased again at month 6. At 3 months serum creatinine levels were significantly higher in the spirulina group compared to the placebo group (p=0.01). </p> <p><b><i>MONOHYDRATED L‐ORNITHINE ALPHA‐KETOGLUTARATE</i> </b> </p> <p><a href="./references#CD004536-bbs2-0005" title="KarsegardVL , RagusoCA , GentonL , HirschelB , PichardC . L‐Ornithine alpha‐Ketoglutarate in HIV infection: Effects on muscle, gastrointestinal and immune functions. Nutrition2004;20:515‐520. ">Karsegard 2004</a> compared glutarate supplementation with an isonitrogenous placebo containing 9g of milk proteins. Nutrition counselling was provided to all participants. No morbidity data were reported. At study endpoint there were no statistically significant differences between the groups in daily energy intake, body weight, fat mass, fat‐free mass or in the CD4 cell counts or viral loads. See <a href="./references#CD004536-fig-0019" title="">Analysis 4.1</a>; <a href="./references#CD004536-fig-0020" title="">Analysis 4.2</a>; <a href="./references#CD004536-fig-0021" title="">Analysis 4.3</a>; <a href="./references#CD004536-fig-0022" title="">Analysis 4.4</a>; <a href="./references#CD004536-fig-0023" title="">Analysis 4.5</a>; <a href="./references#CD004536-fig-0024" title="">Analysis 4.6</a>; <a href="./references#CD004536-fig-0025" title="">Analysis 4.7</a>. The authors conducted ANOVA tests with last known reported values used for missing data and found that there were statistically significant increases in body weight (mean body weight at baseline: 61.2, SD 11.9 in placebo and 56.4 SD 11.2 in OKG group vs mean body weight at 12 weeks: 61.8 SD 11.5 in placebo and 56.8 SD 11.6 in OKG group), BMI (mean BMI at baseline: 20.6, SD 3.0 in placebo and 20.0, SD 2.4 in OKG group vs mean BMI at 12 weeks: 20.8, SD 2.9 in placebo and 20.2, SD 2.5 in OKG group), and triceps skinfold thickness (mean triceps skinfold thickness at baseline: 14.0, SD 5.4 in placebo and 13.4, SD 4.9 in OKG group vs mean triceps skinfold thickness at 12 weeks: 15.5, SD 5.6 in placebo and 15.0, SD 6.1 in OKG group) from baseline in both groups. They do not report specific p values but only p &lt; 0.05 for these outcomes. </p> <p>The authors report that appetite and food tolerance remained stable over time but that frequency of gastrointestinal events was significantly higher in the OKG group (authors' reported p value &lt; 0.05). Of the 22 participants taking OKG, 19 reported at least one GI adverse event compared with 13 out of 24 in the placebo group with participants in the OKG group one and a half times more likely to experience GI adverse events (RR = 1.59, 95% CI: 1.06, 2.39; p = 0.02). </p> <p><b><i>L‐GLUTAMINE AND ANTIOXIDANTS</i> </b> </p> <p><i> </i><a href="./references#CD004536-bbs2-0011" title="ShabertJK , WinslowC , LaceyJM , WilmoreDW . Glutamine‐antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomised, double‐blind controlled trial. Nutrition1999;15:860‐864. ">Shabert 1999</a> compared a supplement comprising L‐glutamine and antioxidants (ascorbic acid, a‐tocopherol, ß‐carotene, selenium and N‐acetyl cysteine) with a placebo supplement comprising 40g glycine. Nutrition counselling and multivitamin supplementation was provided to all participants. </p> <p>Mean weight at study endpoint was not statistically significantly different between the groups (MD: ‐1.30kg; 95% CI: ‐10.18, 7.58; p = 0.77). See <a href="./references#CD004536-fig-0027" title="">Analysis 5.1</a>. Data were not provided to calculate the change in weight over time, but the authors report in the text that the mean change in weight from baseline to week 12 was 2.2kg in the glutamine group and 0.3kg in the placebo group (p =0.04). Similarly mean change in body cell mass (the total mass of all the cellular elements in the body which constitute all the metabolically active tissue of the body; includes muscle tissue, organ tissue, intracellular and extracellular water, and bone tissue) was reported as statistically significantly different between the groups with a greater increase in the glutamine group (mean gain = 1.8kg) than in the placebo (mean gain = 0.4kg). No standard deviations are provided; the authors report a p = 0.007. Mean fat mass was not different between groups at study endpoint (MD: ‐1.00kg; 95% CI: ‐32.40, 30.40; p = 0.95). See <a href="./references#CD004536-fig-0028" title="">Analysis 5.2</a>. </p> <p>Mean CD4 count was not statistically significant between groups (MD: 66.00; 95% CI: ‐53.39, 185.39; p = 0.28). See <a href="./references#CD004536-fig-0029" title="">Analysis 5.3</a>. The authors conducted an assessment of mood questionnaire at baseline and week 12 using a 30‐item profile of the Short Form 36 and report no statistically significant differences between the groups. The authors did not observe any adverse effects in either of the groups. </p> </section> <section id="CD004536-sec-0094"> <h4 class="title">CHILDREN</h4> <p>Three trials were conducted in children. One trial investigated enhanced nutritional support compared with standard nutritional support in children with prolonged diarrhoea (<a href="./references#CD004536-bbs2-0009" title="RollinsNC , van denBroeckJ , KindraG , PentM , KasambiraT , BennishML . The effect of nutritional support on weight gain of HIV‐infected children with prolonged diarrhoea. Acta Paediatrica2007;96:62‐68. ">Rollins 2007</a>), one trial investigated a whey protein concentrate compared to maltodextrin placebo in children with rapidly progressing HIV (<a href="./references#CD004536-bbs2-0007" title="MorenoYF , SgarbieriVC , daSilvaMN , ToroAADC , VilelaMMS . Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. Journal of Tropical Pediatrics2005;52(1):34‐38. ">Moreno 2005</a>) and one trial investigated the effects of spirulina plus traditional meals versus traditional meals alone in malnourished HIV‐infected children (<a href="./references#CD004536-bbs2-0012" title="SimporeJ , ZongoF , KaboreF , DansouD , BereA , NikiemaJ , PignatelliS , BiondiD , RubertoG , MusumeciS . Nutrition rehabilitation of HIV‐infected and HIV‐negative undernourished children utilizing Spirulina. Annuls of Nutrition and Metabolism2005;49:373‐380. ">Simpore 2005</a>). </p> </section> <section id="CD004536-sec-0095"> <h4 class="title">Macronutrient supplementation (fortified with micronutrients) versus no supplement or standard care </h4> <p><i>ENHANCED NUTRITIONAL SUPPORT VS STANDARD NUTRITIONAL SUPPORT IN CHILDREN WITH PROLONGED DIARRHOEA</i> </p> <p>The primary outcome of the study by <a href="./references#CD004536-bbs2-0009" title="RollinsNC , van denBroeckJ , KindraG , PentM , KasambiraT , BennishML . The effect of nutritional support on weight gain of HIV‐infected children with prolonged diarrhoea. Acta Paediatrica2007;96:62‐68. ">Rollins 2007</a> was weight change from enrolment until 8 weeks among 169 HIV‐infected children. The study reported that children receiving enhanced nutrition support had significantly more weight gain in the first 8 weeks than children receiving standard care (weight gain was expressed as the median change in age‐ and sex specific weight standard deviation scores (SDS): +1.02 (enhanced nutritional support group) vs +0.01 (standard nutritional support group), p &lt; 0.0001). </p> <p>Mean weight‐for‐age standard deviation score (WFA‐SDS) at baseline of those who dropped out was not different between groups: (Standard nutritional support group dropouts: –3.24 vs; enhanced nutritional support group dropouts: –3.39; p &gt; 0.05) standard nutritional support group completers: –3.00, vs enhanced nutritional support group completers: –3.19, p &gt; 0.05). Therefore, the observed outcome among the completers appeared to be unaffected by dropout bias. </p> <p>After 8 weeks, weight gain was similar between groups, with only a slight increase in weight‐SDS over time in each group. Median change in weight‐SDS from 8 to 14 weeks of follow‐up: +0.21 (enhanced nutritional support group) vs. 0.00 (standard nutrition support group: 14 to 26 weeks of follow‐up: +0.12 (enhanced nutritional support group) vs. +0.24 (standard nutritional support). </p> <p>Children receiving enhanced nutritional support exhibited significantly higher median attained WFA‐SDS after 8 weeks (‐1.99 vs ‐3.06, p&lt;0.05), 14 weeks (‐1.69 vs ‐2.96, p,0.05) and 26 weeks (‐1.32 vs ‐2.63, p,0.05) compared to the children receiving standard nutritional support. Children in the enhanced nutritional support group who were randomised to continue with the enhanced nutrition support until 6 months showed a further improvement in median attained WFA‐SDS (−1.01 SDS) at 6 months compared to those who reverted back to standard home diet who maintained the same median value attained at 3 months (‐1.68 SDS). </p> <p>No significant differences in CD4 cell counts or viral load between groups or over time were reported. However, it should be noted that changes in viral load could only be assessed in a subset of 70 children. The pattern of morbidity throughout the study was also similar between groups based on the cumulative frequency of clinical signs recorded during the follow‐up intervals of 0–8, 8–14 and 14–26 weeks. </p> <p>Dropout rates at the end of the study were high in both groups (Standard nutritional support: 27/83 (33%); Enhanced nutritional support: 38/86 (44%); difference 11%, 95%CI: −3 to +26). Authors reported the primary reason for attrition in the study was death. There was no significant difference between the two groups for death at 8 weeks (Death at 8 weeks: 10/83 (12%) in standard nutritional support group vs 14/86 (16%) in enhanced nutritional support group; OR: 1.42 95% CI: 0.59, 3.40; p=0.43; See <a href="./references#CD004536-fig-0030" title="">Analysis 6.1</a>) or death at 26 weeks (Death at 26 weeks: 18/83 (22%) in standard nutritional support group vs 25/86 (29%) in enhanced nutritional support group; OR: 1.48 95% CI: 0.74, 2.98; p=0.27; See <a href="./references#CD004536-fig-0031" title="">Analysis 6.2</a>). </p> </section> <section id="CD004536-sec-0096"> <h4 class="title">Specific macronutrient supplements versus placebo, no supplements or usual diet (two trials) </h4> <p>Two trials assessed supplementation with specific macronutrients compared either with a placebo or traditional meals in children. One trial was conducted in Brazilian children with rapidly progressive HIV infection (<a href="./references#CD004536-bbs2-0007" title="MorenoYF , SgarbieriVC , daSilvaMN , ToroAADC , VilelaMMS . Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. Journal of Tropical Pediatrics2005;52(1):34‐38. ">Moreno 2005</a>). One trial, conducted in Africa investigated the effects of Spirulina in undernourished children (<a href="./references#CD004536-bbs2-0012" title="SimporeJ , ZongoF , KaboreF , DansouD , BereA , NikiemaJ , PignatelliS , BiondiD , RubertoG , MusumeciS . Nutrition rehabilitation of HIV‐infected and HIV‐negative undernourished children utilizing Spirulina. Annuls of Nutrition and Metabolism2005;49:373‐380. ">Simpore 2005</a>). </p> <p><b><i>WHEY PROTEIN CONCENTRATE</i> </b> </p> <p><a href="./references#CD004536-bbs2-0007" title="MorenoYF , SgarbieriVC , daSilvaMN , ToroAADC , VilelaMMS . Features of whey protein concentrate supplementation in children with rapidly progressive HIV infection. Journal of Tropical Pediatrics2005;52(1):34‐38. ">Moreno 2005</a> was conducted in Brazil in rapidly progressive HIV vertically infected children (N=18). Participants received whey protein concentrate, maltodextrin or placebo. In the final data analysis the results of the maltodextrin and the placebo groups were combined (will be referred to as the placebo group) and compared with those of the whey protein concentrate group. All children were on some form of ART. </p> <p>Overall attrition was high at 27.7% (5/18), but similar in both groups (3 lost from whey protein concentrate group vs 2 lost from the placebo group). Authors reported that 22.2% (2/9) of the children in the whey protein concentrate group developed co‐infections during the 16 week study compared to 77.7% (7/9) of the children in the placebo group (p=0.0567, author's data). </p> <p>While a non‐significant increase in median CD4 cell count was demonstrated in both groups, no significant difference in median CD4 cell count between the two groups was noted throughout the study. Median CD8 cell count decreased over time in the whey protein concentrate group, with a significant difference noted between the 8 weeks and the 16 week values (p=0.046). Since viral load was only measured in 6 children in the whey protein concentrate group, differences between treatment groups could not be assessed. There was no significant difference between the groups for levels of leukocytes, erythrocytes, hemoglobin and platelets. </p> <p><b><i>SPIRULINA</i> </b> </p> <p>The trial by <a href="./references#CD004536-bbs2-0012" title="SimporeJ , ZongoF , KaboreF , DansouD , BereA , NikiemaJ , PignatelliS , BiondiD , RubertoG , MusumeciS . Nutrition rehabilitation of HIV‐infected and HIV‐negative undernourished children utilizing Spirulina. Annuls of Nutrition and Metabolism2005;49:373‐380. ">Simpore 2005</a> was conducted in undernourished HIV‐negative and HIV‐positive children in Burkina Faso. Only the results of 84 HIV‐positive children who participated in the trial will be reported in this review. The intervention group received 10g spirulina daily along with traditional meals of millet, vegetables and fruit whereas the comparison group received traditional meals only for 8 weeks. </p> <p>There was a significant increase in weight‐for‐height z scores (WHZ) in both groups after 8 weeks. There was no difference in WHZ between the groups at the end of the study. See <a href="./references#CD004536-fig-0032" title="">Analysis 7.1</a>. There was also a significant increase in weight‐for‐age z‐scores in both groups after 8 weeks but no differences between the groups were noted. See <a href="./references#CD004536-fig-0033" title="">Analysis 7.2</a>. </p> <p>Authors reported that treatment compliance was excellent and none of the children dropped out or were lost to follow up.  </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004536-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004536-sec-0097"></div> <section id="CD004536-sec-0098"> <h3 class="title" id="CD004536-sec-0098">Summary of main results</h3> <p>Our review establishes that experimental evidence on the effects of macronutrient supplementation on important clinical outcomes in HIV‐infected adults and children is surprisingly limited; despite an exhaustive search, we found only 14 relatively small randomised controlled trials that met the inclusion criteria of our review. Apart from the two trials evaluating Spirulina, one trial in adults and one trial in children, each of the trials evaluated a different macronutrient supplement. Participants included in the trials also varied quite considerably in terms of stage of HIV, HIV treatment status and general nutrient status. Only three trials reported on mortality, two trials in adults and one trial in children. Meta‐analysis was only possible on one class of supplements, viz. balanced macronutrient supplements fortified with micronutrients plus nutrition counselling versus nutritional counselling alone or standard care. GRADE assessments were conducted on outcomes for this meta‐analysis and included reviewing the data and the potential biases in each trial before grading the level of evidence. None of the trials were graded as providing strong evidence primarily because of small sample sizes (even after meta‐analysis) and the high risk of bias due to a lack of blinding, high attrition and unclear reporting of randomisation methods. </p> <p>In adult participants with weight loss, balanced macronutrient supplements aimed at improving energy intake by 600‐960 kcal/day increased intakes of energy and protein compared with no supplement or nutrition counselling alone, but had no effect on other anthropometric or immunologic parameters. This is an important finding as loss of appetite and consequent decreased food intake is common in people with HIV. The increased energy and protein intake in the supplemented group resulted in increased body weight in most cases. However, only in <a href="./references#CD004536-bbs2-0003" title="deLuisD , AllerR , BachillerP , Gonzalez‐SagradoM , deLuisJ , IzaolaO , TerrobaMC , CuellarL . Isolated dietray counselling program versus supplement and dietary counselling in patients with human immunodeficiency virus infection. Med Clin (Barc)2003;120(15):565‐567. ">de Luis 2003</a> was the increase in body weight in the supplemented group significantly greater than that of the group receiving nutrition counselling alone. </p> <p>As all the supplements included micronutrients supplementation, it is not possible to determine if the observed effects of an increase in energy and protein intake are due to the combination of the macro‐ and micronutrient components or the macronutrient component alone. Variation in the nutritional composition of active supplements and in control interventions across studies, as well as differences in the disease stage of the participants in various studies (which can significantly affect intake and absorption of food) limits the value of meta‐analysis and complicates the interpretation of the findings of this review. All the trials were of a 12 week or less duration making inferences prone to inaccuracies. </p> <p>It is worth noting that patients with acute opportunistic infections are most prone to weight loss and theoretically this sub‐group would be most likely to experience improvements in nutritional status such as weight gain. However, this sub‐group was excluded from all of the studies evaluating balanced macronutrient supplements. Nonetheless, if the finding of increased energy and protein intake in our review is valid, this would be important, given that decreased energy intake, increased resting energy expenditure and accelerated protein turnover is common in people with HIV/AIDS. </p> <p>In contrast to studies in adults with weight loss, balanced macronutrient supplementation did not have any effect on food intake, nutritional status or anthropometry in adults with assumed normal weight (based on results of one small trial, N=66). </p> <p>A relatively large trial (N=1057) conducted in Kenya evaluated the effect of providing supplementary food to malnourished adults either initiating ART or pre‐ART. Overall, malnourished HIV‐infected participants not yet receiving ART (pre‐ART) gained less weight than those receiving ART, regardless of supplement status (i.e. whether receiving supplementary food or not). Although there was no significant difference in body weight in the first three months of initiating ART between the supplemented and non‐supplemented groups in the ART arm of the trial, participants receiving supplementary food showed a significantly greater weight gain and BMI gain (i.e. the change in weight and BMI at each time point in the first 3 months of the trial was significantly greater in the supplemented group compared to the son‐supplemented group)than those not receiving supplementary food. This was evidenced by the significantly greater changes in body weight and BMI at these time points in the supplemented group of the ART arm. These effects did not persist after the first 3 months of the trial. The beneficial effects of supplementary food on body weight, body weight gain, BMI and BMI gain was more pronounced and more prolonged in the pre‐ART participants than in the ART participants. At almost every time point in the first 9 months of the trial, pre‐ART participants receiving supplementary food weighed significantly more and had a significantly higher BMI than the non‐supplemented participants. Supplementary feeding did not affect CD4 cell count or serum albumin levels in either ART or pre‐ART participants. Supplementary feeding had a significant beneficial effect on haemoglobin levels in both ART and pre‐ART participants. In the initial stages of the trial supplementary food had a significant beneficial effect on the quality of life of pre‐ART participants in particular. </p> <p>In India, providing supplementary food to TB/HIV co‐infected adult participants not yet receiving ART did not significantly alter risk of death at 6 months, TB cure rate at 6 months or TB treatment failure before 6 months compared to TB/HIV co‐infected participants not receiving supplementary food. The provision of supplementary food did not significantly alter CD4 cell counts or viral load compared with values from the non‐supplemented participants. </p> <p>HIV infection is most prevalent in parts of the world where food security is compromised. These populations at high risk of HIV infection lack appropriate nourishment prior to infection by HIV. Poor nutrient status in HIV‐infected individuals is an independent predictor of mortality in both untreated and treated individuals with HIV (<a href="./references#CD004536-bbs2-0084" title="MarazziMC , LiottaG , GermanoP , GuidottiG , AltanAD , CeffaS , LioMM , Nielsen‐SainesK , PalombiL . Excessive early mortality in the first year of treatment in HIV type 1‐infected patients initiating antiretroviral therapy in resource‐limited settings. AIDS Res Hum Retroviruses.2008;24(4):555‐560. ">Marazzi 2008</a>; <a href="./references#CD004536-bbs2-0075" title="KoetheJR , HeimburgerDC . Nutritional aspects of HIV‐associated wasting in sub‐Saharan Africa.. Am J Clin Nutr.2010;91(4):1138S‐1142S. Epub 2010 Feb 10. ">Koethe 2010</a>; <a href="./references#CD004536-bbs2-0079" title="LiuE , SpiegelmanD , SemuH , HawkinsC , ChalamillaG , AveikaA , NyamsangiaS , MehtaS , MtasiwaD , FawziW . Nutritional status and mortality among HIV‐infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis.2011;204(2):282‐290. ">Liu 2011</a>). These two trials evaluating supplementary feeding in low‐income countries are important as they provide some evidence of the effectiveness of macronutrient supplementation in these populations who are likely to benefit the most from such interventions.    </p> <p>Four small trials evaluated four different specific macronutrient interventions so meta‐analysis was not possible. In adult participants with unintentional weight loss of 5% or more supplementation with an amino acid mixture containing arginine, glutamine and beta‐hydroxy‐beta‐methylbutyrate (HMB) significantly increased body weight and fat free mass and significantly reduced viral load. Various anthropometric and immunological outcomes were not significantly affected by daily supplementation with 10g of spirulina compared to placebo of green clay in malnourished, antiretroviral naive participants. It was reported that participants receiving spirulina had a significantly higher Karnofsky score and significantly fewer cases of pneumonia compared to the participants receiving placebo. </p> <p>In adult participants with assumed normal weight, supplementation with monohydrated L‐ornithine alpha‐ketoglutarate (OKG) did not significantly alter anthropometric or immunological outcomes compared with a placebo as both groups showed similar increases in all of the measured indices throughout the study. Although there was no significant difference in mean body weight between the groups at the end of the study, supplementation with l‐glutamine and antioxidants resulted in a significantly greater mean weight gain over 12 weeks compared with placebo. </p> <p>Three small trials were conducted in children. All of the trials were conducted in low‐ to middle‐income countries, namely South Africa, Brazil and Burkina Faso. In children with prolonged diarrhea enhanced nutritional support (providing an extra 50kcal/kg/day, double the amount of protein and 5% more protein as a percentage of total calories than standard nutritional support) resulted in significantly greater weight gain after 8 weeks compared with the standard nutritional support. Attrition was high in both groups, mainly due to death of participants. It is worth noting that 43 children died during the 6 month trial. None of these children were receiving ART as was standard care in South Africa at the time of the trial. </p> <p>The only notable result from the small trial evaluating the effects of whey protein concentrate in rapidly progressive HIV vertically‐infected children was the significant reduction in the number of co‐infections experienced by the children receiving the whey protein concentrate, compared to those receiving placebo. While this is a very important finding it should be interpreted with caution as this was a very small trial of 18 children and attrition was high in both groups (33% in whey protein concentrate group and 22% in the control group). All of the children were on some form of ART. In undernourished HIV‐infected children the addition of 10g of spirulina to daily traditional meals did not significantly alter weight‐for‐height or weight‐for‐age z scores compared to the children not receiving spirulina. Compliance was excellent and there was no attrition. </p> </section> <section id="CD004536-sec-0099"> <h3 class="title" id="CD004536-sec-0099">Overall completeness and applicability of evidence</h3> <p>Only two of the 14 trials included in this review evaluated the same supplements. Of those trials that evaluated similar classes of supplements, none of the supplements were identical in composition, formulation or quantity. Comparisons and control interventions also differed across every trial. The length of follow‐up varied from 6 weeks to 12 months and few trials measured the same suite of outcomes. Due to this high degree of variation, it was not possible to conduct meta‐analysis on most of the trials, leading to reduced confidence in the results arising from single trials. Stronger evidence would be gained from replicating trials of each of the supplements evaluated. This would also facilitate meta‐analysis. </p> <p>Earlier trials evaluated the effects of supplements on body weight and other measures of body composition, but few report on outcomes related to morbidity or mortality. While mortality and morbidity were not the primary outcomes measures of the more recent trials, the majority of them do report on these important outcomes. </p> <p>Seven of the eight trials included in the original version of this review were conducted in high‐income countries, in relatively well nourished (in terms of body mass index) adult males and females between the ages of 30 and 50, almost all of whom were on some type of ART. It is promising to note that all of the six new trials added to the review were conducted in low‐to middle‐income countries (four trial in Africa) and the interventions tested in these trials are relevant and accessible to the populations in these countries. The addition of three studies conducted in children is also noteworthy. There are major differences between HIV‐infected individuals in rich and poor countries with regard to income level, availability of adequate nutrition, and access to basic healthcare or life‐prolonging antiretroviral treatment. In addition, patient groups vary in terms of their response to the virus, stage of the disease, susceptibility and exposure to opportunistic infections, nutritional status, and individual response to the various treatments received. These observations highlight some challenges in applying the findings of trials conducted in high‐income countries to people in resource‐constrained countries, where nutritional status is generally poor and access to antiretroviral therapy is limited. In other words, where supplementation may be most needed. </p> <p>Importantly this review identified only two potentially eligible trials (<a href="./references#CD004536-bbs2-0058" title="KindraG , CoutsoudisA , EspositoF . Effect of nutritional supplementation of breastfeeding HIV positive mothers onmaternal and child health: findings from a randomized controlled clinical trial. BMC Public Health2011;11:946. ">Kindra 2011</a>; <a href="./references#CD004536-bbs2-0059" title="van derHorstC , ChaselaC , AhmedY , HoffmanI , HosseinipourM , KnightR , et al. Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemporary clinical trials2009;30(1):24‐33. [PUBMED: 18805510] ">van der Horst 2009</a>) which were conducted in pregnant and lactating women infected with HIV. Under normal conditions, successful pregnancy and lactation requires an increase in energy intake. In HIV‐infected women, HIV‐associated anaemia can be exacerbated during pregnancy. This review has identified that we do not have evidence from trials in support of macronutrient supplementation (either fortified with micronutrients, such as iron, or not) in this population. </p> <p><a href="#CD004536-tbl-0002">Table 1</a> provides information on RCTs comparing two or more macronutrient interventions in HIV‐positive individuals. While we did not include the results of these trials in our review we have provided this information for the sake of completeness. </p> </section> <section id="CD004536-sec-0100"> <h3 class="title" id="CD004536-sec-0100">Quality of the evidence</h3> <section id="CD004536-sec-0101"> <h4 class="title">GRADE assessments</h4> <p>GRADEPro was used to create Summary of Findings tables for meta‐analyses using the outcomes pre‐specified by the WHO expert group. In determining the level of evidence for each outcome, both the efficacy results and the assessment of the risk of bias was integrated into a final assessment of the level of evidence and full details of the decision provided in footnotes. All primary and secondary outcomes were rated as critical by the WHO expert group and received a score of ‘9’ indicating the highest level of importance to patients. For other outcomes included in the meta‐analysis, levels were determined at discretion of the authors. </p> <p><b>Balanced supplementation versus counselling</b> </p> <p>See <a href="#CD004536-fig-0004">Figure 4</a> for complete assessment and rationale for ratings. </p> <div class="figure" id="CD004536-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="GRADE Summary of Findings Table for balanced macronutrient supplements versus counselling" data-id="CD004536-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>GRADE Summary of Findings Table for balanced macronutrient supplements versus counselling</p> </div> </div> </div> <p>For the outcomes of an increase in the mean change in energy and protein intake the level of evidence was rated as <b>low</b>.  </p> <p>For body weight, and fat mass measured in percentage of total body weight, the level of evidence was rated as <b>moderate</b>.  </p> <p>Evidence for fat‐free mass and change in CD4 count from baseline to study endpoint was rated as <b>low</b>.  </p> <p>The evidence for an effect on viral load was rated as <b>very low</b> with this result coming from only one trial. </p> </section> </section> <section id="CD004536-sec-0102"> <h3 class="title" id="CD004536-sec-0102">Potential biases in the review process</h3> <p>In the meta‐analysis of trials evaluating balanced macronutrient supplements fortified with micronutrients and nutrition counselling versus nutrition counselling we combined data reflecting both mean change from baseline to end‐point and final mean at the end‐point of the study as described in the <i>Cochrane Review Authors’ Handbook</i>. Caution must be used when interpreting the outcomes of this meta‐analysis as certain effects of the interventions may be hidden when combining these two types of data. Furthermore, the lengths of follow up of the trials included in this meta‐analysis were also different (two trials had a 6 week follow up, one trial had an 8 week follow up and one trial had a 12 week follow up). This could also introduce bias into the results of the meta‐analysis. Finally, the interventions evaluated in the trials were similar, in a very broad sense, but not identical. </p> <p>Biases in the review process were minimised by performing a comprehensive search of the literature, independently selecting and appraising the studies, and extracting the data in duplicate. Where data was missing, we sought additional information and data directly from authors where this was possible to do so. We also consulted product web sites to gain more detailed product information regarding several of the commercial supplements. </p> <p>Although an extensive hand‐search for grey literature was not conducted, it is unlikely that important trials have been missed given the high profile nature of the topic and the close partnership established with agencies and organizations working in this area. Indeed, due to the involvement of the WHO in this review, the authors were presented with data from the unpublished FANTA‐KEMRI trial. However, the review remains at risk of publication bias from less prominent trials. We attempted to reduce this risk by identifying relevant conference abstracts. A 2010 search of the HIV/AIDS‐specific conference database, NLM Gateway, yielded two relevant trials, both of which were already included in the review. Given that NLM Gateway is no longer maintained, conducting an additional search of the new HIV/AIDS conference database, <a href="http://www.aegis.com" target="_blank">www.aegis.com</a>, could potentially yield unpublished studies and is warranted to reduce  the possible impact of publication in this review. </p> <p>The search of the trials registry, <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>, to identify trial protocols and ongoing trials yielded 28 potentially relevant trials protocols. These will require further assessment and exploration to either 1) link them to trials already included in the review, or 2) if not included, to attempt to obtain the completed trial reports. This task is time‐consuming and has to be balanced against feasibility and time constraints. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004536-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004536-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004536-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004536-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="GRADE Summary of Findings Table for balanced macronutrient supplements versus counselling" data-id="CD004536-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>GRADE Summary of Findings Table for balanced macronutrient supplements versus counselling</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 1 Energy intake (kcal/day)." data-id="CD004536-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 1 Energy intake (kcal/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 2 Protein intake (g/day)." data-id="CD004536-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 2 Protein intake (g/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 3 Body weight." data-id="CD004536-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 3 Body weight. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 4 Fat mass measured in % of TBW." data-id="CD004536-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 4 Fat mass measured in % of TBW. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 5 Fat free mass." data-id="CD004536-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 5 Fat free mass. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 6 CD4." data-id="CD004536-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 6 CD4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 7 Viral load (log10 copies/ml)." data-id="CD004536-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss, Outcome 7 Viral load (log10 copies/ml). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART, Outcome 1 Body weight." data-id="CD004536-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART, Outcome 1 Body weight. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART, Outcome 2 Change in body weight (kg)." data-id="CD004536-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART, Outcome 2 Change in body weight (kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART, Outcome 3 Body mass index (BMI)." data-id="CD004536-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART, Outcome 3 Body mass index (BMI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART, Outcome 4 % lean body mass." data-id="CD004536-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART, Outcome 4 % lean body mass. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Arginine rich supplements versus nutritional placebo or arginine‐free supplements, Outcome 1 Mean change in body weight baseline to 8 weeks." data-id="CD004536-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Arginine rich supplements versus nutritional placebo or arginine‐free supplements, Outcome 1 Mean change in body weight baseline to 8 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Arginine rich supplements versus nutritional placebo or arginine‐free supplements, Outcome 2 Change in fat mass measured in kg." data-id="CD004536-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Arginine rich supplements versus nutritional placebo or arginine‐free supplements, Outcome 2 Change in fat mass measured in kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Arginine rich supplements versus nutritional placebo or arginine‐free supplements, Outcome 3 Change in fat free mass." data-id="CD004536-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Arginine rich supplements versus nutritional placebo or arginine‐free supplements, Outcome 3 Change in fat free mass. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 1 Mean daily energy intake at study endpoint." data-id="CD004536-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 1 Mean daily energy intake at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 2 Mean daily protein intake in kcal at study endpoint." data-id="CD004536-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 2 Mean daily protein intake in kcal at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 3 Mean fat mass in kg at study endpoint." data-id="CD004536-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 3 Mean fat mass in kg at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 4 Mean weight in kg at study endpoint." data-id="CD004536-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 4 Mean weight in kg at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 5 Mean fat‐free mass in kg at study endpoint." data-id="CD004536-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 5 Mean fat‐free mass in kg at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 6 Mean CD4 count in cells/mm3 at study endpoint." data-id="CD004536-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 6 Mean CD4 count in cells/mm<sup>3</sup> at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 7 Mean viral load in log10 at study endpoint." data-id="CD004536-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 7 Mean viral load in log<sub>10</sub> at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 8 Proportion with gastrointestinal event (at least one)." data-id="CD004536-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Ornithine alpha‐ketoglutarate (OKG) versus placebo, Outcome 8 Proportion with gastrointestinal event (at least one). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 L‐glutamine (GLN) versus placebo, Outcome 1 Mean weight in kg at study endpoint." data-id="CD004536-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 L‐glutamine (GLN) versus placebo, Outcome 1 Mean weight in kg at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 L‐glutamine (GLN) versus placebo, Outcome 2 Mean fat mass in kg at study endpoint." data-id="CD004536-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 L‐glutamine (GLN) versus placebo, Outcome 2 Mean fat mass in kg at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 L‐glutamine (GLN) versus placebo, Outcome 3 Mean CD4 count in cells/mm3 at study endpoint." data-id="CD004536-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 L‐glutamine (GLN) versus placebo, Outcome 3 Mean CD4 count in cells/mm<sup>3</sup> at study endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Enhanced nutritional support vs std nutritional support in children, Outcome 1 Death at 8 weeks." data-id="CD004536-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Enhanced nutritional support vs std nutritional support in children, Outcome 1 Death at 8 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Enhanced nutritional support vs std nutritional support in children, Outcome 2 Death at 26 weeks." data-id="CD004536-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Enhanced nutritional support vs std nutritional support in children, Outcome 2 Death at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Spirulina versus traditional meals in children, Outcome 1 Weight for height z score (WHZ)." data-id="CD004536-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Spirulina versus traditional meals in children, Outcome 1 Weight for height z score (WHZ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004536-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/urn:x-wiley:14651858:media:CD004536:CD004536-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_t/tCD004536-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Spirulina versus traditional meals in children, Outcome 2 Weight for age z score (WAZ)." data-id="CD004536-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Spirulina versus traditional meals in children, Outcome 2 Weight for age z score (WAZ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/media/CDSR/CD004536/image_n/nCD004536-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004536-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Balanced nutritional supplement compared to counselling or nutritional placebo in patients with weight loss for reducing morbidity and mortality in people with HIV</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Balanced nutritional supplement compared to counselling or nutritional placebo in patients with weight loss for reducing morbidity and mortality in people with HIV</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with reducing morbidity and mortality in people with HIV <br/> <b>Settings:</b> <br/> <b>Intervention:</b> Balanced nutritional supplement <br/> <b>Comparison:</b> counselling or nutritional placebo in patients with weight loss </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect <br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants <br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence <br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Counselling or nutritional placebo in patients with weight loss</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Balanced nutritional supplement</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Energy intake (kcal/day)</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean energy intake (kcal/day) ranged across control groups from <br/> <b>1,777 to 2,412 kcal/day</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean energy intake (kcal/day) in the intervention groups was <br/> <b>393.57 higher</b> <br/> (224.66 to 562.47 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131 <br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Protein intake (g/day)</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean protein intake (g/day) ranged across control groups from <br/> <b>79 to 81 g/day</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean protein intake (g/day) in the intervention groups was <br/> <b>23.35 higher</b> <br/> (12.68 to 34.01 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Body weight</b> <br/> Follow‐up: 6 ‐ 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight ranged across control groups from <br/> <b>71.8 to 73.3 kg</b><sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight in the intervention groups was <br/> <b>0.17 lower</b> <br/> (1.1 lower to 0.75 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 <br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fat mass measured in % of TBW</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fat mass measured in % of tbw ranged across control groups from <br/> <b>8.5 to 15.5 %</b><sup>8</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fat mass measured in % of tbw in the intervention groups was <br/> <b>1.14 lower</b> <br/> (2.58 lower to 0.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233 <br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝ <br/> <b>moderate</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fat free mass</b> <br/> Follow‐up: 6 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fat free mass ranged across control groups from <br/> <b>‐0.3 to 3.8 Change in fat free mass in kg</b><sup>9</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fat free mass in the intervention groups was <br/> <b>0.37 lower</b> <br/> (2.77 lower to 2.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218 <br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CD4</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cd4 ranged across control groups from <br/> <b>311 to 559 Cells/mm3</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cd4 in the intervention groups was <br/> <b>114.48 lower</b> <br/> (233.2 lower to 4.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 <br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <br/> <b>low</b><sup>3,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Viral load (log10 copies/ml)</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean viral load (log10 copies/ml) in the intervention groups was <br/> <b>3.71 lower</b> <br/> (12.16 lower to 4.74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 <br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝ <br/> <b>very low</b><sup>11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> All three trial reports were unclear regarding randomisation and selection bias may be present. The trials were not blinded for participants and personnel possibly leading to performance bias. Blinding was not clearly reported for outcome assessment and detection bias may be present. Attrition was high in the Berneis trial at 16%. <br/> <sup>2</sup> The trials are relatively small with Berneis only having 15 participants. This could lead to imprecision <br/> <sup>3</sup> Trial reports were unclear regarding randomisation and selection bias may be present. The trials were not blinded for participants and personnel possibly leading to performance bias. Blinding was not clearly reported for outcome assessment and detection bias may be present. Attrition was high in the Berneis trial at 16%. <br/> <sup>4</sup> Both are small trials, Berneis only has 15 participants so results are likely to be imprecise. <br/> <sup>5</sup> The meta‐analysis included combining mean change scores from baseline to study endpoint (Schwenk and Rabeneck)and actual mean weight measurements at study endpoint (Berneis and De Luis) as described in the Cochrane Review Handbook. No mean weights in the control groups were reported for the two trials in which change scores were provided and the range reported here only reflects that of the Berneis and De Luis trials. <br/> <sup>6</sup> All four trial reports were unclear regarding randomisation and selection bias may be present. The trials were not blinded for participants and personnel possibly leading to performance bias. Blinding was not clearly reported for outcome assessment and detection bias may be present. Attrition was high in the Berneis trial at 16% and in Rabeneck at 24%. Attrition bias is likely. <br/> <sup>7</sup> As all the sample sizes are small, Imprecision is likely in the indiviudal trials. This is reduced by the meta‐analysis. <br/> <sup>8</sup> The meta‐analysis included combining mean change scores from baseline to study endpoint and actual mean measurements at study endpoint as described in the Cochrane Review Handbook. No fat free mass in % TBW was reported in the control group for Rabeneck and so we included the change score instead. In Schwenk it is not clear that the data presented are % TBW as they reflect the Area under the Curve. However the trial adds very little weight (0.6%) so we retained it in the analysis. <br/> <sup>9</sup> The De Luis trial did not report change scores and so the actual mean weights are reported. In the control group this was 57.6kg <br/> <sup>10</sup> Berneis is a small trial with 15 participants leading to imprecision. As there is only one other trial in the meta‐analysis imprecision is likely. <br/> <sup>11</sup> Results are for one trial only with a high risk of selection, performance, and detection bias. <br/> <sup>12</sup> Results are from one trial only and as the sample size is small imprecision is likely. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Balanced nutritional supplement compared to counselling or nutritional placebo in patients with weight loss for reducing morbidity and mortality in people with HIV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004536-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of comparative studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bakeine 1997 (Abstract)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Uganda</p> <p>SETTING:</p> <p>Joint Clinical Research Centre, Kampala</p> <p>FOLLOW UP:</p> <p>At days1 and 56 weight, triceps skinfold, serum albumin and CD4 cell count were evalulated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>Early stage (CDC stage I‐III), largely asymptomatic HIV‐infected patients</p> <p>EXCLUSION CRITERIA</p> <p>Number randomised: 22 (7 males, 15 females)</p> <p>Mean age at baseline: 31±12 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In addition to normal diet patients received daily a 4.2 MJ supplement of either Nutrifil (Nutrifil is cow’s‐ milk‐based, is highly digestible and contains a wide range of micronutrients. It consists of 150g protein, 110g fat, 650g carbohydrate/kg) or Cornsoy blend (160g protein, 60g fat, 660g carbohydrate/kg) for 8 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>                                                                Nutrifil‐supplemented group (<i>n</i> 11)                  CSB‐supplemented group (<i>n</i> 11) </p> <p>                                                                                                                                                                            </p> <p>                                                                      Day 1                    Day 56                              Day 1                          Day 56              </p> <p>                                                                Mean         <i>SE</i>            Mean      <i> SE</i>                 Mean             <i> SE</i>             Mean        <i> SE</i> </p> <p>                                                                                                                                                                                     </p> <p>Body weight (kg)                                 53.4           2.9         55.5**     3.0                 60.4                3.3           61.3*        3.5 </p> <p>TSFT (mm)                                           11.6           1.4         14.7**     1.9                 11.8                2.4           13.3*         2.5 </p> <p>Serum albumin (g/L)                           37.6           1.3         41.8**     1.0                 37.2             1.0         40.2*             1.2       </p> <p>CD4/ mm3                                            423            81          400            81               456                  97           328*          45 </p> <p>Significantly different from day 1,  same group:   *<i>P</i> &lt; 0.05,   **<i>P</i> &lt; 0.005, ( paired tests). </p> <p>The mean increase in the Nutrifil group (2.14 (<i>SE</i> 0.6) kg) was greater than that in the CSB group (0.98 (<i>SE</i> 0.5) kg). Increments in TSFT and serum albumin were also seen in both groups with increases again being greater in the Nutrifil group. Mean CD4 cell counts decreased in the CSB group but remained unchanged in the Nutrifil group. Weight change was positively correlated to changes in the CD4 cell count in the Nutrifil group (<i>r</i>  0.66  <i>P</i> &lt; 0.05), but not in the CSB group (<i>r</i> 0.03, NS). Furthermore, five patients (45%) in the Nutrifil group experienced a rise in CD4 cell count at the end of the study, compared with two (18%) in the CSB group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Charlin 2002 (Full text)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Chile</p> <p>SETTING:</p> <p>AIDS wards in the Jose Joaquin Aguirre and San Juan de Dios Hospitals in Santiago, Chile. </p> <p>DURATION OF RECRUITMENT:</p> <p>Not specified</p> <p>DURATION OF TRIAL:</p> <p>September 1994‐August 1995</p> <p>FOLLOW‐UP:</p> <p>At baseline, 45th and 90th day of trial height, weight and skinfold measurements (to determine fat mass and fat free mass) and CD4 and CD8 cell count were assessed. 24 hour urinary ureic nitrogen was determined as well as Resting Energy Expenditure. Nutritional intake was recorded using 24‐hour recall taken on three alternate days before beginning of study and during the supplementation period. Systemic signs and symptoms were recorded each day. </p> <p>ETHICS: <br/> Not reported on in the trial <br/> TRIAL REGISTRATION: <br/> FUNDING: </p> <p>Study supported from a grant from research project FONDECYT 1940507 and collaboration from Davis Laboratories, Braun Co, Chile </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>HIV‐infected outpatients</p> <p>EXCLUSION CRITERIA:</p> <p>Not specified</p> <p>Participants enrolled: 46 <br/> Participants randomised: 46 <br/> Mean age at baseline: 37 ± 12 years <br/> Sex at baseline: 4 females; 42 males <br/> Mean BMI at baseline: 18.5±1.4 kg.m<sup>‐2</sup> (group 1); 18.6±1.2 kg.m<sup>‐2</sup> (group 2) </p> <p>Stage of HIV: 11 patients category A or B; 35 patients category C (AIDS) according to Centre for Disease Control guidelines, 1992 </p> <p>ARV therapy status: 11 patients on zidovudine therapy in group 1; 12 patients on zidovudine therapy in group 2 </p> <p>At baseline energy intake was greater in group 1 (34.2±8.8 kcal/kg/d) than group 2 (27.2±7.5 kcal/kg/d). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1:</p> <p>Patients received polymetric diet during first 45 days then regular food for 45 days. Polymetric diet consisted of powdered drink containing 103kcal, 3.6g protein (sodium and calcium caseinate: 14% contribution to total energy), 13.0g carbohydrates (maltodextrins) and 4g fats (sunflower seed oil and coconut oil) per 10 dl. This formula provides the US‐RDA requirements for adults of vitamins and micronutrients with 200 dl per day. Regular food consisted of cereals, diary products, eggs albumin˜15% of protein contribution to total energy. </p> <p>Group 2:</p> <p>Patients received regular food for 45 days then polymetric diet for 45 days.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality: 3 patients died in Group 1; 8 patients died in Group 2 in the first 45 days of the trial </p> <p>Significant increase in weight, BMI and fat‐free mass (FFM) was observed in both groups. An increase in fat mass was observed in Group 2. No significant differences were noted in plasma albumin, CD4 and CD8 cell count. Energy intake increased in both groups. with a significant increase noted in group 2 between the 45th day to the 90th day. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Method not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Method not described in report. <br/> Blinding of participants and personnel (performance bias): High risk ‐ Participants could not be blinded as the appearance was different between the supplements. </p> <p>Blinding of outcome assessment (detection bias): Unclear risk ‐ It is not clear if the outcome assessors were blinded. <br/> Incomplete outcome data (attrition bias): 11/46 patients died (24% attrition) <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlebowski 1993 (Abstract)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>USA</p> <p>FOLLOW UP:</p> <p>Parameters evaluated at 0 (baseline), 3, and 6 mo included adherence, weight change, anthropometric measurements, serum biochemical indices, gastrointestinal symptoms, physical performance, and intercurrent health events (including hospitalizations). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>HIV‐infected, early stage, relatively asymptomatic patients</p> <p>EXCLUSION CRITERIA</p> <p>Number randomised: 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Received 2‐3 8 oz cans of ready‐to‐feed peptide‐based enteral formula consisting of 18.7% protein, 65.5% carbohydrate, 15.8% fat and 1.28 kcal/ml per day for 6 months (NEF) </p> <p>CONTROL:</p> <p>Received 2‐3 8oz cans of standard enteral formula consisting of 14% protein, 55% carbohydrate, 31% fat, 1.06 kcal/ml per day for 6 months (SEF). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 patients completed the study. Those supplemented with NEF maintained their body weight significantly (p = 0.04) better, had significantly (p = 0.03) more stable triceps skin‐fold measurements, and had significantly (p = 0.04) lower blood urea nitrogen than patients consuming the SEF supplement. Consumption of the NEF supplement was also associated with significantly reduced hospitalizations during the 3‐ to 6‐mo evaluation period (p = 0.02). The NEF supplement was well tolerated and did not result in untoward clinical effects. These data suggest that supplemental use of an NEF provides superior nutritional management compared with an SEF for patients with early‐stage HIV infection. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attrition rate: 24/80 loss to follow up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comi 1996 (Abstract)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Italy</p> <p>FOLLOW UP:</p> <p>Nutritional status was evaluated by anthropometric parameters, hematological indexes, and by tetrapolar bioelectrical impedance analysis (BIA), before and after one month of diet. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>AIDS patients (CDC stage IV CI)</p> <p>Number randomised: 50 (36 males; 14 females)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group A: treated with normocaloric (35Kcal/kg usual weight), normoproteic (1g/kg usual weight) diet for 1 month; <br/> Group B: treated with an hypercaloric (40Kcal/kg of usual weight), hyperproteic (2g/kg usual weight) dietetic regimen for 1 month. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group A: Statistical significant increase in Body Weight (pre: 59.9±9.9kg; post: 61.2±9.7, p&lt;0.001), BMI (pre: 20.5±3.0, post: 21.0±2.9, p&lt;0.001) and Total Cholesterol (pre:144.3±39.5, post: 162.5±62.8, p&lt;0.04), Triceps skinfold and Mid arm muscle area increased but not significantly. Group B: Significant increase in body weight (pre: 59.1±9.9, post: 60.4±10.4, p&lt;0.001), BMI (pre: 20.3±3.0, post: 20.7±3.0, p&lt;0.001), Tricep skinfold (pre: 6.8±4.1, post: 7.4±4.2, p&lt;0.009), mid arm muscle area (pre: 41.4±11.8, post: 42.9±11.5, p&lt;0.002), HDL Cholesterol (pre: 31.8±10.1, post: 37.8±12.1, p&lt;0.001). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation:</p> <p>Allocation concealment:</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>de Luis 2010</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY</p> <p>Spain</p> <p>SETTING</p> <p>Not reported</p> <p>DURATION OF TRIAL</p> <p>Not reported <br/> FOLLOW UP </p> <p>At baseline and 3 months: prospective serial assessment of nutritional status, nutrient intake (24 hour food recall), GI symptoms, anthropometry, intercurrent health events, blood chemistry, liver function and plasma fatty acids </p> <p>ETHICS</p> <p>Written informed consent received. Ethics and regulatory approval not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA</p> <p> <ul id="CD004536-list-0001"> <li> <p>HIV‐infected patients (30‐60 years old)</p> </li> <li> <p>Previous weight loss (&gt;5% in previous 3 months)</p> </li> <li> <p>Absence of chronic febrile illness</p> </li> <li> <p>Absence of severe GI symptoms (diarrhoea for &gt;30 days or &gt;3 times per day)</p> </li> <li> <p>adequate liver and kidney function</p> </li> <li> <p>Remain on HAART treatment for 3 months prior to and for duration of tria</p> </li> </ul> </p> <p>Number enrolled: 33</p> <p>Number randomised: 30</p> <p>Mean age at baseline:41.6±8.4 years in ENSURE group; 42.1±4.8 years in PROSURE group</p> <p>Mean BMI at baseline:19.2±0.9 kg.m<sup>‐2</sup> in ENSURE group; 18.8±2.2 kg.m<sup>‐2</sup> in PROSURE group </p> <p>All patients receiving HAART therapy</p> <p>CDC class A‐B (%):54.7% in ENSURE group; 55.7% in PROSURE group</p> <p>CDC class C (AIDS, %):53.3% in ENSURE group; 60% in PROSURE group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION</p> <p>2 can of PROSURE per day (236 ml per can) containing:</p> <p> <ul id="CD004536-list-0002"> <li> <p>Caloric density (Kcal/ml): 1.2</p> </li> <li> <p>Protein (g/l): 66 (21.6%)</p> </li> <li> <p>Fat (g/l): 25.6 (18.8%)</p> </li> <li> <p>Carbohydrate (g/l): 183 (59.6%)</p> </li> <li> <p>Dietary fibre (g/l): 20.4</p> </li> <li> <p>n‐3 fatty acids (mg/l): 6.29</p> </li> </ul> </p> <p>Dietary counselling also provided</p> <p>CONTROL</p> <p>2 cans of ENSURE per day (236 ml per day) containing:</p> <p> <ul id="CD004536-list-0003"> <li> <p>Caloric density (Kcal/ml): 1.06</p> </li> <li> <p>Protein (g/l): 37.2 (14%)</p> </li> <li> <p>Fat (g/l): 37.2 (31.5%)</p> </li> <li> <p>Carbohydrate (g/l): 145 (54.5%)</p> </li> <li> <p>Dietary fibre (g/l): 0</p> </li> <li> <p>n‐3 fatty acids (mg/l): 0</p> </li> </ul> </p> <p>Dietary counselling also provided</p> <p>ADHERENCE:</p> <p>Patient reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes were not clearly delineated into primary and secondary. Although reported that study powered to detect 4% change in body weight. Total calorie and protein consumption were similar in both groups at 3 months with a significant increase in each group for both calorie (ENSURE: 18.8% increase; PROSURE: 19% increase) and protein intakes (ENSURE:18.5% increase, PROSURE:18.4% increase). Significant and sustained increase in weight due to increase in fat‐free mass in ENSURE group and increase in both fat‐free mass and fat mass in PROSURE group. No hospitalisations or adverse events reported or observed throughout trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Unclear risk ‐ Not reported for participants and personnel <br/> Blinding of outcome assessment (detection bias): Unclear risk ‐ Not reported for outcome assessors <br/> Incomplete outcome data (attrition bias): Low risk ‐ All randomised participants completed trial <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>de Luis Roman 2001</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Spain</p> <p>SETTING:</p> <p>Not reported</p> <p>DURATION OF TRIAL:</p> <p>Not reported</p> <p>FOLLOW UP:</p> <p>At baseline and 3 months: prospective serial assessment of nutritional status, nutrient intake (24 hour food recall), GI symptoms, anthropometry, intercurrent health events, blood chemistry, liver function and plasma fatty acids </p> <p>ETHICS:</p> <p>Patients provided informed consent (not sure if written or oral). Ethics or regulatory approval not specified in the report </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0004"> <li> <p>HIV‐infected patients aged between 18‐60 years with or without AIDS defining illness</p> </li> <li> <p>Absence of chronic febrile illness</p> </li> <li> <p>Weight stable</p> </li> <li> <p>Absence of severe GI symptoms (diarrhoea for &gt;30 days or &gt;3 times per day)</p> </li> <li> <p>adequate liver and kidney function</p> </li> <li> <p>Remain on HAART treatment for 3 months prior to and for duration of trial</p> </li> </ul> </p> <p>Number enrolled: 91</p> <p>Number randomised: 74</p> <p>Percentage male at baseline: 77.6% in ENSURE group; 78.6% in ADVERA group</p> <p>Mean age at baseline:37.9±10 years in ENSURE group; 38.9±8.8 years in ADVERA group</p> <p>Mean BMI at baseline:22±2.8 kg.m<sup>‐2</sup> in ENSURE group; 21±2.8 kg.m<sup>‐2</sup> in ADVERA group </p> <p>All patients receiving HAART therapy</p> <p>Mean CD4 count at baseline (count/ul): 454±271 in ENSURE group; 561±369 in ADVERA group </p> <p>CDC class A‐B (%):57.2% in ENSURE group; 51.1% in ADVERA group</p> <p>CDC class C (AIDS, %):42.8% in ENSURE group; 48.9% in ADVERA group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION</p> <p>3 can of ADVERA (enterotropic peptide‐based enteral formula with n‐3 fatty acids) per day (236 ml per can) containing: </p> <p> <ul id="CD004536-list-0005"> <li> <p>Caloric density (Kcal/ml): 1.28</p> </li> <li> <p>Protein (g/l): 60 (18.7%)</p> </li> <li> <p>Fat (g/l): 22.8 (15.8%)</p> </li> <li> <p>Carbohydrate (g/l): 215.8 (65.5%)</p> </li> <li> <p>Dietary fibre (g/l): 8.9</p> </li> <li> <p>n‐3 fatty acids (mg/l): 9.46</p> </li> </ul> </p> <p>Dietary counselling also provided</p> <p>CONTROL</p> <p>3 cans of ENSURE per day (236 ml per day) containing:</p> <p> <ul id="CD004536-list-0006"> <li> <p>Caloric density (Kcal/ml): 1.06</p> </li> <li> <p>Protein (g/l): 37.2 (14%)</p> </li> <li> <p>Fat (g/l): 37.2 (31.5%)</p> </li> <li> <p>Carbohydrate (g/l): 145 (54.5%)</p> </li> <li> <p>Dietary fibre (g/l): 0</p> </li> <li> <p>n‐3 fatty acids (mg/l): 0</p> </li> </ul> </p> <p>Dietary counselling also provided</p> <p>ADHERENCE:</p> <p>Patient reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD004536-list-0007"> <li> <p>Treatments with both supplements resulted in a significant and sustained increase in weight (3.2% in ENSURE group and 3.1% in ADVERA group). This increase was mostly due to fat mass (12.8% in ENSURE group and 7.5% in ADVERA group). </p> </li> <li> <p>Total body water and fat‐free mass remained unchanged</p> </li> <li> <p>CD4 counts remained stable in the ENSURE group, while a significant increase was detected in the ADVERA group from baseline to 3 months (576±403 vs. 642±394 cells per mm<sup>3</sup>, P&lt;0.05). At 3 months, the ADVERA group had a significantly higher CD4 count compared with the ENSURE group. </p> </li> <li> <p>The supplemented group had fewer hospitalizations than the standard group, but no statistical differences were found. </p> </li> <li> <p>No side effects to the supplements were reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Unclear risk ‐ Not reported for participants and personnel <br/> Blinding of outcome assessment (detection bias): Unclear risk ‐ Not reported for outcome assessors <br/> Incomplete outcome data (attrition bias): Low risk ‐ All randomised participants completed trial <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gibert 1999</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>USA</p> <p>SETTING:</p> <p>14 administrative units comprising 55 clinics and physician offices</p> <p>DURATION OF RECRUITMENT:</p> <p>Jul 1996 ‐ December 1997</p> <p>DURATION OF TRIAL:</p> <p>Jul 1996 ‐ April 1998 (22 months: end of trial estimated to be four months after last recruitment) </p> <p>FOLLOW‐UP:</p> <p>At baseline, two month and four month visits: height and weight measured with standardized procedures using calibrated scales; body composition calculated using BIA‐101Q analyzer and Body cell mass (BCM) and total body fat (TBF) recorded. </p> <p>At 2 and 4 month visits, 24 hour dietary recall assessed using Minnesota Nutrition Data System NDS‐93 and questionnaire administered regarding aerobic and muscle‐building activities. </p> <p>ETHICS: <br/> Institutional review board approval was obtained at each unit. <br/> TRIAL REGISTRATION: <br/> FUNDING: <br/> National Institute of Allergy and Infectious Disease and Nestle Clinical Nutrition </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0008"> <li> <p>HIV‐infected adults &gt;= 13 years</p> </li> <li> <p>CD4 &lt; 200 cells/mm3</p> </li> <li> <p>Karnofsky scale &gt;= 60</p> </li> <li> <p>Stable weight (loss of no more than loss of 5% body weight recorded in 3 to 6 months prior to trial) </p> </li> <li> <p>Serum creatinine level of &lt;=2.5mg/dL</p> </li> <li> <p>Total bilirubin =&lt; 3mg/dL</p> </li> </ul> </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0009"> <li> <p>Active opportunistic infection</p> </li> <li> <p>Malignancy or Diabetes Mellitus</p> </li> <li> <p>History of phenylketonuria</p> </li> <li> <p>Appetite stimulants</p> </li> <li> <p>Anabolic steroids</p> </li> <li> <p>Caloric supplements</p> </li> <li> <p>Pregnant or breastfeeding</p> </li> <li> <p>BMI &gt;= 29kg/m</p> </li> </ul> </p> <p>Participants enrolled: 536 <br/> Participants randomised: 536 <br/> Mean age at baseline: 40.8 (SD: +/‐ 8.4 years) in the Peptamen intervention group; 39.7 years (SD: +/‐ 8.4 years) in the NuBasics intervention group; 39.9 years (SD: +/‐ 8.2 years) in the control multivitamin group <br/> Sex at baseline: 12.9% women in the Peptamen intervention group; 12.8% women in the NuBasic intervention group; 10.6% in the control group <br/> No significant differences in baseline criteria observed. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Peptamen caloric supplement, each 250ml fluid contained 250kcal comprising:</p> <p> <ul id="CD004536-list-0010"> <li> <p>10g whey protein (16% kcal)</p> </li> <li> <p>9.8g fat with 6.75g medium‐chain triglycerides (33% kcal</p> </li> </ul> </p> <p>The supplementation was a fluid and 250ml was taken twice daily</p> <p>INTERVENTION:</p> <p>NuBasics caloric supplement, each 250ml fluid contained 250kcal comprising:</p> <p> <ul id="CD004536-list-0011"> <li> <p>8.75g whey protein</p> </li> <li> <p>9.2g fat</p> </li> </ul> </p> <p>The supplementation was a fluid, bar or coffee and 500kcal was required daily. <br/> <br/> CONTROL: <br/> A daily multivitamin and mineral supplement. Form not reported. <br/> DURATION: <br/> Four months <br/> CO‐INTERVENTIONS: <br/> None reported. <br/> COMPLIANCE: <br/> Participants reported the amount of supplement consumed in the previous week to visit based on a 24 hour dietary recall. 69% was consumed in the NuBasics group and 62% in the Peptamen group using this method. However, on case‐report post the study, adherence was reported as 82% in the NuBasic group and 65% in the Peptamen group. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This three‐armed trial compared two formulations of caloric supplements: Peptamen comprised peptides and medium‐chain triglycerides (MCT) and NuBasics comprised whole protein and long‐chain triglylcerides (LCT), in patients with stable weights (no more than 5% weight loss in three to six months prior to trial). These supplements were compared with each other and with a control group of multivitamins and mineral supplementation. Both the intervention groups received the same multivitamins and mineral supplementation as the control group. Mortality was low in all three groups: one in the Peptamen group, four in the NuBasics group and three in the control group. Disease progression was also measured. For the combined outcome of disease progression or death, the authors report the raw data. In the Peptamen group, four participants progressed or died, 14 progressed or died in the NuBasics group and 12 progressed or died in the control group. We analysed the difference between the Peptamen and control groups in REVMAN and found that participants in the Peptamen group were not statistically significantly less likely to die or progress than those in the control group (RR = 0.34; 95% CI: 0.11, 1.02; p = 0.05). See Analysis 4.1 <br/> <br/> The trial reports means and standard errors for percentage change for outcomes and not the actual weight change itself. We report the outcomes as reported by the authors in the text. For mean percentage changes in body weight, there were no statistically significant differences between the three groups with a mean % change of 0.8% in the Peptamen group, 1.1% in the NuBasics group and 0.7% in the multivitamin groups. Using analysis of variance the authors report a p value of 0.74 between the groups. Mean percentage change in body cell mass (BCM) at study endpoint was not statistically significant between groups using analysis of variance (p = 0.63). The mean percentage BCM was 0.7% in the Peptamen group, 1.2% in the NuBasics group and 0.6% in the control group. <br/> <br/> Mean daily caloric intake was statistically significantly higher in the Peptamen and NuBasics groups when compared with the multivitamin control group respectively. Participants in the Peptamen group had a mean intake 325 kilocalories more than those in the control group (MD: 325.00; 95% CI: 79.66, 570.34; p = 0.009). See Analysis 4.2. Participants in the NuBasics group had a mean intake 238 kilocalories more than those in the control group (MD: 238; 95% CI: 11.58, 464.42; p = 0.04). See Analysis 4.3. There was no statistically significant difference in intake between the Peptamen and NuBasics groups (MD: 87.00; 95% CI: ‐142.89, 316.89; p = 0.46). See Analysis 4.4. <br/> <br/> More participants in the Peptamen group (22%) discontinued the trial compared with those receiving NuBasics (7%). One third of the participants discontinuing in the Peptamen group did so because of diarrhoea and nausea. In the NuBasics group none stopped due to side effects. In the control group 5% stopped and a quarter of these did so for reasons of nausea, vomiting, diarrhoea or constipation. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias):Unclear risk ‐ Random blocks of permutation of sizes 3 to 6 with equal probability stratified by unit. Actual method not reported <br/> Allocation concealment (selection bias): Low risk ‐ Allocated by telephone to Central Statistical Center <br/> Blinding of participants and personnel (performance bias): High risk ‐ No blinding of participants and not reported for personnel <br/> Blinding of outcome assessment (detection bias): High risk ‐ Measurements were done by investigators using scales so could be influenced by knowledge of treatment assignment <br/> Incomplete outcome data (attrition bias): Low risk ‐ Attrition in Peptamen = 9/178 (5%); in NuBasics = 8/179 (4.5%); in control = 15/179 (8.4%) <br/> Selective reporting (reporting bias)Unclear risk: Protocol not available. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hellerstein 1994 (Abstract)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>USA</p> <p>FOLLOW UP:</p> <p>Nutrient intake, body composition, GI symptoms, nutritional status and AIDS specific surrogate markers were assessed at 6 weeks, 6 months and 12 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patients with AIDS or HIV‐associated weight loss (13.2±4.2% body wt)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whole protein formula in the form of 2 8oz cans per day for 1 year (WP group)</p> <p>Peptide‐based formula in the form of 2 8oz cans per day for 1 year (PB group)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both formulas were well‐tolerated and there were no adverse effects on GI function or related symptoms. Evaluation of food and formula intake at 6 months revealed an increased intake of calories and protein in both groups. This occurred through supplement intake (500‐600 kcal/day and 17‐28g protein/day) which resulted in some decrease in spontaneous food intake (196‐382 kcal/day and 5.6‐14.45 protein/day). The net increase was approximately 400 kcal/day. REE was elevated compared to normal (110% predicted) at baseline &amp; did not change during supplementation. The response of fat free mass (FFM) at 6 wks was significantly correlated (r2 = ‐0.42, p &lt; 0.01) with baseline hepatic fat synthesis (an index of cytokine presence and metabolic dysregulation). A majority of patients maintained their entrance body weight as only 20% experienced reductions of 2.2 kg or greater. When considering all data from the 1 yr follow up, the risk of a &gt; or = 50% drop from baseline in the CD4 count was 7.4 times greater in the WP than the PB group (p &lt; 0.01). In conclusion, total intake of nutrients increased even after reduction of voluntary food intake was considered. This increased macro and micro nutrient intake resulted in apparent weight maintenance without untoward GI symptom or function. Specific dietary management with the PB formula may provide added clinical benefit based on the CD4 analyses. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mendez 1998</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>USA</p> <p>SETTING:</p> <p>Seven community research sites</p> <p>FOLLOW UP:</p> <p>Weight and body composition by single frequency bioimpedance analysis were measured monthly for 6 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>Clinically‐stable, HIV‐infected subjects with CD4+ lymphocytes below 100 cells/mm3</p> <p>Number randomised: 119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formula containing long chain triglycerides (LCT) vs formula containing medium chain triglycerides (MCT). Subjects were prescribed three cans of coded formulae to take daily as a supplement to their usual diet, for six months. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The two groups were similar at baseline. Dropout rates were high in both groups over the six month follow up. Both groups gained weight, on average, during the study. The LCT group gained significantly more weight than the MCT group (0.63 vs 0.13 kg/month, p = 0.016). In contrast, gains in body cell mass were small and similar in the two groups (0.08 vs 0.06 kg/month, p = 0.655). Subjects who dropped out before the four month follow up were more likely to have lost body cell mass during months 1‐3 than those who continued on study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ndekha 2009 (Full text)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY: <br/> Malawi <br/> SETTING: <br/> Antiretroviral therapy clinic at Queen Elizabeth Central Hospital in Blantyre <br/> DURATION OF RECRUITMENT: <br/> Jan 2006 ‐ Jan 2007 (estimated) <br/> DURATION OF TRIAL: <br/> Jan 2006 ‐ Apr 2007 (16 months) <br/> FOLLOW‐UP: <br/> At baseline, physician examination was conducted, Quality of Life questionnaire was administered and demographic data, clinical status, and anthropometric measurements, including and bioelectrical impedance analysis, were collected. <br/> At 2 weeks, 6 weeks, 10 weeks and 14 weeks clinic visits included all of the above measurements and procedures. A four‐item validated adherence questionnaire was conducted at each visit after enrolment to assess adherence to ART. <br/> Blood samples collected at baseline and 14 weeks. </p> <p>ETHICS: <br/> College of Medicine research and ethics committee, University of Malawi; Human studies committee of Washington School of Medicine; Committee for research on human subjects at University of Witwatersrand <br/> TRIAL REGISTRATION: <br/> Registered on Current Controlled Trials ISRCTN67515515 <br/> FUNDING: <br/> USAID Food and Nutrition Technical Assistance Project of the Academy for Educational Development and AIDS Care Research in Africa </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0012"> <li> <p>HIV‐infected adults &gt; 18 years</p> </li> <li> <p>Met criteria for antiretroviral therapy according to Malawian national HIV treatment guidelines (WHO clinical Stage III or IV or CD4 &lt; 250 cells/mm3) </p> </li> <li> <p>BMI &lt; 18.5</p> </li> </ul> </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0013"> <li> <p>Pregnancy or lactation</p> </li> <li> <p>Participation in another supplementary feeding programme</p> </li> </ul> </p> <p>Participants enrolled: 491 <br/> Participants randomised: 491 <br/> Mea age at baseline: 36 years (SD: +/‐ 11 years) in the intervention group; 36 years (SD: +/‐ 12 years) in the control group <br/> Sex at baseline: 62% women in the intervention group; 58% women in the control group <br/> No significant differences in baseline criteria observed. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Fortified spread 245g/day containing:</p> <p> <ul id="CD004536-list-0014"> <li> <p>35.5g protein</p> </li> <li> <p>91g fat</p> </li> <li> <p>5694kJ energy</p> </li> </ul> </p> <p>Varied micronutrients including vitamins and trace elements</p> <p>The spread was peanut‐based and was provided in 245g plastic bottles and one bottle was consumed daily. </p> <p>CONTROL:</p> <p>Corn‐soy blended flour 374g/day containing:</p> <p> <ul id="CD004536-list-0015"> <li> <p>50g protein</p> </li> <li> <p>26.2g fat</p> </li> <li> <p>5694kJ energy</p> </li> </ul> </p> <p>Varied micronutrients including vitamins and trace elements <br/> The same level of energy was provided in both supplements and was 50% of the daily estimated average energy requirements based on WHO guidelines that take into account that HIV‐infected people require 30% more energy than healthy people. The amounts of micronutrients differed between the supplements but in neither were the amounts in excess of the estimated average requirement. <br/> DURATION: <br/> Taken daily for 14 weeks <br/> COMPLIANCE: <br/> Not clearly reported but in focus groups of 42 participants in the intervention group and 53 in the corn‐soy group following the trial , the supplementation was reported to be highly appreciated and shared with family. Corn‐soy blend was more likely to be shared as required preparation. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants had a BMI &lt; 18.5 at study entry. The trial reported mortality data. Overall 131 participants died with those in the fortified spread being no more likely to die than those in the corn‐soy blend group (RR 1.05; 95% CI: 0.78, 1.41; p = 0.74). See Analysis 7.1. Although 95% Confidence Intervals were reported, no p values were provided. We recalculated the analyses in REVMAN and report these. Participants in the fortified spread group gained significantly more weight than those in the corn‐soy blend group (MD: 1.3kg; 95%CI: 0.52, 2.08; p = 0.001), had a greater gain in fat‐free body mass (MD: 0.70kg; 95% CI: 0.15, 1.25; p = 0.01) and in mid‐upper arm circumference (MD: 0.60cm; 95% CI: 0.27, 0.93; p = 0.0003). See Analysis 7.2; Analysis 7.4; Analysis 7.5. Change in BMI was also statistically significantly greater in the fortified spread group compared with the corn‐soy blend group (MD: 0.6kg; 95% CI: 0.3 to 0.9; p &lt; 0.0001). See Analysis 7.3. <br/> <br/> Change in mean CD4 count at study endpoint was not statistically significantly different between the groups. See Analysis 7.7. The authors report that viral load and quality of life also did not differ significantly between groups. The authors conducted further analyses stratifying the outcomes by diet quality on enrolment and the type of supplement. Neither of the supplements affected any of the three dietary subgroups differently. Adverse effects were not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Method not clearly reported. Reported as blocks of 50 numbers <br/> Allocation concealment (selection bias): Low risk ‐ Allocation done using sealed, unmarked, opaque envelopes which were opened in an area separate from the research and treatment room. Envelopes contained a unique number from 1 to 500 and staff member then matched the number with the food supplement. <br/> Blinding of participants and personnel (performance bias): High risk ‐ Participants could not be blinded as the appearance was different between the supplements. The personnel were blinded. <br/> Blinding of outcome assessment (detection bias): Low risk ‐ The personnel, including clinicians and nutritionist, were blinded <br/> Incomplete outcome data (attrition bias): High risk ‐ For the primary outcome of BMI and fat‐free body mass, attrition was high due to the high number of deaths: Intervention: 89/245 (32.7%); control: 80/246 (32.5%). For other outcomes, such as death, the attrition would have less potential for bias. <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pichard 1998</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY: <br/> Switzerland <br/> SETTING: <br/> Outpatient, University Hospital, Geneva <br/> DURATION OF RECRUITMENT: <br/> Not reported <br/> DURATION OF TRIAL: <br/> Not reported <br/> FOLLOW‐UP: <br/> At enrolment and at monthly visits, a clinical examination was done with weight to nearest 50g, height, and BMI calculated. <br/> At baseline, 3 months, 6 months and 12 months, bloods were taken for total leucocytes, CD4 and CD8, p24 antigen, and beta2 microglobulin. <br/> At baseline, 3 months and 6 months, the French language validated self‐applied questionnaire derived from the Medical Outcome Study 36‐item short form health survey, was administered. <br/> Food intake was monitored by a standard 3‐day calorie count food intake questionnaire. </p> <p>ETHICS: <br/> Ethics Committee of Department of Medicine at Geneva University Hospital <br/> TRIAL REGISTRATION: <br/> Could not locate trial protocol. <br/> FUNDING: <br/> Sponsorship by Sandoz Nutrition, Bern, Switzerland </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0016"> <li> <p>HIV‐infected adults (adult not defined so assumed to be &gt; 18 years)</p> </li> <li> <p>CD4 &gt;= 100 X 106/L</p> </li> </ul> </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0017"> <li> <p>Change in antiretroviral therapy in 8 weeks prior to the trial</p> </li> <li> <p>Symptomatic neuropathy or myopathy</p> </li> <li> <p>Neoplasia</p> </li> <li> <p>Endocrine disorders</p> </li> <li> <p>Diabetes Mellitus</p> </li> <li> <p>Treatment for hypo‐ or hyperthyroidism</p> </li> <li> <p>Renal failure</p> </li> <li> <p>Liver cirrhosis</p> </li> <li> <p>GIT resection</p> </li> <li> <p>Psychiatric disorders</p> </li> <li> <p>Active intravenous use</p> </li> </ul> </p> <p>Participants randomised: 64 <br/> Baseline characteristics only reported for 55 participants who completed the study. <br/> Mean age at baseline: 36.7 years +/‐ SEM: 1.6 years in the Arginine group; 32.6 years +/‐ 1.8 years in the control group <br/> Sex at baseline: 4/27 (14.8%) women in the intervention group; 7/28 (25%) women in the control group <br/> No significant differences in baseline characteristics were observed. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Enriched omega‐3 fatty acid supplementation containing 606kcal comprising:</p> <p> <ul id="CD004536-list-0018"> <li> <p>33g protein (22% of total energy content)</p> </li> <li> <p>26g casein</p> </li> <li> <p>7.4g arginine</p> </li> <li> <p>16.8g fat (25% of total energy content)</p> </li> <li> <p>4g essential fatty acids</p> </li> <li> <p>2.4g omega‐6 fatty acid</p> </li> <li> <p>1.7g omega‐3 fatty acid</p> </li> <li> <p>80.4g carbohydrates (53% of total energy content)</p> </li> <li> <p>10g dietary fibre</p> </li> </ul> </p> <p>The supplementation was taken as two servings daily of 76g powder) for 6 months.</p> <p>CONTROL:</p> <p>Standard supplementation containing 606kcal comprising:</p> <p> <ul id="CD004536-list-0019"> <li> <p>26 protein (17% of total energy content)</p> </li> <li> <p>26g casein</p> </li> <li> <p>16.8g fat (25% of total energy content)</p> </li> <li> <p>2.4g essential fatty acids</p> </li> <li> <p>2.4g omega‐6 fatty acid</p> </li> <li> <p>0.1 omega‐3 fatty acid</p> </li> <li> <p>0.12g alpha‐linoleic acid</p> </li> <li> <p>88.0g carbohydrates (58% of total energy content)</p> </li> <li> <p>10g dietary fibre</p> </li> </ul> </p> <p>The supplementation was taken as two servings daily of 76g powder for 6 months. <br/> COMPLIANCE: <br/> Compliance reported as percentage of patients completing the trial: 70% completed the trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PRIMARY OUTCOMES:</p> <p>Primary outcomes not clearly reported in the text. Protein intake and weight gain reported prominently. In the abstract main outcome measures listed include: </p> <p> <ul id="CD004536-list-0020"> <li> <p>Disease progression measured by AIDS‐defining events</p> </li> <li> <p>CD4 and CD8 counts</p> </li> <li> <p>Viraemia</p> </li> <li> <p>Tumour necrosis factor soluble receptors</p> </li> <li> <p>Nutritional status determined by anthropometric, bioelectrical impedance and dietetic assessment </p> </li> </ul> </p> <p>SECONDARY OUTCOMES: <br/> Change in fat mass <br/> Total energy intake <br/> ADVERSE EVENTS: <br/> Tolerance and appetite and gastrointestinal symptoms recorded using standard questionnaire. </p> <p>RESULTS:</p> <p>Fifty‐five patients completed the protocol. Compliance with and tolerance of oral nutritional supplement during the 6‐month period was excellent. In both groups of patients the following were found: total energy intake was transiently increased and then returned to baseline level; nitrogen/energy intake ratio was increased throughout the study; gain of body weight and fat mass were approximately 2 and 1kg, respectively, over 6 months, and were similar in both groups. In addition, CD4 and CD8 lymphocyte counts, viraemia, tumour necrosis factor soluble receptors remained statistically unchanged and were similar in both groups. Enrichment of an oral nutritive supplement with arginine and omega‐3 fatty acids did not improve immunological parameters. However, body weight increased in both groups </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Unclear risk ‐ Reported as 'double‐blind' but not stated clearly for participants and personnel <br/> Blinding of outcome assessment (detection bias): Unclear risk ‐ Reported as 'double‐blind' but not stated clearly for outcome assessors <br/> Incomplete outcome data (attrition bias): High risk ‐ Attrition was high: 5/32 (29.1%) in the Arginine group; 4/32 (24.3%) in the standard group <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PrayGod 2011</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY:</p> <p>Tanzania <br/> SETTING: <br/> Four TB clinics in Mwanza city, under the Tanzanian National TB and Leprosy Programme (NTLP) <br/> DURATION OF TRIAL: </p> <p>April 2006‐March 2009 <br/> FOLLOW‐UP: </p> <p>Weight, arm fat area, arm muscle area and hand grip strength assessed at 2 months and 5 months </p> <p>ETHICS: <br/> Based on guidelines according to Declaration of Helsinki. National Medical Research Coordinating Committee of the National Institue of medical Research in Tanzania and approval from the Danish National Committee on Biomedical Research Ethics. Written informed consent obtained from all patients. <br/> TRIAL REGISTRATION: <br/> ClinicalTrials.gov identifier: NCT00311298 <br/> FUNDING: </p> <p>The Danish Council for Independant Research, Danida and the University of <br/> Copenhagen </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p>New or relapse PTB/HIV‐co‐infected patients older than 15 years and residents of Mwanza City </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0021"> <li> <p>Extra‐pulmonary TB</p> </li> <li> <p>pregnancy</p> </li> <li> <p>Terminal illness</p> </li> </ul> </p> <p>Number randomised:377</p> <p>Number included in analyses:166 (2 months); 151 (5 months)</p> <p>Mean age at baseline: 34.7±10.3 years in energy‐protein group; 36.2±9.5 years in control group </p> <p>Sex ratio (M/F) at baseline: 95 males: 94 females in energy‐protein group; 95 males: 93 females in control group </p> <p>Mean BMI at baseline: 18.7±2.9 kg.m<sup>‐2</sup> in energy‐protein group; 18.5±2.8 kg.m<sup>‐2</sup> in control group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Intervention group received 6 daily energy‐protein biscuits for the first 60 days of treatment, of which one contained the additional micronutrients. Energy‐protein biscuit contained 4.5 g protein, 615 kilojoules energy, 120 mg phosphorous, 120 mg calcium, 36 mg magnesium, 70 mg sodium, 150 mg potassium, and traces &lt;1 mg of iron and zinc. Energy‐protein biscuit with additional micronutrients contained all of the above plus 1.5 mg vitamin A, 20 mg thiamin, 20 mg riboflavin, 25 mg vitamin B6, 50 μg vitamin B12, 0.8 mg folic acid, 40 mg niacin, 200 mg vitamin C, 60 mg vitamin E, 5 μg vitamin D, 0.2 mg selenium, 5 mg copper, 30 mg zinc. </p> <p>CONTROL:</p> <p>The control group received one daily energy‐protein biscuit with additional micronutrients.</p> <p>ADHERENCE:</p> <p>Either by direct observation or use of a log book recording intake of supplement</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In energy‐protein group: 37/189 lost to follow up and in control group: 35/188 lost to follow up. There were no effects on any outcome at 2 months, but energy–protein supplementation was associated with a 1·3 (95% CI 20·1, 2·8) kg marginally significant gain in handgrip strength at 5 months. At 2 months, there was an interaction between energy–protein supplementation and CD4 count level for weight (P<sub>interaction</sub> =0·03), which was explained by a 1·9 kg (95% CI 0·1, 3·7; P¼0·04) higher weight gain among patients with CD4 counts of 350 cells/ml or higher, and the lack of effect among those who had CD4 counts below 350 cells/ml (20·2 kg; 95% CI 21·3, 0·8; P¼0·66). Similarly, at 5 months, energy–protein supplementation led to a 2·3 (95% CI 0·6, 4·1) kg higher handgrip strength gain among patients with CD4 counts&lt;350 cells/ml, but not in those with high CD4 counts (P<sub>interaction</sub> =0·04). In conclusion, energy–protein supplementation to PTB/HIV‐co‐infected patients had no overall effects on weight and body composition, but was associated with marginally significant gain in handgrip strength. More <br/> research is needed to develop an effective supplement, before it is recommended to TB programmes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of Bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Low risk 'Computer‐generated randomisation sequence, using permuted blocks of ten' <br/> Allocation concealment (selection bias): Low risk 'The allocation sequence was used by designated research staff to sequentially arrange and label supplement packs with identity numbers ranging from 1 to 500. During the study the randomisation sequence and code were kept in a safe cabinet only accessible by designated research staff. Recruitment was done by clinic staff. The same designated research staff not employed at the study clinics assigned an identity number to the recruited patient and sent the corresponding nutritional pack to the respective clinic'. <br/> Blinding (performance bias and detection bias): High risk Blinding was not possible due to the nature of the intervention <br/> Incomplete outcome data (attrition bias): Low risk At 2 and 5 months, 12.2% and 19.1% of patients were lost to follow‐up. However, the proportions lost to follow‐up were similar across the intervention and control arms of the study. <br/> Selective reporting (reporting bias): Unclear risk. Trial protocol not retrieved. Deaths and cure are not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sattler 2008</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY: <br/> USA and Puerto Rico <br/> SETTING: <br/> 15 Adults AIDS Clinical Trials Group (ACTG) ambulatory research sites based at tertiary hospitals <br/> DURATION OF RECRUITMENT: <br/> Feb 1999 ‐ Dec 1999 <br/> DURATION OF TRIAL: <br/> 13 months (estimated from final recruitment month plus12 weeks follow‐up) <br/> FOLLOW‐UP: <br/> At baseline, physician examination and outcome data collected, including anthropometric measurements with weight measured using a calibrated scale. <br/> At 6 weeks, above repeated and three‐day dietary diary administered by dietician. <br/> At 12 weeks, above repeated and three‐day dietary diary administered by dietician. <br/> Routine overnight fasting bloods taken at all three follow‐up visits </p> <p>ETHICS: <br/> Approved by the Instititional Review Board at each ACTG site. <br/> FUNDING: <br/> Funded by National Institute of Allergy and Infectious Diseases through ACTG 01 grant. <br/> Biomune Systems Inc provided whey protein and control supplement </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0022"> <li> <p>HIV‐infected adults</p> </li> <li> <p>Stable weight loss &gt; 3% over course of HIV infection, but no change in weight in two months prior to enrollment </p> </li> <li> <p>HIV RNA concentration &lt;5000 copies/ml</p> </li> <li> <p>HAART or no HAART</p> </li> </ul> </p> <p>EXCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0023"> <li> <p>Opportunistic infections</p> </li> <li> <p>Malabsorption</p> </li> </ul> </p> <p>Participants enrolled: 66 <br/> Participants randomised: 59 <br/> Median age at baseline: 41 years (range: 31‐ 66) in the intervention group; 41 years (26‐58) in the control group <br/> Sex at baseline: 26:3 men:women in the intervention group; 26:4 men: women in the control group <br/> No significant differences in baseline criteria observed. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>High protein supplement 280kcal serving containing:</p> <p> <ul id="CD004536-list-0024"> <li> <p>40g whey protein</p> </li> <li> <p>20.5g carbohydate</p> </li> <li> <p>4g fat</p> </li> </ul> </p> <p>CONTROL:</p> <p>Isocaloric supplement 280kcal serving containing:</p> <p> <ul id="CD004536-list-0025"> <li> <p>0.6g casein (protein)</p> </li> <li> <p>60.8g carbohydrate</p> </li> <li> <p>4g fat</p> </li> </ul> </p> <p>Control had same texture, appearance and taste as intervention. <br/> DURATION: <br/> Taken orally twice a day between meals for 12 weeks <br/> COMPLIANCE: <br/> Not clearly reported but one participant in intervention group stopped due to disliking the taste </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In Sattler 2008 all analyses were performed using the WiIcoxon rank sum test for non‐normally distributed data. The report also provided means and standard deviations and these were entered into REVMAN for calculations. We report the REVMAN calculations and the Wilcoxon rank sum test data as reported by the authors which are likely to be more accurate if there was a lack of a normal distribution for the outcomes. For daily energy intake, there was no statistically significant difference in the mean change in intake from baseline to week 12 between the whey protein and placebo groups (REVMAN: MD: ‐6.00; 95% CI: ‐637.57, 625.57; p = 0.99). See Analysis 6.1. The authors’ analysis report a non‐significant p = 0.12. For daily protein intake, participants in the whey protein group had a statistically significantly greater intake than the placebo group (REVMAN: MD: 1.17g/kg/day; 95% CI: 0.80, 1.54; p &lt; 0.00001). SeeAnalysis 6.2. This was also significant when analysed using the Wilcoxon rank sum test (reported p &lt; 0.01). <br/> <br/> For mean change in weight, total lean body mass and fat mass from baseline to week 12, there were no statistically significant differences either by REVMAN analysis or reported Wilcoxon rank sum test. See Analysis 6.3; Analysis 6.4; and Analysis 6.5. The authors do not provide final or changes in BMI but conducted an analysis correlating baseline BMI to changes in weight in either group and found no correlation (reported Spearman correlation: whey protein: ‐0.18; p = 0.36; placebo: 0.32; p = 0.12) <br/> <br/> Mean change in triglycerides was statistically significantly lower in the whey protein group compared with placebo at week 12 (MD: ‐55.00; 95% CI: ‐102.62, ‐7.38; p = 0.02). See Analysis 6.6. This was also found to be significant when using the Wilcoxon rank sum test (reported p = 0.03). For mean change in CD4 count the authors conducted a Wilcoxon rank sum test and showed a statistically significant increase in the CD4 count in the whey protein group compared with placebo (reported p = 0.03). In analysis in REVMAN the result was not statistically significant at p = 0.22. See Analysis 6.7. Given that CD4 counts are known to be non‐normally distributed it is likely the authors’ use of Wilcoxon rank sum test is more accurate. <br/> <br/> No adverse effects were reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Low risk ‐ Participants and personnel reported as blinded and control supplement had same texture, taste and appearance as intervention supplement <br/> Blinding of outcome assessment (detection bias): Low risk ‐ Personnel reported as blinded. <br/> Incomplete outcome data (attrition bias): High risk ‐ Attrition was high in the intervention group 12/29 (41%) at 12 weeks follow‐up and less in the control group 6/30 (20%). The observations completed at 6 weeks were carried forward for analysis but the differential follow‐up between the groups is a possible source of bias. <br/> Selective reporting (reporting bias): Unclear risk ‐ Protocol not obtained </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Suttmann 1996</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COUNTRY: <br/> Germany <br/> SETTING: <br/> Outpatient clinic, not clearly stated, assume at the Medizinische Hochschule, Hannover <br/> DURATION OF RECRUITMENT: <br/> Not reported <br/> DURATION OF TRIAL: <br/> Not reported but cross‐over trial of 8 months duration per participant <br/> FOLLOW‐UP: <br/> At baseline and at monthly visits for 32 weeks, a clinical examination was done. <br/> Every two months, weekly dietary records were obtained: the nutrient intake was determined by computer analysis of 7‐day diet records <br/> Anthropometry and bioelectrical impedance analysis and bloods were done monthly. </p> <p>ETHICS: <br/> Ethics Committee of Medizinische Hochsculle, Hannover, Germany <br/> TRIAL REGISTRATION: <br/> Could not locate trial protocol. <br/> FUNDING: <br/> Not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INCLUSION CRITERIA:</p> <p> <ul id="CD004536-list-0026"> <li> <p>HIV‐infected adults &gt; 18 years</p> </li> <li> <p>Estimated survival &gt; 8 months</p> </li> <li> <p>Platelet count &gt; 50,0000 /µL</p> </li> <li> <p>No malignancies</p> </li> <li> <p>No mycobacteriosis or cytomegalovirus</p> </li> <li> <p>No intravenous drug use</p> </li> <li> <p>No immune‐modulating treatments</p> </li> <li> <p>Stable medication for 1 month prior to study entry</p> </li> </ul> </p> <p>Participants randomised: 10 cross‐over <br/> Baseline characteristics only reported for 55 participants who completed the study. <br/> Mean age at baseline: 32.6 years +/‐ SEM: 1.8 years in the Arginine group; 36.7 years +/‐ 1.6 years in the control group <br/> Sex at baseline: 7/27 (26%) women in the intervention group; 4/28 (14.3%) women in the control group <br/> No signficant differences in baseline characteristics were observed. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>INTERVENTION:</p> <p>Enriched arginine formula containing 500kcal comprising:</p> <p> <ul id="CD004536-list-0027"> <li> <p>27.9g protein</p> </li> <li> <p>21.7g casein</p> </li> <li> <p>6.2g arginine</p> </li> <li> <p>13.9g fat</p> </li> <li> <p>3.2g essential fatty acids</p> </li> <li> <p>1.9g n‐6 fatty acids</p> </li> <li> <p>1.4g n‐3 fatty acids</p> </li> <li> <p>1.8g Linolenic acid</p> </li> <li> <p>67g carbohydrates</p> </li> </ul> </p> <p>The supplementation was taken as a daily liquid formula for 16 weeks and then crossed over to control formula for 16 weeks. </p> <p>CONTROL:</p> <p>Non‐enriched formula containing 500kcal comprising:</p> <p> <ul id="CD004536-list-0028"> <li> <p>21.7g protein</p> </li> <li> <p>21.7g casein</p> </li> <li> <p>13.9g fat</p> </li> <li> <p>3.7g essential fatty acids</p> </li> <li> <p>3.6g n‐6 fatty acids</p> </li> <li> <p>0.1g n‐3 fatty acids</p> </li> <li> <p>3.6g Linolenic acid</p> </li> <li> <p>73.2 carbohydrates</p> </li> </ul> </p> <p>The control supplementation was taken as a daily liquid formula for 16 weeks and then crossed over to the enriched formula for 16 weeks. <br/> COMPLIANCE: <br/> Mean intake of formula reported as 638 +/‐ 117 kcal/day for the intervention and 695 +/‐ 118 kcal/day with no statistically significant differences in intake between groups. (assume this measurement is taken from reported weekly dietary records) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was no statistically significant difference in energy intake between the arginine‐enriched formula group and the non‐enriched formula groups (MD: ‐10kcal/day; 95% CI: ‐459.96, 439.96; p = 0.97). See Analysis 2.1. Body weight was significantly increased by a mean of 3.40kg and could be as much as 5.29kg or as little as 1.51kg (MD: 3.4; 95% CI: 1.51, 5.29; p &lt; 0.0004). Authors state that no significant differences between groups for lean body mass and fat mass but the numerical data is not reported. The change in CD4 counts did not differ statistically significantly between the arginine‐enriched formula group and the non‐enriched formula group (MD: ‐50.00; 95% CI: ‐151.73, 51.71; p = 0.34). See Analysis 2.5. Viral load is not reported as an outcome. Adverse effects: a high temperature was reported by two patients (one in arginine‐enriched formula group and one in the non‐enriched formula group), and diarrhoea was reported by two patients (one in the arginine‐enriched formula group and one in the non‐enriched formula control group), but the authors state that the differences observed were not significant between the two periods. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Random sequence generation (selection bias): Unclear risk ‐ Cross‐over trial but method of randomisation not reported. <br/> Allocation concealment (selection bias): Unclear risk ‐ Not reported. <br/> Blinding of participants and personnel (performance bias): Unclear risk ‐ Reported as 'double‐blind' but not clearly specified. <br/> Blinding of outcome assessment (detection bias): Unclear risk ‐ Reported as 'double‐blind' but not clearly specified. <br/> Incomplete outcome data (attrition bias): Low risk ‐ Nil. All participants remained in study <br/> Selective reporting (reporting bias): Unclear risk ‐ Trial protocol not located and cannot exclude selective reporting bias as primary outcomes not stated. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of comparative studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/full#CD004536-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004536-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Energy intake (kcal/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>393.57 [224.66, 562.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Protein intake (g/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.35 [12.68, 34.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐1.10, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fat mass measured in % of TBW <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐2.58, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fat free mass <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐2.77, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CD4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐114.48 [‐233.20, 4.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Viral load (log10 copies/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.71 [‐12.16, 4.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Balanced macronutrient formulas plus nutrition counselling vs nutrition counselling in participants with weight loss</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004536-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Body weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ART arm: body weight at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.47, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 pre‐ART arm: body weight at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.60, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 ART arm: body weight at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [‐0.62, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 pre‐ART arm: body weight at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [‐0.59, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 ART arm: body weight at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.99, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 pre‐ART arm: body weight at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [1.02, 4.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 ART arm: body weight at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐1.50, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 pre‐ART arm: body weight at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.67 [1.50, 5.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 ART arm: body weight at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐3.19, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 pre‐ART arm: body weight at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [‐0.41, 4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in body weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ART arm: change in body weight at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.40, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 pre‐ART arm: change in body weight at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.28, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 ART arm: change in body weight at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.29, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 pre‐ART arm: change in body weight at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.31, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 ART arm: change in body weight at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [‐0.30, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 pre‐ART arm: change in body weight at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.82, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 ART arm: change in body weight at 12 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐1.78, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 pre‐ART arm: change in body weight at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [‐0.79, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Body mass index (BMI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ART arm: BMI at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.15, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 pre‐ART arm: BMI at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.07, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 ART arm: BMI at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.08, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 pre‐ART arm: BMI at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.05, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 ART arm: BMI at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.07, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 pre‐ART arm: BMI at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.31, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 ART arm: BMI at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [‐0.07, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 pre‐ART arm: BMI at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.22, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 ART arm: BMI at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.72, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 pre‐ART arm: BMI at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [‐0.25, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 % lean body mass <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ART arm: % lean body mass at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.96, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 pre‐ART arm: % lean body mass at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.51, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 ART arm: % lean body mass at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐1.20, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 pre‐ART arm: % lean body mass at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐1.40, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 ART arm: % lean body mass at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐2.13, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 pre‐ART arm: % lean body mass at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [‐0.70, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 ART arm: % lean body mass at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐1.48, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 pre‐ART arm: % lean body mass at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [‐0.79, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 ART arm: % lean body mass (kg) at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.53 [‐3.55, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 pre‐ART arm: % lean body mass (kg) at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [‐1.82, 3.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Supplementary food plus nutrition counselling vs nutrition counselling in malnourished adults on ART and pre‐ART</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004536-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Arginine rich supplements versus nutritional placebo or arginine‐free supplements</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean change in body weight baseline to 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [0.72, 4.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in fat mass measured in kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐2.69, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in fat free mass <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.25 [1.25, 5.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Arginine rich supplements versus nutritional placebo or arginine‐free supplements</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004536-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Ornithine alpha‐ketoglutarate (OKG) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean daily energy intake at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐66.0 [‐564.63, 432.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean daily protein intake in kcal at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐18.71, 17.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean fat mass in kg at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐2.00, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean weight in kg at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐11.68, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mean fat‐free mass in kg at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.10 [‐11.11, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean CD4 count in cells/mm<sup>3</sup> at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐28.0 [‐134.93, 78.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mean viral load in log<sub>10</sub> at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.58, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Proportion with gastrointestinal event (at least one) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.06, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Ornithine alpha‐ketoglutarate (OKG) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004536-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">L‐glutamine (GLN) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean weight in kg at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐10.18, 7.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean fat mass in kg at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐32.40, 30.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean CD4 count in cells/mm<sup>3</sup> at study endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>66.0 [‐53.39, 185.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">L‐glutamine (GLN) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004536-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Enhanced nutritional support vs std nutritional support in children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.59, 3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.74, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Enhanced nutritional support vs std nutritional support in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004536-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Spirulina versus traditional meals in children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Weight for height z score (WHZ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.21, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Weight for age z score (WAZ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.44, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Spirulina versus traditional meals in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004536.pub3/references#CD004536-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004536.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD004536-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD004536-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004536-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004536-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD004536-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="pt#CD004536-note-0002">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004536\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004536\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004536\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004536\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004536\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=u3GUW7vS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004536.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004536.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004536.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004536.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004536.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716664322"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004536.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716664326"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004536.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da5080cfa9368',t:'MTc0MDcxNjY2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 